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Summary
Human adenovirus type S is a dsDNA virus which replicates in the nucleus of the
infected cell, exploiting a number of host cell mechanisms. This close association with
the eukaryotic cell has made adenovirus the target of numerous studies attempting to
understand how cellular systems function. This study focuses on the E4 transcription
unit, which has the potential to encode at least 7 distinct polypeptides from reading
frames accessed by differential splicing of a single primary transcript. In this study, the
pattern of expression of these mRNAs during lytic infection was examined, and two
distinct temporal classes were defined; early and late. It had been previously shown
that adenovirus mRNAs produced late in the infection depended on a virus-coded
RNA transport regulator, EIb-S5K, for optimal cytoplasmic accumulation. However,
only one of the E4 late class mRNAs was dependent on this EI b protein for
cytoplasmic accumulation leading to the hypothesis that for an E4 late mRNA to be
dependent on EIb, it had to retain intact splice sites or intronic sequences. To examine
this hypothesis, a virus was built lacking an important splice site of the E4 region to
see if, by removing this splice site, the mRNA could leave the nucleus in the absence of
the El b complex. The results of initial experiments reported here supported this
hypothesis.
Two of the E4 open reading frames (ORFI and ORF2) identified in Ad2 were
disrupted in the published AdS E4 sequence, but these differences were subsequently
found to be sequencing artefacts. The presence of these two proteins in the infected
cell had never been previously demonstrated so polyclonal antisera were generated
against bacterially expressed ORFI and ORF2. The ORF2 antiserum allowed the
identification of the ORF2 protein in the cytoplasm of infected cells, from early stages
of the infection. No associations of ORF2 with other infected cell components were
detected. In contrast, the ORFI antiserum only reached a low titre and no ORFI
protein was detected in infected cells. Now that ORF2 has been found in the infected
cell more work needs to be undertaken to elucidate its function.
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Chapter 1.
Introduction
1.t. Adenoviruses - A General Introduction
1.1.1. The adenovirus family
Adenoviruses were first isolated from tonsil and adenoid biopsies from children by
Rowe et al. (1953) Since then adenoviruses have been shown to be the aetiological
agents of a wide variety of diseases in birds and mammals including a number of acute
febrile respiratory illnesses, epidemic keratoconjunctivitis, acute haemorrhagic cystitis
and gastro-enteritis (reviewed in Horwitz, 1990b). Some adenoviruses have also been
associated with the induction of malignant tumours in rodents although there is no
evidence of these viruses having oncogenic potential in humans.
Adenoviruses are of the family Adenoviridae which is divided into two genera;
Mastadenoviridae and Aviadenoviridae. The Mastadenoviridae genus contains
human, simian, bovine, equine, porcine, ovine and canine viruses. The human
adenoviruses have been classified into six subgroups (A-F) by a number of serological
and biochemical techniques such as haemagglutination patterns of rat and rhesus
monkey red blood cells, oncogenic potential in rodents, DNA base composition and
homology, and the ability to transform cells in tissue culture. The antigenic
determinants important in the classification of adenoviruses are found on the hexon,
penton and fibre proteins, for example all human adenoviruses share a cross-reacting
group antigen (a) on the hexon capsomer while the type-specific antigens (s and y) are
found on the hexon and fibre proteins respectively (reviewed inHorwitz, 1990a).
This study focuses on a human subgroup C virus, adenovirus serotype S (AdS).
Subgroup C viruses are characterised by their partial agglutination of rat erythrocytes,
their inability to induce tumours in rodents, their ability to transform cells in tissue
culture and the high G+C content (57-59 %) of their genomes. Of the subgroup C
viruses isolated, serotypes 2 and S have been studied in greatest detail. The genomes
of these viruses have been completely sequenced, Ad2 in 1984 by Roberts et al. and
AdS in 1992 by Chroboczek et al., amended by Dix and Leppard (1992). Sequence
analysis shows 94.7 % homology between the two viruses, with virtually identical gene
2
organisation. The differences between the sequences of these two viruses are
concentrated in regions encoding hexon, fibre and some of the E3 proteins (Kinloch et
al., 1984~Cladaras and Wold, 1985~ Chroboczek and Jacrot, 1987), probably due to
selective pressure exerted by the host immune system during infection as the hexon and
fibre proteins contain major antigenic determinants. As these two serotypes are so
closely related, data derived from one or other of these viruses is routinely taken to
apply to both serotypes; in the introduction to this study no distinction between the
two serotypes is usually made.
1.1.2. Structure of adenoviruses (Fig. 1.1.)
The structure of the adenovirus virion has been well characterised and is reviewed by
Horwitz (1990a). Adenovirus virions are non-enveloped, regular icosahedrons of
about 65 to 80 nm in diameter which comprise a double stranded DNA molecule of
about 36,000 bp (Ad5 is 35938 bp) surrounded by a protein shell (capsid) made of at
least 11 distinct structural proteins (figure 1.1). The capsid comprises 240 hexon
capsomeres (3 x 120 kd polypeptide II molecules) and 12 penton capsomeres (5 x 85
kd polypeptide III molecules noncovalentIy attached to 3 x 62 kd polypeptide IV
molecules; the fibre structure). The penton capsomeres are located at each of the 12
vertices of the capsid with the fibre structure projecting out from the virion. Each of
these penton capsomeres is surrounded by five hexon capsomeres (the peripentonal
hexons) associated with polypeptide lIla (66kd). Also associated with the hexon
capsomeres are 3 further polypeptides; VI (24 kd), VIII (13 kd) and IX (12 kd), which
are probably involved in stabilising the capsid structure. Within the capsid shell of the
virion is the core structure which contains the DNA genome covalently attached to the
55 kd terminal protein (TP) at its 5' ends and polypeptides V (48.5 kd), VII (18.5 kd)
and Jl (4 kd). Polypeptides V and VII are basic proteins which form irregular
nucleosome-like structures along the viral genome, each spanning approximately 200
bp; the Jl protein has no assigned function.
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Figure 1.1. Schematic representation of the adenovirus virion (reproduced from
Horowitz, 1990a). The f..l protein and the probable virion protein, L3-23K protease,
are not featured as their location within the virion is not known. The thread-like strand
within the virion shown below is representative of the virion genome.
Il- Hexon
III - Penton base
lIla - Penton associated
protein
TP - terminal protein
V - Core protein
IV - Fiber
VI - Hexon associated
protein
VII - Core protein
VITI - Hexon associated
protein
IX - Hexon associated
protein
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1.1.3. Adenovirus replication (reviewed by Horwitz, 1990a)
The adenovirus lytic cycle in cultured cells results in the production of about 10,000
virions per infected cell during the course of one virus life cycle (ca. 36 hours). The
lytic life cycle of adenovirus has been divided, by convention, into two phases, early
and late, separated by the onset of viral DNA replication, with distinct patterns of gene
expression in each phase. This division of the virus life cycle is not rigid, early mRNAs
are also made after vDNA replication has begun and some late mRNAs can been found
prior to vDNA replication.
Adenoviruses enter the host cell by receptor-mediated endocytosis, attaching to the
host cell receptor via the C terminus of the virion fiber protein (Devaux et al., 1987).
The nature of the host cell receptor is, at present, vague although initial studies have
indicated that the virus binds to a 50 kd protein identical to the receptor used by the
coxsackie B3 virus (Lonberg-Holm et aI., 1976; Hennache and Boulanger, 1977). The
penton cap somers at the base of the fibre protein then interact with cell surface av
integrins via an RGD peptide sequence within the penton protein (Bai et al., 1993;
Wickham et al., 1993). This secondary interaction is required for efficient virus
internalisation, allowing the formation of endocytic vesicles or receptosomes. Within
the receptosome the pH drops, which is thought to alter the structure of the virion
capsid, rupturing the endocytic vesicle, releasing the virion into the cytoplasm of the
cell (Seth et al., 1985). It has been postulated that the penton protein plays an
important role in the rupture of the receptosome, possibly through the interaction with
cellular integrins (Seth et al., 1984). The penton capsomere is believed to be lost
during this process (reviewed by Nemerow et al., 1994).
The virion is then transported through the cytoplasm to the nucleus of the infected cell
in a process which probably involves the interaction of the hexon capsomeres with the
microtubules of the host cell. The viral DNA and the core proteins (V, VII, TP and J.1)
then enter the nucleus through the nuclear pores leaving the remainder of the virion
proteins in the cytoplasm.
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The viral genome then undergoes early transcription. The virus appears to rely almost
exclusively upon the host cell machinery for transcription and RNA processing with
transcripts being spliced, capped and polyadenylated in a manner similar to host
transcripts (Ziff, 1980~Darnell, 1982~Tooze, 1982~ Sharp, 1984). Transcription from
the six early transcription units (E1a, Elb, E2, E3, E4 and L1) results in the synthesis
of a variety of mRNAs which encode proteins required for subsequent events in the
lytic cycle, such as transcriptional activation, viral DNA replication and mRNA
metabolism. Early transcription from these transcription units results in the production
of only low levels of viral mRNA, compared to the level of viral mRNAs late in the
infection.
The late phase of the infection is marked by the onset of DNA replication, about 10-12
hours post infection. Viral DNA replication has been extensively studied, the current
model incorporating both type I (duplex template) and type II (single stranded
template) replication to produce progeny genomes. Replication initiates at either end
of the parental duplex molecule, displacing one of the parental strands to produce a
semi-conservatively replicated genome and a single stranded molecule (type I
replication). The inverted terminal repeats of the genome allow the single-stranded
molecule to form a panhandle structure where the double-stranded region resembles
the end of a duplex genome. This is then replicated by a type II replication mechanism
to produce a second daughter genome (reviewed by Stillman, 1989). In vivo and in
vitro studies have demonstrated that only three viral proteins are directly involved in
DNA replication; the 140 kd viral DNA polymerase, the 72 kd ssDNA binding protein,
and the 80K precursor to the terminal protein (reviewed by Stillman, 1989). Recently
it has been demonstrated that the ORF3 and ORF6 proteins of the E4 region are
implicated in the regulation of vDNA replication (Weiden and Ginsberg, 1994, see
section l.4.2.3.). Three host proteins are also important in viral DNA replication;
nuclear factors I and III, transcription factors which bind adjacent to the core origin of
replication; and nuclear factor II, a type I topoisomerase, (reviewed by Stillman ,
1989).
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Following the onset ofviraI DNA replication the nuclear structure is reorganised with
both DNA replication and late transcription occurring in association with the nuclear
matrix in discrete viraI inclusion bodies (Moyne et al., 1978~ Zhonghe et al., 1986~
Walton et al., 1989~ Moen et aI., 1990~ Jimenez-Garcia and Spector, 1993).
Transcription occurring in these inclusion bodies results in the production of late
mRNAs, primarily encoded by the major late transcription unit (MLTU). These late
mRNAs, which mainly encode the structural proteins of the virion, can account for up
to 20-40% of the total cellular mRNAs (Flint, 1986). As the structural proteins are
produced, the progeny virions are assembled in the nucleus of the infected cell; initially
the penton and hexon polypeptides assemble into capsomeres in the cytoplasm and
then form a 600S capsid intermediate within the nucleus. At this stage the viral DNA
enters the capsid along with the core proteins, by virtue of packaging signals located
between 290 and 390 bp from the left end of the genome, at an opening at one of the
vertices. The last stage in virion assembly is the processing of some of the proteins
(pVI, pVII, pVIII, pTP) within the virion, which are assembled in precursor form, by
the viral protease (L3-23 kd) to produce the mature virion. This entire process is
aided by virus-encoded scaffolding proteins which are necessary during virion
formation but are absent from the virion (e.g. L4-100 kd and IVa2-50 kd). The
mechanism of virion release from the cell has not yet been clearly elucidated (reviewed
by Horwitz et aI., 1990a).
Cellular macromolecular synthesis undergoes major changes during the late phase of an
adenovirus infection, with both cellular DNA replication and protein synthesis being
inhibited. The gradual cessation of cellular DNA replication is probably a secondary
effect of the inhibition of cellular protein synthesis. The block in cellular protein
synthesis has been shown to be at the level of translation and not at the level ofmRNA
transcription or mRNA transport into the cytoplasm as cytoplasmic levels of cellular
mRNAs are still high when host protein synthesis is shut off (see section 1.2.6.)
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1.1.4. Adenovirus gene function
Gene expression from the 36 kbp adenovirus genome is a very complicated process,
with transcription of most of both strands of the double stranded genome as can be
seen in Fig. 1.2. (reviewed by Flint et al., 1986 and Horwitz, 1990a). The regulation
of this expression is discussed in section 1.2 ..
1.1.4.1. The Ela region
The El a transcription unit is encoded on the r strand of the genome. Five mRNAs are
derived from this region by the differential splicing of the primary transcript: two
predominant early mRNAs (I2S and l3S); a predominant late mRNA (9S); and two
minor late mRNAs (lOS and lIS) (Fig. IJa.). The two major products from this
region are encoded by the 12S and l3S mRNAs; the 243R and 289R proteins, which
are identical apart from 46 internal residues. Both these proteins contain discrete
regions conserved among the different adenovirus serotypes, the CRI and CR2
regions, while only 289R contains a third conserved region, CR3. Both proteins also
contain two auxiliary regions (ARI and AR2), shown to be important in functional
studies in addition to CRI-3, and a C terminal nuclear localisation signal (Fig. 1.3b).
The 243R and 289R proteins of Ela are involved in the induction of cellular DNA
synthesis which is related to their role in transformation of non-permissive cells. The
mechanism of action of these proteins in cellular transformation is not fully understood
but it is known that they form complexes, via the CRI and CR2 regions, with cellular
proteins involved in cell cycle control, including the tumour repressor protein p l OSRb
and other related proteins (reviewed by Dyson and Harlow, 1992).
The CR3 domain of 289R is involved in the transactivation of Ela-dependent
promoters. The E Ia protein activates transcription by a number of different
mechanisms (reviewed by Akusjarvi, 1993): it regulates certain transcription factors
(e.g. E2F, E4F and TFIIIC) by phosphorylation (Roemer et al., 1988; Bagchi et al.,
1989; Raychaudhuri et al., 1989); it can bind upstream activating sequence (UAS)-
binding transcription factors bringing its own transcriptional activation domain into
8
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Figure 1.2. Transcription and translation map of adenovirus type 2 (reproduced
from Horwitz, 1990a). Early mRNAs are represented by thin lines, late mRNAs (and
early mRNAs which are transcribed late, e.g. L1 transcripts) by bold lines,
polyadenylation sites by arrow heads, nonstructural gene products by their molecular
mass, and virion components by Roman numerals. The three components of the major
late tripartite leader are designated 1, 2 and 3. Some minor mRNA species and
corresponding polypeptides are not shown at this scale.
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proximity with the core promoter proteins (Liu and Green, 1990~ Chatton et al.,
1993)~ Ela can also interact directly with the TBP (TATA Box binding protein)
activating transcription (Horikoshi et al., 1991~Lee et al., 1991).
The CRI and CR2 domains of 243R and 289R can also transactivate transcription via
their interaction with tumour suppressor proteins, such as p l OSRb, as this interaction
can cause the dissociation of transcription factors from these regulatory, inhibitor
proteins (Bandara and La Thangue, 1991~ Chellappan et al., 1991). A well studied
example of this phenomenon is the E2F-pl0SRb interaction, where E2F has no
transactivating function when bound to plOSRb but in the presence of the El a protein
it is released in an active form, as El a interacts with plOSRb displacing E2F.
The multifunctional E Ia proteins may therefore regulate one promoter in a number of
different ways, e.g. the E2 early promoter. The E2 promoter consists of an activating
transcription factor (ATF) binding site and two inverted E2F sites. It is activated by
El a by three distinct mechanisms: ATF can bind to the upstream ATF binding site and
transactivate the promoter via Ela which associates with ATF; Ela can dissociate E2F
from pIOSRb_E2F complexes where E2F is inactive and it can also phosphorylate E2F,
so increasing its DNA binding activity and so its ability to transactivate the E2
promoter (Bagchi et al., 1989~ Bandara and La Thangue, 1991~ Chellappan et al.,
1991~Chattonetal., 1993).
Evidence is mounting that Ela-243R can also inhibit the activation of some promoters,
a function shown to be a property of the N terminus of the protein (Berk, 1986). The
Ela-243R protein, which lacks the transactivation domain CRJ, is believed to repress
transcription by interacting with a TFIID protein from the core of the transcription
machinery and so reducing expression from certain promoters (Ielsma et al., 1989~
Stein et al., 1990~Bautista et al., 1991).
1.1.4.2. The Elb region
The EI b transcription unit is also on the r strand of the genome and encodes proteins
important in virus replication and cellular transformation. At least 5 mRNAs are
10
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Figure 1.3. The Eta region. Panel A: The Ela mRNAs (from Harper and Manley,
1991). The open boxes represent exon regions while the lines represent intron regions.
Indicated above the mRNAs are the transcriptional start sites, splice sites and
polyadenylation sites. Indicated to the left of the mRNAs are the popular names given
to the mRNAs. Panel B: The multifunctional domains of the major Ela proteins,
289R and 243R. 289R and 243R are the products of the 12 and 13S mRNAs
respectively. CRI, CR2 and CR3 are regions conserved in Eia proteins of all the
adenovirus serotypes. ARI and AR2 are auxiliary regions shown to be functionally
important in addition to the CR regions. NLS is the nuclear localisation signal.
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derived from this region (not including the pIX mRNA) which potentially encode 7
distinct proteins (perricaudet et al., 1979; Bos et al., 1981; Anderson et al., 1984;
Virtanen and Petterson, 1985; Lewis and Anderson, 1987; Takayesu et al., 1994, see
Fig. l.4.). A 2.2kb mRNA is predominant early in the infection and is translated to
produce the major E1b proteins 19K (176R) and 55K (496R), the E1b-55K protein
being translated from a reading frame overlapping that of the 19K protein, initiating at
a site within the 19K reading frame. Late in the infection a 1.0 kb mRNA accumulates,
due to differential splicing, encoding the 19K protein and an 84 residue protein (84R)
which comprises the N- and C- termini of the 55K protein. Also produced at late
times are three less abundant mRNAs of 0.86 kb, l.26 and l.31 kb producing various
products related to the major El b products.
The 19K protein is involved in a number of different aspects of the viral infection
including the protection of viral DNA, and in non-permissive cells, cellular
transformation (Chinnadurai, 1983; Subramanian et al., 1984; Stillman, 1986; White
and Stillman, 1987). The 19K protein also protects against programmed cell death
(apoptosis), induced as a result of the disruption of cell growth control pathways by
Ela (White et al., 1991; 1992; Rao et al., 1992; Debbas and White, 1993), and
cytolysis induced by the tumour necrosis factor-a (White et al., 1992). The 19K
protein may also have the ability to transactivate early viral genes (Yoshida et al.,
1987), although no transcritpional activity was found by Telling et al. (1994).
The 55K protein is also a multifunctional protein being involved in cellular
transformation (Barker and Berk, 1987; McLorie et al., 1991) and in the cytoplasmic
accumulation of late mRNAs, host cell shutoff and late protein synthesis during lytic
infection (Babiss and Ginsberg, 1984; Babiss et al., 1985; Pilder et al., 1986a,b;
Williams et al., 1986). The 55K protein derives some or all of its transforming activity
from its interaction with the tumour suppressor protein p53 (Samow et al., 1982; Kao
et al., 1990), inhibiting p53-mediated transcriptional activation (Yew and Berk, 1992).
Malette et al. (1983) demonstrated that the 55K protein is phosphorylated at three
distinct sites. Subsequent studies have shown that this
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Figure 1.4. The predicted Ad5 Elb products (reproduced from Takayesu et al.,
1994). The Elb mRNAs are depicted as lines, with the protein products indicated by
boxes. The 3 translation reading frames are shown by different shading. Also included
are the relevant nuc1eotides for translation start and stop sites and for splice start and
donors.
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phosphorylation is important in regulating 55K function, especially in transformation
(Teodoro et al., 1994). Although the El b-55K protein is multifunctional, the viral
replication and transforming functions are not divided into discrete functional
domains, as in the El A proteins, although the two functions can be separated by
mutational analysis (Yew et al., 1990). The function of the Elb-5SK protein in viral
replication is dealt with in detail in section 1.3. The functions of the minor El b
proteins has not yet been established.
As mentioned, both the Ela and the Elb proteins are involved in the immortalisation
and transformation of primary rodent cells infected with adenovirus, however an
extensive review of the literature reporting these functions is outside the scope of this
thesis. In addition to the above references the subject is reviewed by Horwitz et al.
(1990a) and Boulanger and Blair (1991).
1.1.4.3. The E2 region
The E2a region encodes a nuclear phosphoprotein with an apparent molecular weight
of 72 kDa (DBP) which is essential in viral DNA replication, binding non-specifically
to single-stranded and double-stranded DNA changing its structure (reviewed by Hay
and Russell, 1989; Stillman 1989; Horwitz et al., 1990a). It has also been
demonstrated to be involved in the regulation of transcription (Nevins and Winkler,
1980; Johnston et al., 1985), mRNA stability (Babich and Nevins, 1981), mRNA
processing (see section 1.2.4.) and in virus assembly (Nicolas et al., 1983).
The E2b region encodes two phosphoproteins; the 80 kDa pre-terminal protein (PTP)
and the 140 kDa DNA polymerase. The DNA polymerase catalyses the covalent
attachment of dCMP to a serine residue of the pTP protein in the presence of specific
DNA residues at the origin of replication. This acts as a novel priming mechanism for
DNA replication (reviewed by Hay and Russell, 1989; Stillman, 1989). Later in the
infection the protein is cleaved by the L3-23K viral protease to give the 55K form
(TP). The pTP/TP has a number of functions; it attaches the DNA to the nuclear
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matrix so allowing efficient transcription and possibly DNA replication (Shaack et al.,
1990; Fredman and Engler, 1993), it protects the DNA ends from exonuclease activity
(Dunsworth-Browne et al., 1980), it prevents the attachment of DNA termini binding
proteins which inhibit DNA replication (DeVries et al., 1989) and it ensures the
correct initiation site for DNA replication (reviewed by Hay and Russell, 1989;
Stillman, 1989).
The viral DNA polymerase is involved in the initiation and elongation of the nascent
DNA strand and is probably regulated by phosphorylation (reviewed by Hay and
Russell, 1989; Stillman, 1989).
1.1.4.4. The E3 region
The E3 region is not required for viral replication in tissue culture, being involved in
the virus' ability to circumvent immune surveillance in the natural host (reviewed by
Wold and Gooding, 1991). The AdS E3 region expresses approximately 9
alternatively spliced and polyadenylated mRNAs coding for at least seven proteins;
gp19K, 14.7K, 14.SK, 12.SK, 11.6K, 10.4K, and 6.7K. The 14.7K, 14.SK and the
10.4K proteins prevent tumour necrosis factor (TNF)-mediated cytolysis of the
infected cell. The 10.4K and 14.SK proteins also form a complex which down-
regulates the cell surface epidermal growth factor receptor levels although it is unclear
whether this function is linked to the proteins' ability to prevent TNF-mediated
cytolysis. Recently the 10.4K and 14.SK proteins have been associated with the down
regulation of the expression ofEla gene products, at the level of translation (Zhang et
al., 1991, 1994). This reduction in Ela gene expression is believed to cause a
reduction in cytolysis by adenovirus-specific T cells (Zhang et a!., 1991). The gp19K
binds to the major histocompatibility complex (MBC) class I antigens and retains them
in the endoplasmic reticulum so preventing their transport to the cell surface. This
failure of virus-infected cells to present MHC class I antigens, and consequently virus
peptide antigens, on their cell surface results in virus specific cytotoxic T-lymphocytes
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of the host immune system failing to recognise and lyse virus-infected cells. No
functions have yet been ascribed to the 12.5K, 1l.6K or the 6.7K proteins.
l.l.4.5. E4 region
The E4 region encodes potentially seven different polypeptides; E4-0RF1, ORF2,
ORF3, ORF3/4, ORF4, ORF6, and ORF6/7. The expression and functions of these
proteins will be discussed in detail in section 1.4.
l.l.4.6. Late transcription units
Late in the infection the major late promoter (MLP) is strongly activated to produce 5
families of late transcripts (LI-L5) by alternative splicing and polyadenylation. Every
RNA from the MLTU contains an identical 5' non-coding region of about 200
nucleotides called the tripartite leader which is believed to be important in the
translation of MLTU transcripts (see section l.2.6.). Most of the late proteins are
encoded by these MLTU transcripts although the minor late polypeptides IX and IVa2
are encoded elsewhere on the genome. The expression of the late products is
restricted to the period after viral DNA replication with the exception of L 1 mRNA
which is also expressed at low levels during the early phase. In addition to structural
proteins, the MLTU encodes a number of late, nonstructural proteins such as
'scaffolding' proteins, involved in virion assembly (e.g. LI-55K, L4-100K), and other
nonstructural proteins (e.g. L4-33K).
Three other late-specific transcription units are also active late in the infection, IVa2,
IX and E2-L. The IVa2 and IX transcription units are often referred to as the
intermediate transcription units as they are transcribed before late MLTU transcription,
at the end of the early phase. The IVa2 region encodes a 50K scaffolding protein
while region IX encodes a 12K virion protein. The activation of the E2-L promoter at
late times results in an increase in the levels of the viral proteins required for DNA
replication.
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l.l.4.7. VARNA
Adenoviruses also encode two distinct virus-associated (VA) RNAs; VA RNAI and
VA RNAn, each about 160 nucleotides long, transcribed by RNA pol III (Price and
Penman, 1972; Weinmann et al., 1974; Mathews, 1975; Pettersson and Philipson,
1975). These RNAs are initially synthesised early in the infection but production
increases at late times and has been shown to be necessary for efficient viral mRNA
translation (see section l.2.6.).
1.2. The regulation of gene expression in an adenovirus infection
1.2.1 Introduction
Adenovirus genes are expressed in a highly regulated fashion during the course of a
lytic infection. This regulation of gene expression results in a clearly defined temporal
expression pattern of the gene products so that they are produced at the required times
and at the required levels to ensure the efficient replication of the virus. This highly
regulated pattern of gene expression has been the subject of intense research, in an
attempt to elucidate the mechanisms by which the virus controls gene expression.
Studies have shown that adenovirus gene expression is regulated both at the level of
transcription and at post-transcriptional levels. Details of these studies are summarised
below.
1.2.2. Transcription initiation (reviewed by Akusjarvi, 1993)
Adenovirus genes are transcribed by two host cell, DNA-dependent RNA polymerases;
RNA polymerase II which transcribes both strands of the virus producing over 99% of
the viral mRNAs, and RNA polymerase III which transcribes the short, noncoding
RNAs known as VA RNA (sections 1.1.4.7. and l.2.6.2.). Transcription from the
adenovirus genome occurs from five early (Ela, Elb, E2, E3 and E4) and four late
(MLTU, IX, IVa2 and E2-L) promoters. These genes can be subdivided further into
immediate early (Eta), delayed early (Elb, E2, E3 and E4) and intermediate (IVa2,
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IX) genes according to when transcription initiates in the virus lytic cycle. This
temporal regulation is not fully understood but a number of viral proteins have been
demonstrated to be involved in the formation and the activity of transcription
complexes within adenovirus infected cells, so regulating gene expression. Firstly,
Ela transactivates Ela, Elb, E2, E3, E4, VA RNA and a limited number of cellular
promoters such as hsp70, c-fos, c-jun and proliferating cell nuclear antigen (peNA).
This transactivation has been shown to be due to a number of indirect mechanisms
(reviewed in section 1.1.4.1.). Secondly, both the Elb-19K and the Elb-55K proteins
also have the potential to regulate transcription during an adenovirus infection.
However, mutational analysis suggests that these proteins have no significant effects
on viral promoters during lytic infection (see sections 1.1.4.2. and 1.3), but their
involvement in promoter transactivation is probably limited to cellular transformation.
Thirdly, the multifunctionalE2-DBP protein has a specific repressive effect on the E4
promoter, although the mechanism by which this repression occurs is unclear.
Fourthly, two E4 proteins have been shown to be possibly important in transcriptional
regulation, the ORF617protein and the ORF4 protein. The ORF617protein can bind
to the host transcription factor E2F and induce the co-operative binding of this factor
to the two inverted E2F binding sites in the E2 early promoter so inducing E2
transcription (see section 1.4.2.7.). The importance of the E4-0RF4 protein in
transcription is not yet clear; initial experiments have shown it is involved in the
phosphorylation of a number of transcription factors, so regulating their activity (see
section 1.4.2.5.).
1.2.3. mRNA polyadenylation
The formation of a 3' end is an essential part in the biogenesis of a mature mRNA
molecule. In higher eukaryotes (and adenovirus) the 3' end is formed by
endonucleolytic cleavage of a pre-mRNA molecule followed by the addition of 200 to
250 adenylate residues to the new 3' OH terminus (reviewed by Proudfoot, 1991;
Wahler and Keller, 1992). Transcription units usually contain one poly(A) site but
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within the adenovirus genome there are a number of 'complex' transcription units
which produce multiple mRNAs from a single promoter by utilising alternative splice
sites and/or polyadenylation sites (Flint et al., 1986; Leff et al., 1986). The utilisation
of alternative polyadenylation signals can lead to the production of different gene
products and in the case of the adenovirus MLTU, can be temporally regulated.
The MLTU produces five 3' co-terminal families of mRNA, Ll through to L5, each
defined by a unique polyadenylation site (reviewed by Nevins and Chen-Kiang 1981;
Horwitz 1990a). By the temporally regulated utilisation of these sites the virus
regulates the production of the structural and nonstructural proteins encoded by this
region. Early in the infection Ll through to L3 RNAs are transcribed but the
utilisation of the L 1 site is three times that of the L3 site. This difference is even
higher in the cytoplasmic mRNA population indicating many of the L3 polyadenylation
events non-productive, resulting in mRNAs which fail to be exported from the nucleus.
After DNA replication all 5 polyadenylation sites are utilised with L3 RNA out
numbering the Ll RNA by 3:1 (Nevins and Darnell, 1978; Chow et al., 1979; Shaw
and Ziff, 1980; Akusjarvi and Persson, 1981; Nevins and Wilson, 1981). This change
in polyadenylation allows the virus to produce nonstructural proteins at early times and
structural proteins later in the infection from the same transcription unit.
Recently, Larsson et al. (1992) proposed that there is an intermediate step between the
early and late patterns of MLTU polyadenylation, with mRNAs from regions L 1 and
L4 being selectively over expressed as compared to the L2, L3, and L5 mRNAs. They
proposed that for the late pattern of polyadenylation to occur both viral DNA
replication and late protein synthesis are required.
Although a number of the sequences involved in poly(A) site selection have been
identified, along with some of the protein factors responsible for the recognition and
processing of poly(A) sites, the selection and regulation of alternative poly(A) sites is
not understood. Work carried out on the MLTU has suggested the involvement of the
RNA sequence of the poly(A) sites (DeZazzo et al., 1991; Prescott and Falck-
Pederson, 1992, 1994; Sittler et al., 1994), nuclear factors that either selectively
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enhance or depress the use of a specific poly(A} site and the relative levels of general
factors involved in poly(A} site usage (late in the infection the high levels of MLTU
precursor RNA may sequester the factors involved in the formation ofthe 3' termini of
mRNAs, so reducing their relative levels in the nucleus (Mann et al., 1993}).
The other adenovirus transcription unit which contains more than one polyadenylation
site is the E3 unit. This region contains multiple splice sites and two polyadenylation
sites, E3A and E3B, allowing the regulation of gene expression from this region by
alternative splicing and polyadenylation (reviewed by Wold and Gooding, 1991; Brady
eta!',1992).
1.2.4. RNA splicing
1.2.4.1. Introduction
Eukaryotic pre-mRNA splicing is one of the steps in the nuclear processing of
precursor RNA (pre-mRNA) into mature, translatable mRNA, common to almost all
eukaryotic transcripts. RNA splicing occurs within large, nuclear ribonucleoprotein
complexes, known as spliceosomes, where RNA sequences (introns) are precisely
excised from the pre-mRNA and the remaining RNA sequences (exons) are accurately
ligated together. The mechanism by which cells accomplish RNA splicing has been
studied intensively but is still not fully understood (reviewed by Smith et al., 1989;
Green, 1991).
All but one of the adenovirus primary transcripts (the exception is IX) are spliced, with
transcripts often being differentially spliced to produce more than one mRNA from a
given transcription unit. This alternative pre-mRNA splicing is not unique to
adenovirus, being found m a number of cellular transcription units (e.g. n-
tropomyosin, calcitoninlCGRP, immunoglobulin 1C light chain). In adenovirus, primary
transcripts can be differentially spliced by the use of either alternative 5' donor sites
with the same 3' acceptor site (e.g. Ela), or the same 5' donor site but alternative 3'
acceptor sites (e.g. MLTU), or a combination of both of these events as in E4.
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There are some notable differences between cellular and viral exon-intron
arrangements: first, adenoviral transcripts have relatively few introns, the maximum
discovered is six (the fibre mRNAs) and these introns are relatively short (probably
because the genetic material has to be kept as short as possible if it is to be compressed
into the viral capsid) while cellular genes commonly have numerous large introns;
second, the viral introns tend to occur in the 5' or 3' untranslated regions (UTRs) of the
transcripts while cellular genes generally have introns disrupting the actual coding
regions, although a number of cellular genes have now been found where differential
splicing only alters the UTRs, e.g. colony stimulating factor-1 RNA (Ladner et al.,
1987). The difference in the positioning of the introns is probably due to a subtle
difference between the function of viral intronslexons and those intronslexons found in
cellular genes. Eukaryotic cells differentially splice transcripts in order to: (a) localise
proteins to alternative cell compartments (e.g. immunoglobulin Il, neural cell adhesion
molecules, decay-acceleration factor, all of which are generated as either membrane-
bound or secreted forms (Alt et al., 1980; Caras et al., 1988; Gower et al., 1988»); (b)
modulate the function of a protein either by deleting a region (e.g. the Drosophila
transposase involved in the germ line-dependent transposition of P elements (Laski et
al., 1986)) or exchanging a segment(s) of a protein for an alternative sequence to
produce a isoform of the protein (e.g. troponin-T, pyruvate kinase (Medford et al.,
1984»; (c) produce proteins with completely different functions from the same
transcript (e.g. calcitonin and the calcitonin gene-related peptide (Amara et al., 1982»;
(d) regulate the efficiency of mRNA stability, transport and translation (e.g. CSF-l
(Ladner et al., 1987». In comparison, the majority of alternative splicing found in
adenovirus gene expression is involved in the production of several completely distinct
viral proteins from a single promoter (one exception is the El a transcription unit where
transcripts are differentially spliced to produce the two protein isoforms 243R and
289R).
Alternative splicing of most eukaryotic gene transcripts is regulated either in a
developmental or cell type specific manner, whilst the regulation of alternative splicing
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in an adenovirus lytic infection is regulated in a temporal manner, with the early
splicing pattern within a given transcription unit often being different from the pattern
late in the infection. Studies of the biochemistry of temporal splicing regulation in
adenovirus infections have drawn various conclusions as to the mechanisms for
splicing regulation (1.2.4.2. to 1.2.4.4.). The mechanisms identified can be arranged
into a number of groups but it must be noted that these are not mutually exclusive but
are probably highly interlinked.
1.2.4.2. Mechanism 1: Viral splicing factors
Recent work by Nordqvist et al. (1994) has demonstrated that adenovirus produces
functional analogues of some splicing factors so regulating the temporal splicing of
MLTU transcripts. All the MLTU mRNAs contain the tripartite leader sequence at
their 5' end consisting of exons 1,2 and 3. The splicing of this tripartite leader is
temporally regulated with an extra exon being included at early times to give a leader
of 1-2-i-3. Ohman et al. (1993) and Nordqvist et al. (1994) demonstrated that this
shift was due, in part at least, to two E4 proteins: ORF3-11K and the ORF6-34K.
These two E4 proteins had different effects on the splicing of the tripartite leader
sequences, with the E4 ORF3-11K protein facilitating 'i' leader exon inclusion while
the E4 ORF6-34K protein facilitated 'i' leader exon exclusion (Nordqvist et al., 1994).
They suggest that the ORF3-11K and ORF6-34K have antagonistic functions in the
modulation of RNA splicing comparable to that of the ASF/SF2 and hnRNP Alldistal
splicing factor (DSF) proteins respectively (Ge and Manley, 1990~Harper and Manley,
1991~ Krainer et al., 1991~ Mayeda and Krainer, 1992). It was also proposed that
these E4 proteins may actually be involved in splice site selection (Ohman et al., 1993;
Nordqvist et al., 1994). However the homology between the E4 proteins and the
ASF/SF2 and hnRNP A2IDSF proteins is poor, as are the homologies for ORF3-11K
and ORF6-34K with all the other known splicing factors, although the ORF6-34K
protein does have a weak homology to an RNA binding domain at its C-terminus
(Nordqvist et al., 1994).
22
Nordqvist et al. (1994) argued that it is excessive for the virus to produce two proteins
just to regulate the expression of the 'i' leader exon, which only encodes a non-essential
(in tissue culture) 16K protein. They subsequently demonstrated the possible
involvement of the E4 proteins in other splicing events such as the early-to-late shift in
splicing of El b region RNA and the splicing of a chimeric p-globin transcript in vitro.
This would suggest a more general relevance for the E4 ORF3-11K and E4 ORF6-
34K proteins in the processing of viral and cellular mRNA.
Klessig and Chow (1980), Anderson and Klessig (1984) and Ross and Ziff (1992) all
implicated another viral protein in the regulation of splicing: the DBP protein. They
demonstrated the importance of a functional DBP in the correct splicing of fibre and
E4 mRNAs in monkey cells. Ross and Ziff (1992), working with E4 transcripts,
proposed that DBP interacts with cellular components, overcoming a factor which
restricts splicing to the early pattern, allowing the late pattern of RNA splicing. Ross
and Ziff (1994) also observed other defects in the processing of MLTU RNAs in
abortive infections of monkey cells, where the DBP does not function correctly.
However they could not ascertain whether the defects were at the level of splicing or
RNA transport. They also noted that the complex phenotype observed may be due to
secondary effects of the DBP, as the Elb-55K/E4 ORF6-34K heterodimer (see section
1.3) is not believed to be produced efficiently due to aberrant processing of the El b
and E4 transcripts (see section 1.4.1.).
1.2.4.3. Mechanism 2: cis-acting sequences
The actual sequence of the primary transcript has been shown to be very important in
regulating the temporal shift in splicing. For example, L 1 pre-mRNAs are alternatively
spliced in a temporal manner with a single 5' donor site spliced to two alternative 3'
acceptor sites. Early in the infection the 52/55K mRNA (proximal 3' splice site used)
is predominant, while at late times the IlIa mRNA (distal 3' splice site used) is
predominant (Chow et al., 1979; Akusjarvi and Persson, 1981; Nevins and Wilson,
1981). It has been shown that the lIla 3' splice site is a less efficient site than the
23
52/55K 3' splice site having a poor polypyrimidine tract compared to that found in the
52/55K 3' splice site (Kreivi et al., 1991) This, combined with its distal position in the
transcript, results in its inefficient use at early times. It has been hypothesised that the
virus produces a novel splicing factor (or modifies at host splicing factor) at late times
(mechanism I) which enhances the usage of the Ilia 3' splice site. This, combined with
a virus induced repression of 52/55K splicing, may lead to the production of IlIa
mRNA at late times (Kreivi and Akusjarvi, 1994).
Another example of the importance of the transcript sequence in the regulation of
splicing is found in the Ela region (section 1.1.4.1.). The lOS and lIS mRNAs are
produced only at low levels because of an unusually long distance (>50 nucleotides as
compared to the usual 18 to 40 nuc1eotides) between the branch point and the 3' splice
site in the first intron (Gattoni et al., 1988; Chebli et al., 1989). Chebli et al. (1989)
demonstrated that a cis-acting element, a hairpin structure present between the branch
point and the 3' splice site, is important in allowing the excision of this intron. It has
been hypothesised that this hairpin has the effect of shortening the effective distance
between the branch point and the 3' splice site allowing the excision of the intron,
albeit inefficiently. This inefficient splicing ensures only a low level of the lOS and 11S
mRNAs are made, so regulating gene expression.
1.2.4.4. Mechanism 3: General splicing factors
Studies of the Ela transcription unit (1.1.4.1.) have suggested that the levels of
ubiquitous splicing factors may be crucial in the temporal regulation of adenovirus
splicing. The onset of production of the 9S mRNA at late times has been shown to be
due, in part, to a change in levels of general splicing factors (Gattoni et al., 1991;
Larsson et aI., 1991). Also in vitro experiments have demonstrated that the
concentration of splicing factors can be critical in splice site choice (Ge and Manley,
1990; Krainer et al., 1990). Larsson et al. (1991) hypothesised that during the late
phase of the infection many of the general splicing factors are efficiently sequestered by
the high concentration of MLTU transcripts, so heightening the competition between
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splice sites for factors and favouring the splicing of efficient sites. This would result in
a different pattern of mRNAs early and late in the infection.
The results of experiments carried out by Adami and Babiss (1991) indicated that
global changes in trans-acting splicing factors cannot explain totally the observed
temporal changes in Ad splicing. They staggered a co-infection of two distinguishable
viral genomes and observed that both early and late genomes could exist
simultaneously in the nucleus; El b mRNA was spliced in both early and late patterns
depending on its genome of origin, indicating that neither genome had influence on the
other. They also demonstrated that the role of potential cis-elements is not as simple
as thought; they introduced an SV40 gene, which displayed no regulated splicing
during an SV40 infection or SV40/adenovirus co-infection of COS cells, into the
adenovirus genome. On infection with the recombinant virus the splicing of the RNA
from the SV40 gene was regulated. A possible hypothesis is that RNA processing in
adenovirus-infected cells is linked to the state of the DNA template or to the DNA
being present within a distinct nuclear subcompartment, with trans-acting splicing
factors only having a local effect. Experiments exploring the compartmentalisation of
the adenovirus genome within the nucleus have indicated that it is closely associated
with the nuclear matrix and that this association is important for viral transcription and
replication (Bodnar et al., 1989, Shaack et al., 1990). During the late phase of the
infection, adenovirus DNA is found within viral inclusion bodies or replication
factories, which are believed to be the sites of DNA replication, late transcription and
possibly RNA processing (Moyne et al., 1978~ Zhonghe et al., 1986~ Walton et al.,
1989~ Moen et al., 1990~ Jimenez-Garcia and Spector, 1993). This would imply that
viral RNA production and processing occur in discrete centres in the adenovirus-
infected nucleus, each of which may present different microenvironments for gene
expression. This may explain how RNA transcribed from two genomes in the same
cell can be processed differently. Work exploring RNA metabolism in uninfected cells
has also suggested that RNA processing and transport occurs in discrete sites on the
nuclear matrix (Xing et al., 1993~Carter et al., 1993~Zachar et al., 1993~ reviewed by
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Rosbash and Singer, 1993~ Xing and Lawrence, 1993) giving extra weight to the
hypothesis that the product of individual viral genomes can be processed differently
according to their microenviroment. Alternatively, the nature of the DNA template
may affect the processing of its transcripts: progeny DNA may be transcribed
differently from input virion DNA late in the infection, with possibly different
elongation rates, pausing or even different transcriptional machinery. This change in
transcription may then affect splice site choice since it has been shown that RNA
transcription and processing are closely linked (Sisodia et al., 1987; Beyer and Osheim,
1988~Neuberger and Williams, 1988~Moen et al., 1990~ Jimenez-Garcia and Spector,
1993~ Bridge et al., 1993a~ reviewed by Xing and Lawrence, 1993~ Rosbash and
Singer, 1993).
1.2.4.5. Summary
The regulation of the alternative splicing found in adenovirus-infected cells is a
complex process which we are only just beginning to comprehend. The three
mechanisms of regulation described above are not mutually exclusive but are highly
interrelated. The balance of these regulatory systems results in the production of
precisely spliced viral mRNAs at the required time during the infection and at the
required level.
1.2.5. mRNA export
To function, the cell has to traffic macromolecules in and out of the nucleus in an
ordered, regulated fashion. Compared to the transport of proteins into the nucleus,
very little is known about the mechanism of RNA export from the nucleus. The term
'mRNA export' encompasses two distinct steps: firstly the mRNA must leave its site of
production on the nuclear matrix and travel through the nuclear subcompartments to
the nuclear periphery. Secondly the RNA must cross the nuclear membrane and enter
the cytoplasmic pool of actively translating mRNAs.
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Alterations in this pathway of RNA transport can result in the altered accumulation of
cytoplasmic mRNA and so a different pattern of gene expression. This step in gene
expression is targeted by certain viruses when altering the gene expression in the
infected cell; examples are human immuno-deficiency virus type 1 (HIV-I), influenza
A virus and adenovirus. The HIV -1 Rev protein mediates the stabilisation and the
nuclear export of un spliced and partially spliced viral pre-mRNAs (reviewed by Chang
and Sharp, 1990~ Krug, 1993). Early in the replication of HIV only spliced viral
mRNAs are exported to the cytoplasm. One of these fully spliced RNAs encodes the
Rev protein which then allows the export of partially and unspliced messages to the
cytoplasm, which encode the structural proteins of the virus. It is believed that the N-
terminal of the Rev protein interacts with the cis-acting Rev response element (RRE)
found in a major intron sequence of the HIV transcript while a domain in the C-
terminal interacts with the transport machinery, facilitating the export of unspliced
messages. The NS 1 protein of influenza virus has been shown to be involved in the
inhibition of splicing and a general block in the transport of mRNA from the nucleus, .
but as yet it is unclear as to how it functions or what role it plays in the influenza
infection (Alonso-Caplen et al., 1992~Fortes et al., 1994; reviewed by Krug, 1993).
Adenovirus regulates RNA transport via the Elb-55K and E4 ORF6-34K proteins.
For a detailed discussion of the function of these two proteins see sections 1.3. and
1.4.2.3.
1.2.6. Translation
1.2.6.1 Introduction
The late phase of an adenovirus infection is marked by the inhibition of cellular protein
synthesis, with the preferential translation of late viral mRNAs (late viral mRNAs
constitute about 20% of the mRNA found in the cytoplasm but about 90-95% of the
mRNAs found in polysomes (Tal et al., 1975). This virus-induced decrease in cellular
protein synthesis is believed to be due to an inhibition of cellular mRNA translation.
The concurrent decrease in cellular mRNA export from the nucleus is thought to play
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only a minimal role in inhibiting cellular protein synthesis for three reasons. First,
Babich et al. (1983) observed that the shut-off of protein synthesis from selected genes
was complete when the block in mRNA transport was only minimal early in the late
phase. Second, Moore et al. (1987) noticed that mRNAs which escape the block in
transport, such as hsp70 and hsx70, still fail to be translated indicating a block to
protein synthesis at the level of mRNA translation. Third, some drugs prevent the
adenovirus shut-off of translation without affecting the block in the transport of host
mRNAs (Huang and Schneider, 1990).
Other possible mechanisms have been proposed for the shutoff of protein synthesis
such as the degradation of cellular mRNA, the modification of cellular mRNA so
rendering it untranslatable or the swamping of the translation systems with viral
transcripts so preventing the translation of cellular mRNA. These have all been
discounted in the adenovirus system as host mRNAs remain in the cytoplasm through
the late phase of the infection in a translatable state (Thimmappaya et al., 1982). Also
Tal et al. (1975) demonstrated that late viral mRNAs only constitute about 20% of the
total cytoplasmic pool of mRNAs, not enough to prevent the almost 100% shutoff of
host translation observed by a simple competition mechanism.
So how does adenovirus achieve preferential translation of viral mRNAs in the late
phase? Evidence has accumulated over the past few years that adenovirus regulates
translation by at least three different mechanisms mediated by the VAl RNA, the L4-
lOOK protein, and the MLTU tripartite leader. It is unclear whether these mechanisms
represent an integrated effort by the virus to modulate translation or whether they are
distinct mechanisms that act separately.
1.2.6.2. VAl RNA (reviewed by Mathews and Shenk, 1991)
In the absence of VAl RNA there is little or no translation of viral or cellular mRNAs
within the cell (Thimmappaya et al., 1982). This inhibition is due to the inactivation of
the initiation factor eIF-2 through the phosphorylation of its a-subunit (Reichel et al.,
1985' Schneider et al., 1985) by the interferon-induced protein kinase, DAI (dsRNA,
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activated inhibitor). DAI is activated by the presence of dsRNA which results from the
symmetrical transcription of the viral genome late in the infection (Moran and
Mathews, 1988). VAl RNA prevents the phosphorylation of eIF-2a. by directly
binding to DAI so inhibiting its function (Katze et al., 1987~ Kostura and Mathews,
1989).
O'Malley et al. (1989) also proposed that VAI RNA is important in the selective
translation of late viral mRNA late in the viral infection. They observed that late in the
infection about 30% of cellular eIF-2 is phosphorylated, and so inactive. It is known
that this level of phosphorylation completely inhibits protein synthesis in uninfected
cells but in infected cells viral late mRNAs are still translated. This, and other
observations, led O'Malley et al. to propose that viral and host mRNAs may be
segregated into functionally distinct compartments in the late infected cell. Translation
of host mRNAs would be inhibited because ofDAI activity, but viral mRNAs would be
still translated because a specific association between these RNAs and VAl RNA
(Mathews, 1980) causes inhibition of the action of the DAI kinase in the local vicinity
of the viral late mRNA.
1.2.6.3. L4-100K
The L4-100K protein is a non-structural protein expressed late in the infection. It is
essential for in the construction of virus particles (Cepco and Sharp, 1983), but also
has a role in the regulation of translation. The L4-100K protein is found in close
association with mRNA (Adam and Dreyfuss, 1987) and is believed to be involved in
the initiation of translation of late viral mRNAs (Hayes et al., 1990; Riley and Flint,
1993). The specificity of this function of the lOOK protein is not yet clear, nor is the
mechanism by which it acts.
1.2.6.4. The MLTU tripartite leader (reviewed by Zhang and Schneider, 1993)
Late in the infection the majority of viral mRNAs are transcribed from the MLTU and
therefore possess an identical 200 nucleotide long 5' UTR known as the tripartite
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leader (Berget et al., 1977). This leader sequence is required for the translation of
MLTU transcripts late in the infection (Logan and Shenk, 1984~Berkner and Sharp,
1985), when most other translation events have been inhibited.
In an uninfected cell, the 5' end of an mRNA is unwound by the eIF-4F cap-dependent
helicase, so allowing translation (reviewed by Rhoads, 1988). However in the late
phase of an adenovirus infection it is believed that this action of eIF-4F is inhibited by
an alteration in its phosphorylation state, possibly by the activity of the DAI kinase
(Huang and Schneider, 1991). This would result in the inhibition of translation of any
mRNAs with secondary structures in their 5' ends which would probably include most
of the cellular mRNAs. However, the 5' tripartite leader of the MLTU mRNAs lacks
any secondary structure (Dolph et al., 1990) and so these mRNAs are still translated
efficiently in the absence of eIF-4F helicase activity.
Adenovirus is not alone in disabling the eIF-4F helicase to achieve selective translation
of its proteins. Polio virus is known to degrade one of the eIF-4F components so
rendering it inactive. It circumvents the requirement for eIF-4F in the translation of its
mRNAs by binding ribosomes internally on the RNA (Sonenberg, 1987~ Pelletier and
Sonenberg, 1988).
1.3. Elb-55K and cytoplasmic viral mRNA accumulation
1.3.1. Introduction
Two adenoviral proteins are involved in the accumulation of viral mRNAs in the
cytoplasm of infected cells, the Elb-55K and E4 ORF6-34K proteins. Co-
immunoprecipitation studies with the Elb-55K protein have found it physically
associated with the E4 ORF6-34K protein within infected cells (Samow et al., 1984)
although unassociated populations of both proteins have also been identified (see
below). Genetic evidence that this complex acts as a functional unit has also been
found since it was observed that E4 ORF6-34K, Elb-55K and E4 ORF6-34KlElb-
55K double mutants all displayed similar phenotypes (Halbert et al., 1985~Cutt et al.,
30
1987~ Samulski et al., 1988~ Bridge and Ketner, 1990). Thus in the following
discussion ofE1b-55K it is presumed that the E4 ORF6-34K is also required for the
functions described.
It is believed that the E1b-55K1E4 ORF6-34K heterodimer facilitates the cytoplasmic
accumulation of viral mRNAs in the cytoplasm of infected cells by altering the RNA
transport machinery, although it is conceivable that it may function at the level of RNA
stability. Discussed in the following section are the current models for RNA transport,
El b function and the evidence for them. A detailed discussion of the function of the
E4 ORF6-34K protein can be found in section l.4.2.3.
1.3.2. RNA transport models
It is thought that in the uninfected cell, RNA, transcribed from decondensed stretches
of chromatin, travels on defined paths through RNA processing sites on route to the
cytoplasm. The basis for this model of RNA transport comes from several
observations. Jackson and Cook (1985), Zeitlin et al. (1989) and Ciejek et al. (1983)
demonstrated the close association of mRNA transcription and subsequent maturation
steps with the nuclear matrix while Ciejek et al. (1982) observed that pre-mRNA, in
several stages of maturation, is also associated with the nuclear matrix. This suggests
that the production of mature mRNA occurs in association with the nuclear matrix,
probably in a controlled, regulated manner as opposed to pre-mRNAs being processed
while diffusing freely in the nucleoplasm. This association with the nuclear matrix is
believed to be due to the interactions of the RNA exons and ribonucleosome proteins
(reviewed by Agutter, 1991) while excised introns are free to diffuse within the nucleus
(Zeitlin et al., 1987~Xing et al., 1993). Poly(A)+ RNA (believed to represent most of
the nuclear pre-mRNA) has been shown to accumulate within 20-50 'transcript
domains' that coincide with the location of a number of proteins involved in splicing
(Carter et al., 1991, 1993~ Xing and Lawrence, 1991) including the spliceosome
assembly factor, SC-35 (Fu and Maniatis, 1990). It is believed that these 'transcript
domains' are also associated with active transcription (reviewed by Spector, 1993).
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Beyer and Osheim (1988) and LeMaire and Thummel (1990) also reported the close
association of transcription and RNA processing. Elaborate in situ hybridisation
experiments, targeting certain RNA species, have confirmed the above observations
with RNA species being found on defined tracks within the nucleus (Lawrence et aI.,
1989; Huang and Spector, 1991; Xing et al., 1993), suggesting that pre-mRNAs are
constrained from free diffusion, possibly due to the interaction of the RNA with the
nuclear matrix. These tracks originate from sites of transcription and contain both
intronic and exonic sequences at the end proximal to the site of transcription but only
exonic sequences at the distal end (Xing et aI., 1993). Xing et al. (1993) also
observed that these tracks co-localised with the 'transcript domains' and proposed that
splicing occurs within these tracks in a spatially ordered manner. However, only a few
of the tracks observed extend from the site of transcription to the nuclear membrane,
possibly because an mRNA may exit the nucleus very rapidly after processing is
completed, so making it undetectable by the methods employed.
It should be noted however that an alternative model has been proposed by Zachar et
al. (1993) (reviewed by Kramer et al., 1994). Zachar et al. (1993) observed that
specific transcripts moved away from their parental gene to the nuclear surface, in a
pattern indicative of simple diffusion. In their model they suggest that RNA processing
factors also interact with the RNA by simple diffusion within a nuclear
subcompartment. They explain the tracks observed in mammalian cells, believed to be
complete RNAs undergoing processing, as nascent transcripts still intimately
associated with their corresponding gene. Co-transcriptional splicing evidence (Beyer
and Osheim, 1988; LeMaire and Thummel, 1990) explained the presence of intronic
sequences only in the end of the transcript proximal to the site of transcription, as the
3' end of the transcript could still be colinear with the parental gene. Experiments by
Jackson et al. (1993) and Wansink et al. (1993) also argue that nascent RNA is not
associated with the 20 to 50 'transcript domains' but is in fact located in hundreds of
domains though out the nucleus. This lends support to the idea that RNA processing
occurs outside of the transcript domains, and that the transcript domains are simply
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storage centres for the splicing machinery. It is not clear, however, if this simple
diffusion model, derived from data obtained largely in Drosophila cells containing
polytene chromosomes, can be applied to diploid mammalian cells or whether the
mechanism of RNA transport is different in these cells.
As yet it is unclear which, if either, model is correct (for an extensive discussion of the
subject see Rosbash and Singer, 1993~ Spector, 1993~ Xing and Lawrence, 1993~
Kramer et al., 1994).
Our understanding of the translocation of mRNA across the nuclear membrane is also
limited. Electron microscopy studies of nuclear pore complexes have shown that
rnRNA, associated with hnRNP proteins, exits the nucleus via the nuclear pore
complexes (NPCs), (Dworetzky and Feldherr, 1988: Mehlin et aI, 1992). The
RNNhnRNP complex associates with fibrous material extending from a pore and then
passes through the pore in a 5' to 3' orientation (Mehlin et al., 1992). These
observations were confirmed by NPC inhibition studies where anti-pore proteins and
wheat germ agglutinin, which inhibit the protein transport function of the NPC,
inhibited RNA export (Featherstone et al., 1988; Bataille et al., 1990; Neuman de
Vegvar and Dahlberg, 1990~ Dargemont and Kuhn, 1992~ Michaud and Goldfarb,
1992).
The mechanisms that regulate these steps in the uninfected cell are still poorly
understood. RNA export is known to be a saturable and energy-dependent process
implying the involvement of proteins as carriers of the RNA. (Zasloff, 1983;
Dworetzky and Feldherr, 1988~ Khanna-Gupta and Ware, 1989; Bataille et al., 1990;
Dargemont and Kuhn, 1992). Using competition experiments, Jarmolowski et al.
(1994) suggested that the export of different classes of RNAs (i.e. RNAs from RNA
pol I (rRNAs), RNA pol II (mRNAs and snRNAs) and RNA pol III (tRNAs and SS
rRNA» is mediated by specific rather than common factors, at least for some of the
steps in RNA export. The identity of these factors is unclear, but it is known that
within the nucleus RNA pol II transcripts are associated with a number of nuclear
proteins, collectively known as the heterogeneous nuclear ribonucleoprotein (hnRNP)
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proteins (reviewed by Dreyfuss et al., 1993). Further work by Pifiol-Roma and
Dreyfuss (1991, 1992) has suggested that these hnRNP proteins are important in
mediating RNA transport as a number of them are associated with poly(A) transcripts
both in the nucleus and in the cytoplasm (reviewed by Pifiol-Roma and Dreyfuss,
1993).
The fact that most primary transcripts require post-transcriptional processing to
achieve their functional form means that there are many RNA molecules in the nucleus
that, because of incomplete processing, must not exit to the cytoplasm. This implies
the existence of signals which allow the export machinery to discriminate between
mature and immature transcripts. It seems unlikely that a common signal sequence lies
in the primary sequence, especially for mRNAs, as different mRNAs display no
obvious sequence homology. It has been proposed that signals for RNA export are
located at the termini of RNA pol II transcripts; Hamm and Mattaj (1990) and
Dargemont and Kuhn (1992) demonstrated that the 5' mono-methylated cap structure
of RNA pol II transcripts was involved in RNA export. This work was later confirmed
when a 80K cap-binding protein was isolated, and found to be involved in RNA export
(Izaurradle et al., 1992). However the 5' m7G cap structure is not the sole
requirement for export; working on the RNA pol II transcript of U3 RNA, Terns and
Dahlberg (1994) demonstrated that RNAs could possess a 5' m7G cap structure but
not be exported from the nucleus. This would suggest either the presence of additional
signals and/or that the localisation of the transcript within the nucleus is important.
Working with histone RNA, Eckner et al. (1991) identified another positive signal
important in RNA transport; the formation of the 3' end of the transcript. However it
is unclear whether this processing is important in all RNA export events or specific to
histone RNA export. Another study, investigating SS rRNA, has shown the
importance of secondary structures in nuclear export (Allison et al., 1993). The
importance of secondary structures to RNA export may not be unique to 5S rRNA as
there is growing evidence that RNA structures such as helices, loops, bulges,
mismatches and pseudoknots are key elements in protein-RNA interactions (reviewed
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by Draper, 1989). He et al. (1994) have also demonstrated the importance of the Alu
sequence present in some mRNAs in mRNA transport, although the key element here
may still be the secondary structure of this region.
Evidence also exists for the presence of negative signals in RNA transport. Intact
introns present in the RNA molecule have been shown to act as nuclear retention
signals, blocking efficient RNA export (Ciejek et a!., 1982; Chang and Sharp, 1989;
Legrain and Rosbash, 1989; Hamm and Mattaj, 1990). It has been proposed that there
is a competition effect between the proteins involved in intron identification and the
transport machinery. Changes in the efficiency of splice site recognition (be it cis-
acting elements or trans-acting factors) or changes in the efficiency of the transport
machinery can potentially alter the levels of partially or even unspliced messages in the
cytoplasm. It is unclear whether intron recognition and nuclear sequestration
necessarily guarantee that a pre-mRNA will be incorporated into a complex committed
to splicing or whether further nuclear interactions have to take place. However it is
clear that the formation of splicing complexes on the pre-mRNA prevents the export of
any nascent mRNAs that retain intronic sequences.
For a complete discussion of the regulation of RNA export see Izaurralde and Mattaj
(1992), Hanover, (1992), Miller and Hanover (1992) and Elliot et al (1994).
1.3.3. The Elb-55K protein - subcellular localisation
The Elb-55K protein is a phosphoprotein initially expressed early in the infection.
Studies have found that the Elb-55K protein is localised primarily in the nucleus of
infected cells, although low levels can be detected in the cytoplasm (Samow et al.,
1982; Rowe et a!., 1983; Smiley et al., 1990; Omelles and Shenk, 1991). Using
subnuclear fractionation and immunofluoresence, Smiley et al. (1990) attempted to
locate precisely the intranuclear location ofElb-55K. Two distinct populations of the
Elb protein were found within the nucleus: 30-50% of the total nuclear Elb-55K was
released on RNase A digestion of the nuclei while the rest of the Elb-55K protein
localised in the pore complex-lamina fraction. Within the pore complex-lamina, both
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free Elb-55K and Elb-55K1E4 ORF6-34K complex were found, but it was noted that
neither form of the protein appeared to form a stable or intimate association with the
pore complexes. However, Ornelles and Shenk (1991), employing immunofluoresence
and immuno-electromicroscopy to localise Elb-55K, found that the E4 ORF6-34K
protein was required for association of the Elb-55K1E4 ORF6-34K complex with
nuclear viral inclusion bodies, believed to be the sites of transcription and DNA
replication (Moyne et al., 1978; Zhonghe et al., 1986; Walton et al., 1989; Moen et
al., 1990; Jimenez-Garcia and Spector, 1993). They found the Elb-55K protein in five
different sites within the cell. In the cytoplasm it was found in a diffuse, reticular
pattern and also in association with a fibrous body adjacent to the nucleus. In the
nucleus it was found in a diffuse, granular pattern excluded from the nucleolus, in
randomly distributed, discrete spicules and also associated with viral inclusion bodies.
When the E4 ORF6-34K protein was mutated, the E1b-55K protein failed to
associated efficiently with the viral inclusion bodies, while the other populations of
E1b-55K were apparently unaffected. Other studies have demonstrated that such E4
mutants display defects in mRNA metabolism (Halbert et al., 1985; Cutt et al., 1987;
Samulski et al., 1988; Bridge and Ketner, 1990) suggesting that these inclusion bodies
are the probable site of action of the E1b-55K protein, although the involvement of
'free' Elb-55K protein in mRNA metabolism cannot be completely discounted. The
experiments of Orne lIes and Shenk (1991) also indicated that a sequence within the E4
ORF6-34K protein or within the complex, but not in Elb-55K alone, is required for
the association with the viral inclusion bodies.
The large number of intracellular sites found in these studies have also been observed
by biochemical fractionation (Rowe et al., 1983) and may reflect different functional
forms of the protein (i.e. E1b-55K/p53, E1b-55K1E4 ORF6-34K etc.). Cutt et al.
(1987) noted that the formation of the Elb-55K1E4 ORF6-34K complex was not co-
translational, with complex formation taking a number of hours. This could explain
why both free E1b-S5K and E1b-55K1E4 ORF6-34K complex are found within the
cell.
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1.3.4. The elucidation of Elb-55K function
When the Elb-55K gene was mutated by Babiss and Ginsberg (1984) and Logan et al.
(1984), an impaired growth phenotype in HeLa cells was observed with virus yields
reduced to 10% or less of wild type. More detailed studies demonstrated that the El b-
55K protein was required for the cytoplasmic accumulation of viral late mRNA (the
early mRNAs studied showed no dependence on the Elb-55K protein) and for the
inhibition of the cytoplasmic accumulation of host cell mRNAs during a lytic infection
(Babiss and Ginsberg, 1984~Babiss et al., 1985~Pilder et al., 1986a,b~Williams et al.,
1986). This observed decrease was not due to a defect in late RNA transcription as
the transcription rate across the MLTU early in the late phase of the mutant infection
was unchanged while there was a substantial decrease in cytoplasmic MLTU mRNA
accumulation (Babiss et aI., 1985; Pilder et al., 1986a,b). Later in the infection the
transcription rate across the MLTV did decrease in the mutant infection as compared
to wild type, probably due to secondary effects of altered gene expression. Nuclear
post-transcriptional RNA processing events, such as splicing and polyadenylation,
were also not the cause of this defect as the processing of the MLTV RNA was normal
in the Elb mutant infection (Babiss et al., 1985; Pilder et aI., 1986a,b; Williams et al.,
1986). These results suggested that neither the transcription nor post-transcriptional
processing of late viral mRNAs was the primary site of Elb-55K action, but it was
concluded that the Elb-55K protein acted at the level ofmRNA transport or possibly
RNA stabilisation post-maturation.
Cytoplasmic accumulation of mRNAs is dependent on two factors, the rate of nuclear
export ofmRNAs and the stability ofmRNAs in the cytoplasm. Pilder et al. (1986b)
observed some variation in cytoplasmic stability of L5 mRNA late in the infection but
concluded that this was probably a secondary effect of the Elb-55K mutation because
no difference was observed in L5 mRNA cytoplasmic stability early in the late phase
while at the same time there was still a substantial decrease in L5 mRNA cytoplasmic
accumulation. Williams et al. (1986) also explored the effect of Elb on late mRNA
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cytoplasmic stability. They found some reduction in hexon rnRNA cytoplasmic
stability (no time post-infection was given) but still this reduction could not account
for the level of hexon mRNA reduction observed in the cytoplasm. To conclude, it
would appear that the primary site ofElb-55K action is the transport ofmRNA from
the nucleus of the infected cell while the differences observed in late mRNA
transcription and cytoplasmic stability in Elb-55K mutant infections are secondary
effects of the mutations.
The Elb-55K protein also prevents the continued accumulation of cellular mRNAs in
the cytoplasm (Babiss and Ginsberg, 1984; Babiss et al., 1985; Pilder et al., 1986a,b;
Williams et al., 1986). This effect is coincident with the inhibition of host protein
synthesis late in the infection but is not thought to be the primary cause, as cellular
mRNAs remain intact in the cytoplasm throughout the late phase but are not
translated. This change of synthetic activity in the infected cell is believed to be due
primarily to a block at the level of translation of host cell mRNAs (see section l.2.6.).
The block to the accumulation of cellular mRNA in the cytoplasm is thought to be due
to an effect on mRNA transport or mRNA cytoplasmic stability as cellular RNA
transcription occurs as normal (Babiss et aI., 1985; Pilder et al., 1986a,b). It is unclear
if the reciprocal effects of El b-55K on viral and cellular mRNA accumulation in the
cytoplasm are the result of two distinct functions of the protein or whether Elb-55K
directly affects one process and as a result indirectly affects the other (see below).
However it appears that this block in cellular mRNA accumulation in the cytoplasm is
selective as a number of distinct cellular species do continue to accumulate in the
cytoplasm of infected cells, i.e. p-tubulin, hsp70 (Moore et al., 1987). Moore et al.
(1987) proposed that the process of transcriptional induction allowed the resulting
mRNA to escape the viral block to cytoplasmic accumulation.
The exact site of Elb-55K action on the transport pathway of RNA is unknown.
Leppard and Shenk (1989) examined at which step in the RNA transport pathway the
Elb-55K protein acted by exploiting the cold-sensitivity ofa Elb-55K mutant (d1338).
At 32°C the phenotype of the Elb-55K mutation is exacerbated and the RNA
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transport pathway is slowed down as compared to the same infection at 37 °C. This
allowed them to study RNA metabolism in infected cells. Cells were pulse labelled in
vivo, the label chased for varying periods and then fractionated into one cytoplasmic
and four nuclear fractions (nuclear membrane, DNase I-soluble, salt soluble and
nuclear matrix). The fractions were subsequently probed for various late RNA species.
Newly synthesised late RNA was first found in association with the nuclear matrix
(where it was transcribed), then seen to accumulate in the DNase-I and salt soluble
fractions before exiting the nucleus through the nuclear membrane and entering the
cytoplasmic fraction. In the Elb-55K mutant infection, late viral mRNAs left the
nuclear matrix fraction and accumulated in the nuclear membrane fraction more slowly
and less efficiently than late viral mRNAs from a wild type virus. These transcripts
also failed to accumulate in the DNase-I soluble fraction of the nucleus indicating they
were degraded before or when reaching this compartment. Early viral mRNAs
displayed no difference in accumulation at any step between the mutant and wild type
virus infections. From these observations it was concluded that the Elb-55K protein
functions at an early step in the transport pathway for late mRNAs, possibly at the step
of RNA release from the nuclear matrix. This Elb-55K functional data correlates well
with the localisation studies carried out by Smiley et al. (1990) and Ornelles and Shenk
(1991).
It has also been noted that not all viral mRNAs are dependent on the Elb-55K protein
for optimal cytoplasmic accumulation. Early viral mRNAs are not dependent on the
Elb-55K protein for cytoplasmic accumulation (Babiss and Ginsberg, 1984~ Pilder et
al., 1986a, 1986b~ Williams et al., 1986~ Leppard, 1993) including the Ll 52/55K
mRNA expressed early in the infection. Only RNAs expressed late in the infection
have any dependence on EI b-55K for optimal cytoplasmic accumulation, including the
Ll 52/55K mRNA expressed late in the infection. Initial studies of late mRNAs
focused on the MLTU mRNAs but Leppard (1993) demonstrated that mRNAs from
the other late promoters (E2-L, IVa2 and IX) are also dependent on the Elb-55K
protein for optimal cytoplasmic accumulation although to varying degrees. From the
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data accumulated by Leppard (1993) it appears that the MLTU transcripts are not
equally dependent on the Elb-55K protein for optimal accumulation, with the longest
mRNA of a 3'-coterminal family displaying the greatest dependence.
Some non-adenovirus transcripts are also dependent on Elb-55K for optimal
cytoplasmic accumulation. Samulski and Shenk (1988) demonstrated that the El b-
55K protein and E4 ORF6-34K protein were required for the optimal cytoplasmic
accumulation of adeno-associated virus (AAV) - derived transcripts.
To summarise, the Elb-55K product (probably in conjunction with the E4 ORF6-34K
protein) acts post-transcriptionally on RNA metabolism, facilitating the transport and
cytoplasmic accumulation of late viral mRNAs to varying degrees. Conversely,
cellular mRNAs are prevented from accumulating in the cytoplasm of infected cells by
Elb-55K late in the infection. Elb-55K could potentially function at any of the steps
in RNA transport but function and localisation studies have indicated that it acts at an
early step, most probably the release of the RNA from the matrix. This action ofElb-
55K allows the cytoplasmic accumulation oflate viral mRNAs and so the translation of
the late gene products.
1.3.5. A model for Elb-55K function
Our current working model for RNA export during an adenovirus infection is based
upon the first model in section 1.3.2., in which RNA follows discrete paths within the
nucleus, and encompasses the 'gene gating' hypothesis of Blobel (1985), (Moore et al.,
1987; Leppard and Shenk, 1989; Omelles and Shenk, 1991; Leppard 1993). Blobel
proposed that the eukaryotic genome has a complex 3-D organisation with regions
actively transcribed being structurally expanded and linked, or 'gated', to nuclear pore
complexes, so facilitating the exit of their transcripts to the cytoplasm. All transcripts
of a particular gene would leave the nucleus via a single, linked nuclear pore; RNA
export from a gene not linked to a nuclear pore would be possible but very inefficient.
This arrangement was suggested to be dynamic, so that when transcription halted, the
gene was removed from the site of facilitated RNA transport and vice versa. Blobel
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envisioned the export of RNA from these gated genes to take the form of non-
diffusable tracks along which the RNA processing occurs in agreement with the model
reviewed by Xing et al. (1993). Further evidence for this hypothesis comes from the
observation that expanded chromatin (i.e. chromatin undergoing active transcription) is
localised around the nuclear periphery of the nucleus (Hutchinson and Weintraub,
1985; Krystosek and Puck, 1990~ De Graaf et al., 1991), possibly suggesting that
active genes are close to, or organised with respect to, nuclear pores, thereby
facilitating RNA export. Huang and Spector (1991) also observed that e-fos
transcripts exit the nucleus at a very limited area in the nuclear membrane, suggesting
that certain transcripts are targeted to a small number of nuclear pores, consistent with
the hypothesis ofBlobel.
The model suggests that there is a limited capacity in the nucleus for the export of
RNA, and that the process of RNA transport can be saturated (as observed by Zasloff,
1983~ Khanna-Gupta and Ware 1989~ Bataille et al., 1990~ Dargemont and Kuhn,
1992). Applying this model to an adenovirus infection, it is proposed that, early in the
infection, a viral transcription complex would occupy one of these facilitated sites, as
the system would not be saturated by the transcription and subsequent transport of
cellular RNAs, so allowing the transport of early mRNAs independently of the Elb-
55K1E4 ORF6-34K complex. However, late in the infection, after the onset of DNA
replication, there would be considerably more viral transcription complexes present
within the nucleus as transcription would now be occurring from the numerous
progeny viral genomes. This large number of transcription complexes would saturate
the facilitated sites and, in the absence of a vacant site, these transcription complexes
would either have to compete for a site already occupied by another transcription
complex or be transcribed elsewhere in the nucleus in a site less favourable for RNA
export. In either scenario, it is hypothesised that the Elb-55K1E4 ORF6-34K complex
would circumvent this situation, which arises late in the infection, either by (a) actively
displacing cellular genes from these facilitated sites allowing viral transcription
complexes to occupy the sites, or by (b) recruiting transport factors from existing sites
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(so rendering them inoperative) for the transport of viral mRNAs, or by (c) creating a
novel, virus-specific, RNA export mechanism. Which of these mechanisms actually
operates is unclear, but Jimenez-Garcia and Spector (1993) observed the recruitment
of transcription and splicing factors to sites of active adenovirus transcription (the viral
inclusion bodies) late in the virus infection, suggesting that the virus facilitates viral
pre-mRNA processing and transport by a recruitment mechanism, possibly by the
action ofElb-55K found in association with the inclusion bodies. The identification of
a potential RNA binding motif within the Elb-55K protein (K. Leppard, unpublished
observations) may be important in this function. It is also of note that Moen et al.
(1990) observed that Ad2 DNA, late in the infection, was localised in foci at the
nuclear periphery, as expected according to this model. Only the first two mechanisms
explain the block in host cell mRNA export as an indirect effect of facilitated viral
RNA export, but it is possible that the Elb-55K1E4 ORF6-34K complex directly
inhibits host cell mRNA transport in addition to having a direct effect on viral RNA.
This model explains a number of observations. Firstly it explains why only late gene
transcripts are dependent on the Elb-55K1E4 ORF6-34K complex for optimal
cytoplasmic mRNA accumulation. Secondly it accounts for the general block in the
cytoplasmic cellular mRNA accumulation while transcripts of some genes, such as the
Ela-induced p-tubulin, accumulate normally; Blobel hypothesised that transcriptionally
induced genes would have an increased linkage to the transport machinery, so allowing
them to compete effectively with viral transcription complexes. Thirdly it explains why
Ll 52/55K mRNA is independent of the Elb-55K1E4 ORF6-34K complex for optimal
cytoplasmic accumulation early in the infection while late in the infection it is
dependent. Fourthly it can account for the observation made by Leppard and Shenk
(1989) where it was noticed that early and late messages were handled differently; viral
early messages and the host p-actin message were strongly biased toward the
cytoplasm while viral late messages were found in significant amounts within the
nucleus. Finally it can account for the observations made in Ad 12 by Schramayr et al.
(1990) where it was found that Elb-55K plays a role in the decondensation of the
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chromatin at a limited number of sites. This phenomenon was not observed in AdS but
does suggest a role for the Elb-55K protein in the reorganisation of the nuclear
architecture.
The model can also be adapted to explain the observations made by Leppard (1993)
where it was noted that the longest mRNA species from each MLTU family was more
dependent for cytoplasmic accumulation on the Elb-55K protein than the shortest
member. Leppard (1993) hypothesised that it was not the length of a mRNA that
made it more dependent on Elb-5SK but the presence of unused splice sites; the longer
mRNAs from a MLTU family also contain more splice sites and potential intronic
sequences than do the short mRNAs. RNAs containing such sequences may be
recognised as incompletely processed by the host RNA processing machinery and so
be retained in the nucleus. In the my system, it has been noted that the presence of a
single intron in an mRNA can cause its retention in the nucleus (Chang and Sharp,
1989). Many processed MLTU mRNAs retain some intact splice sites (due to the
alternative splicing events) and these could interact with the splicing machinery or
nuclear matrix so preventing the export of the mRNA. Such effects would explain the
observed differences in dependence of various late mRNAs on the Elb-S5K protein for
optimal cytoplasmic accumulation.
It is not clear however if the observed difference in the dependence of RNAs on the
Elb-S5K protein for cytoplasmic accumulation is due to an indirect effect of the
protein's hypothesised ability to gate genes to nuclear pores or if it is a separate,
distinct function of the protein. One appealing adaptation of the simple model
described above is as follows: mature late mRNA is made, but not transported
efficiently when not in a facilitated site (i.e. in an Elb-5SK mutant infection), as the
transport mechanism is non-existent or very inefficient. In contrast, in a facilitated site
(due to the action of the Elb-55K1E4 ORF6-34K complex), the transport mechanism
is more efficient, so is more capable of competing with the splicing machinery for the
mRNA and so facilitating mRNA export. mRNAs containing no intronic sequences or
splice sites would still be dependent on the Elb-55K protein for optimal cytoplasmic
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accumulation as they need to be in a facilitated site, provided by the Elb-SSK protein,
for efficient export. However they would not have such a dependence on the Elb-SSK
protein as mRNAs containing splice sites, as they do not possess these possible nuclear
retention signals.
Bridge and Ketner (1990) also proposed that the Elb protein is involved in the
stabilisation of late viral unprocessed messages in the nucleus. This is not
inconceivable as the role ofElb-SSK in RNA transport may also promote stability in
viral messages. Evidence for decreased stability of late mRNAs in Eib mutant
infections was also observed by Leppard and Shenk (1989), however Ohman et al.
(1993) found no evidence that Elb-SSK was involved in nuclear RNA accumulation.
1.4. The E4 Region
1.4.1. E4 expression
The E4 region of AdS is located between 32803 bp and 35614 bp on the viral genome
and is transcribed from right to left. E4 transcription is induced by the indirect action
of El a, beginning in the early phase and continuing, although at a reduced rate, into
the late phase of infection. Studies of the E4 promoter have identified a repeated
sequence element critical for Ela-mediated E4 transcription (Lee and Green, 1987),
which is known to bind a number of transcription factors including those of the
activating transcription factor (ATF) family (Hai et al., 1988). It is believed that the
ATF proteins bind to the DNA of the promoter and recruit Ela by a CR3-specific,
protein-protein interaction. This subsequently allows the El a protein to interact with
other components of the transcriptional machinery, activating transcription (Lillie and
Green, 1989~Liu and Green, 1990~Martin et al., 1990~ reviewed by Akusjarvi, 1993).
Raychaudhuri et al. (1987) and Rooney et al. (1990) have also implicated the cellular
transcription factor E4F in El a-mediated transactivation of the E4 promoter. E4F can
bind to two of the ATF binding sites within the E4 promoter, with kinetics which
parallel those of E4 activation (Raychaudhuri et al., 1987). This E4F DNA binding
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activity is dependent on phosphorylation (Raychaudhuri et al., 1989), possibly
regulated by the Ela protein. As yet it is unclear whether both factors (ATF and E4F)
are required for El a-mediated transactivation of the E4 promoter during an adenovirus
infection (Rooney et al., 1990; Jones and Lee, 1991; Bondesson et al., 1992).
E4 transcription is down-regulated after the initiation of DNA replication due to the
action of the DBP binding to the promoter late in the infection so sterically blocking
the transcription machinery (Nevins and Winkler, 1980). In vitro experiments
confirmed this observation, demonstrating that while E4 transcription is inhibited by
the presence of DBP, the transcription of the Ela, Elb and MLTU regions is
unaffected (Handa et aI., 1983).
There is some degree of heterogeneity in the 5' end of the E4 mRNAs, with transcripts
starting within a 6 base pair region, 35614 to 35608 bp (Baker and Ziff, 1981;
Hashimoto et al., 1981; Virtanen et al., 1984; Dix and Leppard, unpublished
observations). Polyadenylation occurs at a unique site between 32803/32802 bp to
produce a primary transcript of between 2805 and 2811 nucleotides in length. This is
then subject to a complex pattern of differential splicing, producing up to 25 mRNAs
(Berk and Sharp; 1978; Chow et al., 1979; Freyer et al., 1984; Tigges and Raskas,
1984; Virtanen et al., 1984). Although these studies ofE4-derived mRNAs come to
similar conclusions they do not completely agree, possibly due to the different methods
employed in the detection of the mRNAs. These studies will be discussed further in
chapter 4. The nomenclature employed for the E4 mRNAs for the purposes of this
thesis is the one proposed by Virtanen et al. (1984) with RNAs8 M, Nand 0 identified
by Freyer et aI., 1984 (see Fig. 1.5.).
It was observed by Tigges and Raskas (1984) that splicing of the E4 primary transcript
was temporally regulated, with a 2.1 kb mRNA being the major product early in the
infection while at late times a 0.8kb mRNA class predominated. It was proposed by
Tigges and Raskas (1984) that this temporal change in splicing was due, in part at
least, to the E2A-DBP protein, as viruses lacking this protein failed to accumulate the
late O.8kb mRNA. This was confirmed by Ross and Ziff(l992) but they also observed
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Figure 1.5. The observed mRNA species from the E4 region with encoded ORFs
shown as open rectangles (in the notation of Virtanen et al. (1984)). The right
terminal portion of the Ad5 genome (bp 32500 - 35938) is shown as a line scale. The
splice sites are shown below the transcription map, acceptor sites A4 and AS are the
additional sites observed by Freyer et aI. (1984). mRNAs Nand 0 are incomplete and
represent the pGY4 and pGY9 cDNA clones of Freyer et al. (1984), respectively. The
papers reporting the existence of each mRNA are inidcated at the right in parenthesis
with the key to the number code below.
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that the DBP was not required for the expression of the late pattern of E4 splicing if
the E4 mRNAs were expressed from a plasmid rather than a viral template. They
proposed that before DNA replication a factor besides the DBP would restrict E4
splicing to the early pattern. At late times during an infection the DBP would
overcome the effects of this factor and allow the expression of the late E4 splicing
pattern. In transfected cells this additional factor is thought to be absent. Alternatively
the difference in E4 splicing observed between an infection and a transfection may be
due to the state of the DNA template. Adami and Babiss (1991) demonstrated that
two identical templates can produce RNAs which are spliced differently in the same
cell suggesting the state of the DNA template is very important in determining the
splicing pattern of an RNA (see section 1.2.4.). It is conceivable that the DBP protein
is required to produce late E4 splicing in an infection and not in a transfection, simply
because the DNA templates are in different microenviroments (it is believed that late
transcription and RNA processing occurs within viral inclusion bodies which are not
observed early in the infection or presumably in transfections (Moyne et al., 1978~
Zhonghe et al., 1986~ Walton et al., 1989~ Moen et al., 1990~ Jimenez-Garcia and
Spector, 1993».
Sequence analysis combined with the information obtained from ImRNA mapping
indicated that E4 potentially encodes at least 7 polypeptides (Tigges and Raskas
(1984) suggested as many as 16), designated ORF1, ORF2, ORF3, ORF3/4, ORF4,
ORF6, and ORF617, of which four, ORF3, ORF4, ORF6 and ORF617, have been
identified during the course of an AdS infection in tissue culture (Downey et al., 1983~
Sarnow et al., 1982, 1984~Cutt et al., 1987; Bridge et al., 1993b). The ORFI protein
has also been identified in an adenovirus infection but only in Ad9 (Javier, 1994).
1.4.2. The functions of the E4 proteins
1.4.2.1. Introduction
The functions of the proteins from the E4 region have been studied over the last 10
years, primarily by mutation analysis. These studies revealed that the E4 proteins were
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required for the normal progression of the virus infection into the late phase of the
infectious cycle. Viruses lacking the entire E4 region display a very complex
phenotype, with defects in viral DNA replication, accumulation of late RNA, efficiency
of late protein synthesis, particle assembly and a failure to shut off host cell protein
synthesis (Halbert et et., 1985; Weinberg and Ketner, 1986; Yoder and Berget, 1986;
Cutt et al., 1987; Falgout and Ketner, 1987; Bridge and Ketner; 1990). However,
mutation of the individual E4 reading frames revealed an unexpected result, as only
mutation of the E4 ORF6-34K protein compromised the virus' ability to grow in
human cells and then only to a moderate extent (Halbert et al., 1985). This suggested
that the other ORFs were not required for growth in tissue culture, although they
presumably play an important role during virus propagation in its natural host. The
details of this work and subsequent studies are discussed below.
1.4.2.2. ORFI and ORF2
To date, no evidence has been demonstrated for the presence of the ORFI-14K or
ORF2-14K proteins in AdS or Ad2-infected cells. Mutation of the ORFI-14K or the
ORF2-14K reading frames in AdS had no significant effect on virus propagation
(Halbert et al., 1985; Huang and Hearing, 1989a). Huang and Hearing (1989a), using
a virus mutated in ORFs 1, 2 and 3 (dll-3), also demonstrated that viral DNA
accumulation in HeLa cells was unaffected in the absence of these proteins, as was late
protein synthesis. However it should be noted that Huang and Hearing (1989a) also
observed that a virus mutated in all the E4 proteins apart from ORFs 1 and 2 grew 10
fold better than a total E4 deletion (dI366) suggestingthat these two ORFs do make a
minor contribution to viral growth in tissue culture.
Recently Javier (1994) raised an antiserum to the Ad9 E4 ORFI-14K and found the
protein in Ad9-infected tissue culture cells. Ad9 elicits oestrogen-dependent mammary
tumours in female rats (Ankerst et al., 1974; Ankerst and Jonsson, 1989; Javier et al.,
1991) while Ad26, another oncogenic subgroup D adenovirus very closely related to
Ad9, displays no evidence of this, producing sarcomatous tumours at the site of
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inoculation (Javier et al., 1991). Javier et al. (1992) and Javier (1994) concluded that
Ad9 encoded a novel protein that targets tumourigenesis to the mammary gland. On
investigation it was established that the E4 ORFl-14K protein was responsible for this
observed phenotype. It was also found that Ad9 E4 ORFl-14K protein could
transform continuous rat embryo fibroblasts (CREF cells) in tissue culture (Javier,
1994). These data indicate that the Ad9 ORFl-14K protein is an oncoprotein.
The Ad9 ORFl-14K protein is probably not the sole cause of mammary tumours in
female rats infected with Ad9, but probably interacts with the well known adenoviral
oncogenes E1a and E1b. Javier et al. (1991) implicated E1a in Ad9 oncogenesis when
Ela mRNA was detected in rat mammary tumours, however, no E1b mRNA was
found indicating that E1b is either not involved or is active at undetectable levels. The
Ad9 ORFI-14K protein can transform CREF cells without the aid of any other
proteins. Surprisingly the Ad26 ORFI-14K protein can also transform CREF cells in
tissue culture, although the Ad26 virus cannot elicit mammary oncogenesis in rats like
Ad9. Javier (1994) proposed that this could be due to either a difference in the ORF1-
14K protein in the two viruses or due to a difference between other regions of the
viruses, i.e. the two ORFI-14K proteins could be identical with respect to
transformation and oncogenesis but another region could dominantly repress mammary
oncogenesis in Ad26 infections. Mutant analysis suggests that the E4 ORF2 and/or
ORF3 regions are possible candidates for such a repressive function (it was noted that
the Ad9 ORF3 protein had negative effect on mammary oncogenesis), (Javier et al.,
1992~Javier, 1994).
AdS displays no oncogenic potential for either mammary or other tissues in vivo,
although its El region is able to transform CREF cells (Horwitz, 1990a). The E4
ORFI sequences of AdS and Ad9 display strong similarities (see chapter 3) suggesting
that they have similar functions in an adenovirus infection, but Javier (1994) found that
the AdS E4 ORFl-14K could not transform CREF cells in tissue culture. However,
the effect of the Ad5 E4-0RFI-14K protein on cell growth may be more subtle; work
carried out with the group A adenovirus, Ad12 ORFI-14K protein demonstrated that
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it had no transforming potential in CREF cells (Javier, 1994) but that the Ad12 E4
region was able to confer an increased potential for growth in soft agar on Ad12 El-
transformed cells (Shiroki et al., 1984). This effect may have been due to the Ad12 E4
ORFI-14K protein; what effect the AdS ORFI-14K protein has on similar cells in soft
agar is unknown.
1.4.2.3. ORF3 and ORF6
The E4 ORF3 region encodes a nuclear protein of about 11K in size (Samow et al.,
1982~ Downey et aI, 1983) while the ORF6 protein is known to be 34K in size but
migrates at 2SK on SDS-polyacrylamide gels (Samow et al., 1984). Cellular
localisation studies by Cutt et al. (1987) have demonstrated that about 50% of the
ORF6-34K protein is found complexed with the Elb-55K protein (Samow et al.,
1984) within the nucleus of the infected cell. These two E4 proteins will be discussed
together as it has been observed that they have somewhat redundant functions in an
adenovirus lytic infection.
Halbert et al. (1985) observed that a virus lacking an intact E4 ORF6-34K protein was
modestly defective for growth, with the first observable defect in the life cycle
occurring at the onset of viral DNA replication. It was noted that both viral DNA and
protein production was perturbed in the E4 ORF6-34K mutant virus infection, and that
the virus failed to shut-off host cell metabolism. Measurements of RNA production
revealed that viral RNAs, although produced, failed to accumulate in the cytoplasm
which suggested that the E4 ORF6-34K protein was involved in post-transcriptional
RNA metabolism. This defect in RNA accumulation had also been observed by Logan
et al. (1984) with an Elb-55K mutant, and, together with the data provided by Samow
et al. (1984) documenting that the Elb-55K and E4 ORF6-34K formed a physical
complex in infected cells, suggested that the Elb-55K and E4 ORF6-34K proteins
acted as a functional complex. Cutt et al. (1987) compared late protein synthesis in
three different mutant viruses (Elb-55K minus, E4 ORF6-34K minus, and a double
mutant (Elb-55K1E4 ORF6-34K minus» and found no observable difference between
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the three mutant viruses, all were equally defective in late protein synthesis. The
identical phenotypes of the three mutants confirmed the proposal of Halbert et al.
(1985) that the Elb-55K and E4 ORF6-34K proteins function as a complex to affect
late gene expression. Similar results were obtained by Bridge and Ketner (1990).
However, Sarnow et al. (1984) also observed that DNA replication was delayed with
the E4 ORF6-34K mutant virus but not with the Elb-55K mutant virus, suggesting
that the E4 ORF6-34K protein has other functions in the virus life cycle apart from
those performed in association with the El b-55K protein.
Halbert et al. (1985) noted that the E4 ORF6-34K mutant virus displayed the same
range of phenotypes as a virus defective in its entire E4 region, but the defects of the
E4 ORF6-34K mutant virus were less severe. This suggested that the E4 region
encoded an additional protein(s) important for viral growth which were functionally
related to the E4 ORF6-34K protein and so able to rescue partially a defect in the E4
ORF6-34K protein.
DNA synthesis
The defect in DNA replication in E4 mutants observed by Halbert et al. (1985) was
also seen in a number of other studies (Weinberg and Ketner, 1986~ Huang and
Hearing, 1989a; Weiden and Ginsberg, 1994). However, both Cutt et al. (1987) and
Bridge and Ketner (1989) reported no difference in the level of DNA accumulation
between E4 ORF6-34K mutant and wild type virus infections. This discrepancy in the
results may be due to the experimental design as the results of Huang and Hearing
(1989a) indicate that the defect in DNA replication is a delay in DNA accumulation in
the infection. In their experiment there is a distinct difference in the levels of viral
DNA between the mutant and wild type viruses at 24 hours p.i. but by 48 hours p.i. no
difference in viral DNA levels can be seen. It is conceivable that this defect may be
missed if growth conditions are varied (e.g. an increased MOl) and DNA levels are
observed at only one time point (as in Bridge and Ketner, 1989). Alternatively, the
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difference in DNA replication observed between these groups may be a reflection of
the different mutants used.
Huang and Hearing (1989a) also implicated the E4 ORF3-11K protein in DNA
replication. Viruses mutated in ORF3 accumulated viral DNA at levels comparable to
wild type while ORF6 mutated viruses demonstrated a delayed onset of DNA
replication and viruses mutated in both reading frames had a severe defect in DNA
accumulation (comparable to that of an E4 minus virus). This, combined with the fact
that a virus expressing only ORF3 in its E4 region demonstrated kinetics of DNA
accumulation similar to that of the ORF6 mutated virus, suggested that the ORF3 and
ORF6 proteins have redundant (but probably not equal) roles in DNA replication.
Weiden and Ginsberg (1994) observed that DNA from viruses mutated in both ORF3
and ORF6 formed concatemers during viral DNA synthesis in KB cells while the
presence of just one of these reading frames in the virus suppressed this effect. Weiden
and Ginsberg (1994) tentatively suggest that these proteins are involved in resolving
higher-order forms of the genome to monomers during the course of DNA replication.
It is unclear how the E4 ORF3-11K and E4 ORF6-34K proteins exert an effect on
DNA replication. Their role is probably regulatory or indirect as no E4 products are
required in purified cell-free DNA replication systems (reviewed by Stillman, 1989).
Experiments looking at the phenotypes ofElb-S5K, E4 ORF3-11K and E4 ORF6-34K
combination mutants suggest that facilitation of DNA synthesis may be mediated by
the Elb-S5K1E4 ORF6-34K complex acting in parallel with the E4 ORF3-11K protein
(Bridge and Ketner, 1990). However, it should be noted that defective DNA synthesis
has never been associated with a virus lacking Elb-55K unless it also contains lesions
in the E4 ORF3 and/or ORF6 regions. It would appear therefore that the roles of the
two proteins in the Elb-SSKlE4 ORF6-34K complex are not the same.
As yet it is unclear whether the over-expression of the E2a-72K DBP in some E4
mutants (Halbert et al., 1985~ and inconsistently observed in some experiments by
Huang and Hearing, 1989a) is significant in the defect observed in DNA replication.
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Weinberg and Ketner (1986), Huang and Hearing (1989a), Sandler and Ketner (1989)
and Bridge and Ketner (1990) all concluded that the defect in DNA replication did not
fully account for the complicated phenotype associated with the E4 region since late
protein production was defective in E4 mutant cells even when the DNA levels were
normal (i.e. late in the infection, 48 hours post infection). This is a rather tenuous
argument as the defect observed in DNA accumulation at earlier time points may have
a role in the defect subsequently observed in protein production when DNA levels are
comparable.
Late RNA and protein expression
The redundancy of the E4 ORF3-11K and E4 ORF6-34K proteins in affecting DNA
replication has also been observed in late protein expression (Huang and Hearing,
1989a~Bridge and Ketner, 1989). Huang and Hearing (I989a) analysed a number of
E4 mutants for late protein production and found that while lesions in just the E4
ORF3-11K or E4 ORF6-34K protein resulted in no or only a moderate effect
respectively, viruses mutated in both E4 ORF3-IIK and ORF6-34K were severely
defective for late protein synthesis. This would indicate that these proteins regulate
late protein synthesis independently. Similar results were obtained by Bridge and
Ketner (1989).
A number of groups had suggested that the above defect in late protein synthesis was
due to the defect in late mRNA accumulation in the cytoplasm (Halbert et a/., 1985~
Weinberg and Ketner; 1986; Bridge and Ketner, 1989~Huang and Hearing, 1989a;
Sandler and Ketner, 1989). Bridge and Ketner (1990), working with a series of E4
and Eib mutants, proposed that this defect in late mRNA accumulation in the
cytoplasmwas due to defects in both nuclear RNA stability and mRNA transport from
the nucleus to the cytoplasm (although the transport defect may be a defect in mRNA
stability in the cytoplasm). Their results indicated that the E4 ORF6-34K and the
ORF3-11K protein work in parallel to confer stability on unprocessed and processed
late viral RNA in the nucleus of infected cells (also noted by Bridge and Ketner, 1989;
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Sandler and Ketner, 1989). The semi-quantitative data suggest that these proteins
exert most of their effect on RNA stability on unprocessed RNA transcripts. The E4
ORF3-11K protein appears less efficient than the E4 ORF6-34K in conferring RNA
stability indicating that they may be involved in a different pathways each leading to
nuclear RNA accumulation. It was also observed that the E1b-SSK has a role in
nuclear RNA stability but it was noted that the E1b-SSK and E4 ORF6-34K proteins
ofthe heterodimer do not function equivalently opposite the E4 ORF3-11K protein in
nuclear RNA stability with the E1b-SSK apparently being less efficient in conferring
stability to RNA in the nucleus. This suggests that the E4 ORF6-34K and the E1b-
S5K proteins may have functions independent of the complex or play non-equivalent
roles within the complex. A similar conclusion was reached in transfection studies by
Ohman et al. (1993) where it was concluded that El products gave no, or only a small,
contribution to tripartite leader mRNA accumulation in the nucleus. These functions
are in addition to the role of the E1b-SSKlE4 ORF6-34K heterodimer in regulating
mRNA transport as already discussed (section l.3.). No evidence was found that
suggested the involvement of the E4 ORF3-11K protein in this latter process.
Bridge et al. (1991) examined the substrate specificity of the E4 proteins as previously
the only late mRNAs studied were those from the MLTU. Working with pIX, IVa2
and E2-L transcripts they found that only the pIX displayed any dependence on the E4
products, IVa2 and E2-L transcripts being completely independent for optimal
cytoplasmic accumulation. The pIX transcript, however, was independent of the E4
proteins for nuclear RNA stability and only slightly dependent on the ORF6-34K
protein for mRNA export. These results appear to conflict with the results published
by Leppard (1993) where it was observed that all the late mRNAs were dependent, to
varying degrees, on the Elb-5SK protein (the other half of the ElblE4 heterodimer
involved in RNA transport) for optimal cytoplasmic accumulation. This could be
explained by the E1b-SSK protein having additional functions, within the heterodimer,
in mRNA export. Alternatively it could reflect differences in experimental technique.
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Bridge et al. (1991) explain their result that only the rvILTU transcripts are strongly
dependent on the E4 proteins for nuclear accumulation by suggesting that the Ml,TU
leader sequences are important in conferring E4-dependence on a transcript.
Nordqvist and Akusjarvi (1990) demonstrated that E4 post-transcriptionally stimulated
accumulation of tripartite leader-containing mRNAs by a mechanism that required an
intron in the 5' UTR of the nuclear precursor RNA. Ohman et al. (1993) and
Nordqvist et al. (1994) subsequently demonstrated the involvement of the ORF3 and
ORF6 regions in the accumulation of correctly spliced tripartite leader mRNA in the
nucleus and suggested that they have a role in the regulation of pre-mRNA splicing.
However the ORF3-11K and ORF6-34K proteins did not show any redundancy in
their splicing activities with ORF3-11K facilitating exon inclusion and ORF6-34K
facilitating exon exclusion (see section 1.2.4.). No evidence for the involvement of the
Elb-55K protein in regulation of splicing was found (Ohman et aI., 1993).
It is unclear how the E4 proteins confer stability on late viral RNA in the nucleus. The
E4 proteins could bind to the RNA directly or initiate the binding of the hnRNP
proteins to the RNA so protecting the transcripts from nuclease degradation.
Alternatively the microenviroment of the viral inclusion body may be altered by an
effect of the E4 proteins on DNA replication so enhancing RNA stability. However
Nordqvist et al. (1994), Ohman et al. (1993) and Nordqvist and Akusjarvi (1990)
suggested that RNA stability is the result of the E4 proteins mediating MLTU RNA
metabolism. They argued that the E4 products may enhance the Ml,TU RNA levels
within the nucleus by facilitating spliceosome assembly which presumably would
protect the RNA against nuclease activity. More work needs to be undertaken to
explore the interaction of DNA replication, RNA stabilisation and RNA processing
within the infected nucleus before any definite conclusions can be reached as to how
these E4 proteins work at this level.
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Host cell shut-off
Huang and Hearing (1989a) found redundancy in ORF3 and ORF6 function in the
shut-off of host cell protein synthesis. This may be a secondary effect of the ORF3 and
ORF6 proteins i.e. due to the production of MLTU derived proteins which inhibit
cellular translation (see section 1.2.6.). Halbert et al. (1985) suggested that this defect
in host cell shut-off could be due partially to a block in the accumulation of cellular
mRNAs in the cytoplasm (as observed by Pilder et al. (1986a,b) for the Elb-55K
protein) but this is believed not to be the case (see section 1.2.6.1.). As the ORF3 and
ORF6 products have been shown to be involved in viral RNA stability (Bridge and
Ketner, 1989, 1990~Sandler and Ketner, 1989), Sandler and Ketner (1991) studied the
stability of three representative cellular mRNAs in wild-type and ORF3/0RF6 mutant
infections to see if the ORF3-11 K and ORF6-34K products modulate host cell shut-off
by altering host cell RNA stability. However they concluded that these E4 products
have only a small effect in the stability cellular mRNAs.
Summary
Most of the groups working with E4 ORF3-11K and E4 ORF6-34K conclude that they
function in association with the viral inclusion bodies in the nucleus. The complex
phenotype observed with mutations of these proteins may be the result of the proteins
being multifunctional, acting on DNA replication, RNA splicing, RNA stability and
RNA transport. However, it is more likely that these proteins affect only one or two
events directly and that the complex phenotype observed is an indirect result of this.
At present it is unclear at which step{s) the E4 proteins act; the delay in DNA
accumulation could be due to the altered expression ofMLTU mRNA, and so altered
late protein synthesis, in E4 mutants, or the altered MLTU mRNA expression may be
due to the reduction in DNA accumulation, or the two phenotypes may be completely
separate. It would appear, however, that the E4 proteins function at least at two steps
in the viral life cycle with the effect of the E4 proteins on viral DNA accumulation and
RNA stability in the nucleus being distinct from the secondary function of the E4
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ORF6-34K protein (along with the Elb-55K protein) in mRNA transport to the
cytoplasm (Bridge et al., 1990; Ohman et al., 1993).
For a summary of the conclusions from the studies of the E4 ORF3-11K and ORF6-
34K proteins see Fig.l.6.
1.4.2.4. ORFJ/4
No evidence for the existence of the E4 ORF3/4-7K protein in infected cells has yet
been found. Mutation analysis does not reveal any phenotype other than those
observed in ORF3-11K or ORF4-13K mutants.
1.4.2.5. ORF4
The E4 ORF4-13K protein was first identified in adenovirus infected cells by Bridge et
al. in 1993b. By mutation analysis, Bridge et al. (1993b) also proposed that the E4
ORF4-13K protein was involved in DNA replication. As mentioned in the above
sections, viruses containing gross deletions of the E4 region show a defect in DNA
replication. However, when characterising a set of E4 mutants, Bridge and Ketner
(1989) observed that a mutant lacking E4 ORF3 and ORF6 but retaining ORF4
displayed an even more severe defect in DNA accumulation than the total E4 deletion.
Bridge et al. (1993b) mutated the first methionine of ORF4 in this mutant and found
that this more severe defect in DNA accumulation was lost. They concluded that the
E4 ORF4-13K protein was necessary for the inhibition of viral DNA replication. It
would appear that the ORF4 product antagonises the effect of the ORF3 and 6
products (both involved in promoting DNA replication). The interplay of E4 ORF3, 4
and 6 products may regulate the onset and rate of DNA synthesis in adenovirus
infected cells. However, it should be noted that Huang and Hearing (1989a) observed
a defect in DNA replication no more severe than that observed in a gross E4 mutant
for a mutant virus just expressing the E4 ORF4-13K protein in its E4 region. There
are no obvious reasons why there is a discrepancy in the results from these two groups
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Figure 1.6. The functions of the E4 ORF3-11K, E4 ORF6-34K and the Elb-55K
proteins in the lytic viral cycle. It is unclear whether the functions ofE4 ORF3-I1K
and E4 ORF6-34K in DNA replication, nuclear stability of viral late messages and late
mRNA splicing are separate functions of these proteins. Two pathways are depicted
for genome replication and unprocessed nuclear RNA accumulation as it appears that
the E4 ORF3-IIK and the E4 ORF6-34K proteins function by different mechanisms in
these two processes. It is also unclear whether or not EIb-55K exerts an effect on
unprocessed late viral mRNA stability.
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concerning the ORF4 region. More studies of the E4 ORF4 region need to be
undertaken before the whole picture can be obtained.
If Bridge et al. (1993b) are correct, the E4 ORF4-13K protein may negatively
regulate viral DNA synthesis in a number of ways. Firstly it may directly interact with
the proteins involved in DNA replication so reducing the rate of DNA synthesis.
Secondly it may indirectly interfere with DNA replication by altering the organisation
of the viral replication complex. Thirdly the E4 ORF4-13K protein may regulate DNA
replication via phosphorylation events. Muller et al. (1992) demonstrated that the
ORF4-13K protein has an activity that inhibits a cellular kinase, or activates a cellular
phosphatase, which regulates Ela and c-Fos phosphorylation. Since no exhaustive
search for ORF4 targets has been made, its effects may extend to phosphoproteins
involved in DNA replication, such as NF-III and the viral DNA polymerase (the
activity of both of these proteins in viral DNA replication is known to be regulated by
phosphorylation (reviewed by Stillman, 1989). Fourthly the E4 ORF4-13K protein
may alter the expression of the DNA replication proteins. This could occur either at
the level of transcription or of RNA metabolism. Muller et al. (1992) demonstrated
that ORF4-13K altered the levels of the general transcription factor, AP-l, and altered
the activity of the El a proteins which, via effects on the E2 promoters, could change
the levels of the DNA replication proteins. Alternatively the ORF4-13K protein may
have a role in post-transcriptional RNA metabolism. It is known that ORF4-13K
antagonises the effects of the E4 ORF3-11K and E4 ORF6-34K proteins in DNA
replication and both the ORF3 and 6 products are involved in the metabolism of late
viral mRNA. Maybe these three proteins interact in some way to modulate the post-
transcriptional processing of E2 messages.
The observations by Muller et al. (1992) that the ORF4-13K protein is involved in
regulation of the phosphorylation ofc-Fos and Ela (both are involved in the regulation
of adenovirus transcription) suggest that the protein has a role in general
transcriptional control during an adenovirus infection. This effect of ORF4-13K seems
to be specific to c-Fos and Ela as other phosphoproteins like Elb-55K and JunB are
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not affected. It is unclear if the involvement of the ORF4-13K protein In
phosphorylation events in the infected cell is related to the possible role of the protein
in DNA replication.
Lazinski et al. (1989) identified a potential RNA binding domain within the E4 ORF4-
13K protein. The significance of this motif in the function of the E4 ORF4-13K
protein has yet to be established.
1.4.2.6. ORF5
The E4 ORFS reading frame was first proposed by Herisse et al. (1981). This ORF
had no AUG codon but was proposed to be fused onto the ORF2 reading frame by
RNA splicing to create an ORFlIORF2/0RFS fusion protein. However subsequent
analysis by Freyer et al. (1984), Tigges and Raskas (1984), and Virtanen et al. (1984)
found no evidence for the existence of an mRNA that could encode such a protein. As
a result no attempts have been made to identify such a protein in infected cells so this
potential protein will not be discussed here.
1.4.2.7. ORF617
The E4 ORF6/7 region encodes a 19.5K nuclear protein by the fusion of the N-
terminal part of open reading frame 6 with the open reading frame 7 (Cutt et al.,
1987). This protein has a halflife of just 4 hours (Cutt et al., 1987) and is involved in
the transactivation of the E2a promoter. Kovesdi et al. (1986a,b) noticed that the
binding of the cellular transcription factor E2F to the E2a promoter was dramatically
induced in nuclear extracts from adenovirus cells as compared to extracts of non-
infected cells. The viral function responsible for this induction was subsequently found
to be the E4 ORF6/7-19.SK protein (Huang and Hearing, 1989b~Reichel et al., 1989~
Marton et al., 1990~Neill et al., 1990~Raychaudhuri et al., 1990).
There are two binding sites for E2F within the E2 early promoter (Siva Raman and
Thimmappaya, 1987~Vee et al., 1987). The ORF6/7-19.SK protein has been shown to
bind to the transcription factor E2F and to induce the co-operative binding of two E2F
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molecules to these sites (two-site complex), thereby activating transcription (Huang
and Hearing, 1989b~ Marton et al., 1990; Neill et al., 1990~ Raychaudhuri et al.,
1990). Studies by Obert et al. (1994) indicate that this 'two-site complex' contains two
E2F molecules and at least two ORF617-19.5K proteins. It is believed that the E4
ORF617-19.5K does not cause the association ofE2F molecules before binding to the
promoter, but provides a direct dimerisation function at the promoter or induces a
structural change in E2F bound to its target site which facilitates the binding of a
second E2F molecule.
Mutation analysis of the E4 ORF617 region by O'Conner and Hearing (1991) found
that only the C-terminal 70 amino acids of the 150 amino acid ORF617 protein are
required to complex with E2F and stabilise its binding at the E2a promoter, so
activating transcription. Similar results were obtained by Neill and Nevins (1991) and
Obert et al. (1994) suggesting that the N-terminus, containing ORF6 sequences, is
completely dispensable and is required solely for the purposes of expression. The E4
ORF617-19.5K C-terminus can be divided into three separate regions, two regions
required for interaction with E2F, which flank a third region required for stable two-
site complex formation (Neill and Nevins, 1991). Neill and Nevins (1991) observed
that mutations located in this third region abolish the formation of the two-site
complex but do not impair the interaction of ORF617-19.5K with E2F. They
suggested that a helix-loop-helix domain within this third region is important in E4-
mediated E2F dimerisation, although Obert et al. (1994) suggest this motif is not the
key element in dimerisation. It was also noted that ORF617-19.5K mutants which
failed to promote E2F dimerisation still could transactivate, although not as efficiently,
the E2a promoter (Neill and Nevins, 1991). This would suggest that they can activate
E2a transcription in the absence of stable E2F complex formation. Neill and Nevins
(1991) suggested that the ORF617-19.5K protein can transactivate the E2a promoter
by two mechanisms; firstly through the formation of a stable two-site E2FIORF6/7-
19.5K complex and secondly through a one site E2FIORF617-19.5K complex. In the
second instance the ORF6/7-19.5K protein may act as a transcriptional activation
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domain for E2F, however it should be noted that E2F can activate transcription from a
number of promoters independentlyofORF617-19.SK.
The E4 ORF617-19.SKprotein is not essential for viral propagation in HeLa cells
(Halbert et al., 1986,Bridge and Ketner, 1989;Hemstrom et al., 1991), since ORF617
mutant viruses grow to levels comparable to wild type. This suggests that E4-assisted
activation of the E2a promoter is not critical for E2 expression in tissue culture. So
why has the virus developed this mechanism of activation? The E4 ORF6/7-19.SK
association with E2F may be important in viral infections of the natural host.
'Adenovirus mainly infects quiescent cells that have escaped from the cell cycle; to be
able to replicate efficiently in these cells, the virus probably needs to activate certain
components of the replication machinery of its host' (Hemstrom et al., 1991). This is
known to be accomplished in part by the El a proteins which have been shown to
release transcription factors important in cell growth, such as E2F, from inactive
complexes. It is possible that the ORF6/7 interaction with E2F is important in
regulating virus induced cellular proliferation, as Mudryj et al. (1990) have
demonstrated that E2F is involved in the activation of a number of genes involved in
cell proliferation. However, none of the promoters of these genes contains two
inverted E2F binding sites characteristic of the E2a promoter. Nevertheless the E4
protein may be involved in the activation of transcription of a number of cellular
promoters which contain only one E2F site (Mudryj et al., 1990) through a one site
complex as described above.
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1.5. Project objectives.
It is evident from these studies that E4 expression is highly complex and probably
highly regulated. It is also evident that very little is known about the function of some
of the E4 proteins such as the ORFl, ORF2 and ORF3/4 proteins of AdS. As a result
the objectives of this study were to:
(1) Characterise the expression of the E4 mRNAs over the course of an adenovirus
infection and examine the regulation of this expression, in particular the role of the
Elb-55K protein in E4 mRNA expression.
(2) Identify and characterise the remaining unidentified E4 proteins, predicted to be
encoded by the E4 mRNAs (i.e. E4 ORFl, ORF2 and ORF3/4), in infected cells and if
possible attribute functions to these proteins.
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Chapter 2.
Materials and methods
2.1. Materials
2.1.1. Common Buffers and Solutions
2YT: 1.6% (w/v) bacto-tryptone, 1% (w/v) yeast extract, 86 mM NaCI
Chloroform/amyl alcohol: 96% (v/v) chloroform, 4% (v/v) amyl alcohol
Hypotonic buffer: 10 mM Tris pH7.5, 10 mM NaCt, 1.5 mM MgCI2.
Isotonic buffer (protein extraction): 150 mM NaCI, 50mM Tris pH8.0, 1% NP40.
LB: 1% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 173 mMNaCl
LB-agar: 1% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 173 mM NaCl, 1.5%
(w/v) bacto-agar
PBS: 137 mM NaCI, 2.7 mM KCt, 4.3 mM Na2HP04.7H20, 1.4 mM KH2P04
Phenol/chloroform: 50% (v/v) phenollTNE , 50% (v/v) chloroform/amyl alcohol
PhenolffNE: liquified phenol (Fisons, Tris-buffered) equilibrated with excess TNE
RIPA: 150mM NaCI, 50mM Tris pH8.0, 1% NonidetP40, 0.5% sodium
deoxycholate, and 0.1% SDS.
SOC: 2% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 10 mM NaCI, 2.5 mM KCI,
10 mM MgCI2, 10 mM MgS04, 20 mM glucose
TD: 25 mM Tris base, 137 mM NaCI, 5 mM KCI, 0.7 mM Na2HP04
TE: 10 mM Tris.HCI pH 8.0, 1 mM EDTA pH 8.0
TBE: 89 mM Tris base, 89 mM boric acid, 1 mM EDTA pH 8.0
TNE: 10 mM Tris.HCI pH 8.0, 100 mM NaCI, 1 mM EDTA pH 8.0
TS: 25 mM Tris base, 137 mM NaCI, 5 mM KCI, 0.7 mM Na2HP04, 0.9 mM CaCI2,
1 mMMgCl2
10 x Taq Buffer: 500 mM KCI, 100 mM Tris.HCl pH 8.4, 1 mg/ml gelatin
2.1.2. Oligonucleotide primers (see appendix 2)
All primers are in 5' to 3' orientation
IDB: ATATTGTCGTTAGAACGCGG
IDC: TGATGGATCCACTGTTATGGCTGCCG
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IDD: AGGTGAATTCTCAAACATTAGAAGCCTGTC
IDE: TGATGGATCCGCAGACATGTTTGAGAGA
IDF: AGGTGAATTCCCTCAAGCAGCGAATC
IDG: AGCAAGTATATAGCATGGCC
IDH: GGAGCTGCATGTGTCAGAGG
IDJ: ACAGCTCCTCGGTCATGTCC
IDK: TTTTTACTAAGCTTGCTGACTGTTATGGC
IDL: TAGCCCTGGGGAATACATAC
IDM: TTCATCCACGGTGCCTGACT
2.2. Supplien
The chemicals used in this study were supplied by Sigma Chemical Company Ltd
(poole, Dorset), BDH Laboratory Supplies (Merck Ltd, Poole, Dorset) or Fisons
Scientific Equipment (Loughborough, Leics.), unless otherwise stated below.
PBS, DMEM, neutral red and sterile distilled water were supplied by the media
preparation staff of the Biological Sciences Department, University of Warwick.
Amenham International PLC (Amersham, Bucks.)
32p_UTP, 35S-Methionine, 35S-dATP, Amplify, Hybond C membrane, antibody
conjugates, SDS-P AGE Rainbow markers
Bio-Rad (Hemel Hempstead, Herts.)
Acrylamide, N,N-methylene-bis-acrylamide, ammonium persulphate, TEMED
Boehringer Mannheim UK (Lewes, East Sussex)
Calf intestinal phosphatase, Proteinase K
Dako (High Wycombe, Bucks.)
l,2-phenylenediamene tablets
Difco Laboratories (Basingstoke, Hants.)
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Noble agar, bacto-agar, bacto-tryptone, minimal agar, yeast extract
Dynatech Lboratories Inc. (Billinghurst, West Sussex)
ELISA plates
Gibco-BRL Life Technologies Ltd. (Renfrew shire, Scotland)
DNA modification enzymes, restriction enzymes, T4 DNA ligase, nucleases, immuno-
precipitin, SDS-P AGE standards
Invitrogen Corporation (San Diego, California, USA)
Probond nickel resin
New England Biolabs (CP Laboratories, Bishop Stortford, Herts.)
DNA modification enzymes, restriction enzymes, T4 DNA ligase, nucleases
Northumbria Biologicals Ltd. (Cramlington, Northumbria)
Calf serum, foetal calf serum
Pharmacia Ltd (Milton Keynes, Bucks.)
Glutathione sepharose 4B beads, dNTPs, pGEX vector
Promega Corporation (Madison, Winsconsin, USA)
Taq DNA polymerase, TnT Coupled Reticulocyte Lysate System
Stratagene Ltd (Cambridge)
Nuctrap columns
United States Bioscience (Cambridge Bioscience, Cambridge)
Sequenase DNA-dependent DNA polymerase
Whatman International (Maidstone, Kent)
3MM chromotography paper, GF/C glass microfibre filters, DE52 resin
Qiagen GmbH (Hilden, Germany)
pQE vector
All chemicals used were of molecular biology or analytical grade.
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2.3 Methods
For a general review of most of the methods employed in this study see Sambrook et
al. (1989).
2.3.1. Nucleic Acid Manipulations
2.3.1.1. Ethanol precipitation of Nucleic Acids
Nucleic acid was precipitated out of aqueous solution (minimum volume of 50 ul) by
adding salt to a final concentration of 0.3 M (sodium acetate) or 0.1 M (sodium
chloride) and 2.5 volumes of ethanol. The solution was placed at -20°C for 30 min. or
15 min. at -80°C, followed by a 15 min. centrifugation at 16,000 x g. The resulting
pellet was then washed using 70% (v/v) ethanol at -20°C and re-centrifuged at 16,000
x g for 10 min.. The washed pellet was vacuum dried and resuspended in the required
volume of water or TE. Variations on this method are described in detail where they
arise.
2.3.1.2. Nucleic acid quantification
The concentration of nucleic acid in a solution was quantified by spectrophotometry.
The absorbance of the solution (diluted to give a reading between 0.05 and 0.1
(A260)) was read at A260 and A280. Nucleic acid concentrations were then
calculated from the A260 reading assuming A260 = 1 for 50 ug/ml ds DNA, 40 ug/ml
for ssRNA or 30 J.lglml for ssDNA. The A280 reading allows the calculation of the R
value (A2601A280), an indication of the purity of the solution. Values below 1.8 for
DNA or 2.0 for RNA indicate contaminants in the solution, making the estimated
concentration derived from the A260 value inaccurate.
2.3.1.3. PhenoVchloroform extraction
An equal volume of phenol/chloroform was added to the DNA solution and mixed (for
most procedures this involved vortexing but for higher molecular weight DNA (-10
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kbp plus) repeated inversion was used). The heavier phenol/chloroform fraction was
separated from the lighter aqueous phase by centrifugation at 15,000 x g for 5 min ..
The aqueous phase was then removed and the phenol/chloroform fraction discarded.
An equal volume of chloroform was then added to the aqueous phase, mixed and
centrifuged as before. Again the lighter aqueous phase was removed to a fresh tube
and the chloroform phase discarded. Variation\ on this method are described in detail
where they arise.
2.3.1.4. Restriction endonuclease digestion
Restriction enzyme digests were carried out according to the supplier's instructions;
the reaction buffers used were normally those supplied (by the supplier) as 10 x
concentrates. Typical reactions (i.e. less than 1 ug of DNA) were carried out in 20J..lI
while larger volumes were used when more DNA was cut. This ensured that the
amount of enzyme added was less than 10% of the volume (enzyme dilutions of less
than 1/10 may cause the glycerol concentration (from the storage buffer) to inhibit
enzyme activity). Where possible, multiple restriction digests were carried
simultaneously in a buffer that allowed activity of all the enzymes involved.
2.3.1.5. End-fill repair of 5' overhangs
The DNA polymerase I large fragment (Klenow fragment) was used to fill in the 5'
overhanging ends of dsDNA (resulting from some restriction enzyme digests) so
allowing blunt ended cloning. The reaction conditions used were 50 mM Tris. He} pH
8.0, 10 mM MgC}2, 1 mM DTT, 50 J..lg/mlBSA, 25 J..lMof each dNTP and 1 U of
enzyme per ug of DNA) in 25 J..lI,incubated at 37°e for 30 min.. The reaction was
stopped by phenol/chloroform extraction.
2.3.1.6. T4 DNA polymerase removal of3' overhangs
3' overhangs were removed, to create blunt ends for cloning by T4 DNA polymerase
(BRL). Reactions of 50 J..l}containing 50 mM Tris. He} pH 8.0,5 mM Mgel2, 5 mM
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DTT, 50 ug/ml BSA, 100 ~ of each dNTP and 5 U of enzyme per ug of DNA were
incubated at 11 °C for 30 min.. The reactions were stopped by phenol/chloroform
extraction.
2.3.1. 7. Dephosphorylation (
To prevent the unwanted ligation of dsDNA termini in ligation reactions, the 5'
phosphate groups were removed using calf intestinal alkaline phosphatase. Reactions
were carried out in a 50 ~l volume containing 20 mM Tris. HCI pH 8.0, 1mM MgCI2,
1 mM ZnCI2, 1 mM sperrnadine and 0.1 U of enzyme for every 10 pmol of DNA
termini present (1 ug of 3 kbp linear DNA contains -1 pmol of 5' termini). 5'
overhanging termini phosphate groups were removed by incubation at 37°C for 30
min.. Blunt or 5' recessed ends were dephosphorylated at 37°C with 0.1 U of
enzyme/1 0 pmol of DNA termini for 15 min. followed by the addition of a second
aliquot of enzyme (0.1 U/10 pmol of DNA termini) and incubation at 55°C for 45 min ..
All the reactions were stopped by phenol/chloroform extraction.
2.3.1.8. Agarose gel electrophoresis
dsDNA fragments were separated in horizontal agarose gels containing 0.6 to 2.0%
type 1 agarose and 0.5 ug/ml ethidium bromide, in 0.5 x TBE. 115the sample volume
of5 x loading buffer (50% glycerol,S x TBE, 0.02% bromophenol blue, 0.02% xylene
cyanol) was added to each sample prior to loading. Electrophoresis was carried out at
150V in 0.5 x TBE buffer until the required bands had been resolved. The fragments
were visualised on a ultraviolet transilluminator and photographed using Polaroid 665
or 667 film.
2.3 .1.9. Purification of dsDNA fragments from agarose gels
Fragments of under 10 kbp:
A 2-3 mm slice, the width of the fragment band, was cut out of the gel immediately in
front of the band in question. The amount of running buffer in the tank was reduced so
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that it just covered the gel, ensuring the hole in front of the band was then filled with
buffer. The gel was then run for between 1-3 min. (according to the size of the
fragment and the agarose concentration of the gel) so that the fragment ran into the
hole. The buffer in the hole, now containing the fragment, was removed and extracted
with phenol/chloroform, The DNA was subsequently ethanol precipitated, dried and
resuspended in water or TE.
b) Fragments of over 10 kbp:
The required fragment was cut out of the gel and placed in a short section of dialysis
tubing filled with 0.5 x TDE. The tubing was sealed using clips and placed in a gel
tank containing 0.5 x TBE. The DNA was electroeluted from the gel into the buffer in
the dialysis tubing for 30 min. at 150V. Just prior to removing the sample from the gel
tank, the current was reversed for 30 seconds to remove the DNA from the tubing
wall. The buffer inside the dialysis tubing was then removed and added to a TNE-
equilibrated DE52 (diethylaminoethyl cellulose, Whatman) anion exchange column
(constructed in a Pasteur pipette). The column was washed with 6 ml TNE and the
DNA eluted from the column with I ml of 1M NaCI in TNE. It was then extracted
with phenol/chloroform, ethanol precipitated, dried and resuspended in water or TE.
2.3.1.10. Ligation ofdsDNA
Ligations between DNA fragments with complementary ends (blunt and overhanging)
were carried out using T4 DNA ligase (BRL) in a volume of20 to 50 ul. The reaction
conditions used were 40 mM Tris. HCt pH 7.5, 10 mM MgCt2, 10 mM DTT, 0.5 mM
ATP, 50 ug/ml BSA and 1 U of enzyme (if the ligation was between blunt ended
fragments then IOU of enzyme was used). A typical ligation of insert DNA and
vector was done at a molar ration of about 5: I, using 50-200 ng of vector DNA.
Ligations between cohesive ends were carried out 15°C for about 16 hours, to
encourage the annealing of the DNA, while blunt- ended ligations, where annealing
was not a factor, were carried out at room temperature for 4 hours or more.
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2.3.1.11. Polymerase chain reaction (PCR)
DNA was amplified to a high level using the PCR. Two DNA oligonucleotides were
created which complemented either end of the section of DNA which was to be
amplified. 200 ng of each primer was mixed with 200ng template DNA, ImM
dNTPs, 1 x Taq buffer, 2.5 mM MgCl2 and 3 units Taq polymerase, in a total volume
of 25 ,.11. A drop of paraffin was placed on top of the mixture to prevent evaporation
during the thermal cycling step. Using a DNA Thermal Cycler (Perkin Elmer Cetus)
the reaction mixtures were cycled through 17 cycles of94 "C for Imin., 55 ·C for 1
min. and 72°C for 3 min. followed by 3 cycles of 94 "C for 2 min., 55°C for 2 min.
and 72 °C for 10 min. to ensure that the ends of the PCR product were uniform. The
aqueous phase was then withdrawn and extracted with phenol/chloroform. The
efficiency of the PCR was estimated by running a sample of the product on an
agarose gel, this also confirmed that the correct length of DNA was amplified.
2.3.1.12. Site-directed mutagenesis using PCR
This method is taken from Ito et al (1991). 4 primers were constructed IDJ, IDK, IDL
and 10M (section 2.1.2. and see Fig. 2.1.), IDJ and IDM (about 20 nucleotides long)
matched the DNA to be amplified, while 10K and IDL (about 30 nucleotides long) had
mismatches to the DNA to be amplified. Primer IDK had mismatches across the
region which was to be mutagenised (A) while primer IDL had a mismatch which
destroyed the restriction site RS 1 when used in the PCR. The first 2 PCRs carried out
used the primers [OJ and [OK in one reaction and IDL and 10M in the other, and were
set up as described above (2.3.1.11). The reactions were then cycled through 20
cycles of94 °C for 1 min., 55°C for 1 min. and 72 °C for 3 min .. The aqueous phase
of the reactions were then withdrawn from the reaction tubes and 2.5 JlI of each were
run on an agarose gel (2.3.1.8) to test the reaction products. 2.5 JlI of these samples
(p1 and P2) were then denatured and annealed in the presence of the primers IDJ and
10M in the following reaction mixture by heating to 85°C for 2 min. then allowing the
mixture to cool slowly to room temperature:
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Figure 2.1. Diagram depicting site directed mutagenesis using peR. Primers IDJ,
IDK, IDL, and IDM are indicated by short arrows; A represents the site to be
mutagenised; A· and RS 1· represent sites after being mutagenised; PI and P2
represent the two products produced after the first round of PCR; RS 1 and RS2
represent the two available restriction sites utilised in the cloning of PCR fragments
into a suitable vector and in doing so selecting for mutated clones. Only clones
mutated at A will have intact RS 1 and RS2 so by cloning with these two enzymes the
population of correctly mutated eDNA clones will enhanced.
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PI 2.5 Jolt
P2 2.5 Jolt
Primer IDJ 200 ng
Primer IDK 200 ng
10 x Taq buffer (promega) 2.5 Jolt
25 mMMgCt2 2.5 Joll
Water to 13 Jol1
Then 8 Jol1ofO.125 mM dNTPs, 0.5 ul Taq polymerase (5 U/JolI,Promega), water to 25
Jolland one drop of paraffin were added. The reaction mixture was cycled through 20
cycles of 94°C for 1 min., 55°C for 1 min., 72°C for 3 min. and 1 cycle of 94 °C for
1 min., 55°C for 1 min., 72°C for 7 min. using a DNA Thermal Cycler (Perkin Elmer
Cetus). The aqueous phase was withdrawn and 2.5 Joltrun on an agarose gel (2.3.1.8)
to check the quantity of the DNA present. The remainder of the reaction mixture was
extracted with phenol/chloroform and digested with the restriction enzymes RS 1 and
RS2 (Fig. 2.1.). Only PCR fragments which had a mutagenised site (A*) had both
restriction sites intact so allowing the enhancement of positive clones when the
fragment is subcloned into a suitable vector. Prospective positive clones (ie. those
which have PCR fragments cloned into them using RS I and RS2) were screen by
DNA sequencing (2.3.1.13).
2.3.1.13. DNA sequencing
Denaturation of dsDNA
400 ng of dsDNA was denatured in a volume of 20 Jollcontaining 200 JolMEDT A and
200 mM NaOH for 15 min. at 42°C. The reaction was terminated by the addition of
ammonium acetate pH 4.5 to a concentration of 182 mM and the denatured DNA
precipitated by the addition of2.5 volumes of95% ethanol and placed at -20°C for 30
min.. The DNA precipitate was pelleted by centrifugation at 16,000 x g for 15 min.
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and subsequently washed with 70% ethanol and centrifuged again at 16,000 x g for 15
min.. The DNA pellet was then dried in a vacuum desiccater.
Annealing reaction
25 ng of primer DNA was annealed to the denatured DNA sample or single stranded
M13 DNA (2.3.3.3.). The reaction conditions used were 40 mM Tris.HCl pH 7.5, 10
mM MgCI2, 50 mM NaCI in a volume of 10 J.11for two min. at 65°C. The reaction
was then allowed to cool to room temperature for at least 10 min ..
Sequencing reaction
The annealing mixture was made up to 15.5 J.11to give a reaction mixture which
contained 26 mM Tris.HCl pH 7.5, 6.5 mM MgCI2, 32 mM NaCI, 1.5 J.1M
dG/dC/dTTP (the concentration of dNTPs was decreased if sequence data proximal to
the primer was required, or increased if data more distal from the primer was
required), 6.5 mM DTT, 3.25U Sequenase (DNA-dependent DNA polymerase) and 5
J.1Cia_35S dATP. The reaction was incubated on ice for 5 min. and then divided in to
four 3.5 J.11aliquots. Each aliquot was added to one of four 2.5 J.11ddNTP mixtures
(80 J.1MdNTP, 8 J.1MddNddG/ddC/ddTTP). These were incubated at 42°C for 5
min. when 4 J.11of stop reaction buffer was added (96% formamide, 20 mM EDT A pH
8.0,0.05% (v/v) xylene cyanol FF, 0.05% (v/v) bromophenol blue). The resulting 4
reaction mixtures were subsequently heated to 95°C for 2 min. and placed on ice.
Denaturing polyacrylamide gel electrophoresis using a 6% gel
Using Bio-Rad SequiGen gel apparatus, a 6% polyacrylamide denaturing gel was
prepared in 1 x TBE containing 5.7% acrylamide, 0.3% N.N-methylene-bis-
acrylamide, 46% (w/v) urea, 1 ug/ml ammonium persulphate and 0.25 ul/ml TEMED.
2 J.11of each sequencing reaction was loaded onto a gel (which had been pre-run at
45W for 30 min.) and electrophoresised at 45 W (ca. 50°C) for 2-3 hours depending
on whether the required sequence data were proximal or distal to the primer. The gel
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was then soaked in 10% methanol and 10% acetic acid for 30 min. and dried at 60°C
under vacuum for 1-2 hours onto a piece of paper. The sequence data was visualised
by autoradiography (2.3.12.).
2.3.2. Bacteriological Techniques
2.3.2.1. The growth and maintenance of bacteria required for routine cloning.
Esherichia coli (E. coli) DHI (recAI elldAI thi-l hsdR17 supE44 gyrA96 (Nal")
re/AI) (Hanahan, 1983) were used in all the routine cloning procedures, details of
other strains are given as they arise. Bacteria were grown either in liquid culture form
in LB medium at 37°C in shaking incubators or on LB-agar plates at 37°C. When
transformed bacteria were grown, plasmids encoding ampicillin-resistance genes were
maintained in the culture by supplementing the media with ampicillin at 50 ug/ml.
Cultures were maintained for up to 1 month on agar plates at 4°C. For long-term
storage, 0.5 ml of a stationary phase culture was mixed with 0.5 ml 80% glycerol (v/v)
and rapidly frozen in a dry ice/ethanol slurry and stored at -70°C.
2.3.2.2. The transformation of bacteria with plasmid DNA.
a) Calcium chloride method
Preparation of competent cells:
A single colony of bacterial cells was grown overnight in 4 ml of LB media at 37°C
shaking at 250 rpm. The next day this culture was added to 400 ml of LB media and
shaken at 37°C until the A600 had reached 0.4. The cells were then placed on ice for
10 min. and centrifuged at 2,000 x g for 7 min. at 4°C. The resulting pellet was gently
resuspended in 10 ml of60 mM CaCl2 at 4°C and centrifuged again (as above). The
pellet was again resuspended in 10 ml 60 mM CaCl2 at 4 °C and then left on ice for 30
min .. The cells were then re-centrifuged (as above) and resuspended in 2-3 ml of 60
mM CaCl2 with 15% (v/v) glycerol and frozen at -70°C in 200 ul aliquots. Variations
in this method are given as they arise.
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Transformation Procedure
DNA for transformation was made up to 25 uls with distilled water and incubated with
100 uls of competent cells on ice for 15 min. in a round bottom tube. The mixture was
placed at 42°C for 2 min. exactly and immediately afterwards placed on ice again for
another 15 min.. One ml of SOC media was then added and the mixture shaken at 37 °
C for 1 hour. 2% and 20% of the mixture was subsequently plated onto LB-agar
plates containing a suitable antibiotic and incubated overnight at 37°C. Individual
colonies were picked the next day for small scale preparation of DNA (2.3.2.3.)
b) The electroporation procedure
Preparation of competent cells
A single colony of bacterial cells was grown in 5 ml of LB medium overnight at 37°C
at 250 rpm. The next day 1 ml of the overnight culture was used to inoculate 100 ml
of LB. This was shaken at 37°C until the ~OO reached about 0.6 when it was chilled
on ice for 15 min.. The culture was then centrifuged at 2,000 x g for 10 min. at 4°C,
the pellet resuspended in 100 ml of water and centrifuged a second time. The pellet
was resuspended in 50 ml of water and centrifuged a third time. The pellet was then
resuspended in 2 ml of 10% (v/v) glycerol and centrifuged for the last time. The pellet
was resuspended in a volume of2-300 ,.d of 10% (v/v) glycerol and stored at -70°C in
40 III aliquots.
Electroporation
The DNA for electroporation, purified and desalted as required was resuspended in 20
III of water. 10 III (typically 100 ng) of this was mixed with a 40 III aliquot of
competent cells (thawed briefly on ice) and incubated on ice for 1 min. before placing it
into the electroporation cuvette. The DNA was then electroporated into the bacteria
using a Bio-Rad Gene Pulser with a voltage pulse at 2.5 kV, at a capacitance of 25 IlF
(pulse controller at 200 Os). Immediately after electroporation the cells were mixed
with 1 ml of SOC media and shaken for 1 hour at 37°C. 2% and 20% of the mixture
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was then plated onto LB-agar plates containing a suitable antibiotic and incubated
overnight at 37°C. Individual colonies were picked the next day for small scale
preparation of DNA (2.3.2.3.).
2.3.2.3. Small scale plasmid DNA purification from bacteria (Mini Prep)
This method was published by Zhou et al. (1990). A single colony of transformed
bacterial cells was grown overnight in 5 mI of LB medium supplemented with the
appropriate antibiotic. The following day 1.5 mI of the culture was centrifuged at
16,000 x g for 20 seconds. The supernatant was decanted off leaving 50 - 100 J.lIof
media covering the pellet. This was then vortexed for 5 seconds to resuspend the
bacterial pellet and 300 J.lIof TENS (0.1 M NaOH, 0.5% (w/v) SDS in TE buffer pH
8.0) added. The solution was vortexed for 5 seconds, 150 J.lIof 3 M NaOAc pH 5.2
added and vortexed for a third time for 5 seconds. The solution was then centrifuged
at 16,000 x g for 2 min. and the supernatant transfered to a fresh tube. 1ml of ethanol
at -20°C was added to the supernatant and the mixture centrifuged at 16,000 x g for 2
min .. The resulting pellet was washed twice in 70% (v/v) ethanol, dried in a vacuum
desiccator and resuspended in 20 J.lIof water. 5 J.lIwas used per subsequent restriction
digest analysis.
2.3.2.4. Large scale plasmid DNA preparation from bacteria (Maxi Prep)
500 m1 of LB-Amp was inoculated with 100 J.lIof an overnight culture and shaken at
37°C for 6 hours at which point the cultures were supplemented with 50 ug/ml
chloramphenicol and left to incubate overnight at 37°C. The following day the cells
were pelleted at 2,500 x g for 15 min. at 4 °C and resuspended in 4 mI of GTE (50
mM glucose, 25 mM Tris.HCl pH 8.0, 10 mM EDTA). 1 mI of GTEL (50 mM
glucose, 25 mM Tris.HCI pH 8.0, 10 mM EDTA, 25 mg/mI Lysozyme) was added and
left at room temperature for 10 min.. 10 mI of 0.2 M NaOH and 1% (v/v) SDS
solution was then added and left a further 10 min. on ice. Afterwards, 7.5 mI of 3M
KOAc, I.3M formic acid (pH adjusted to 5.5 with acetic acid) was added to the lysed
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cells, allowed to stand on ice for 10 min. and centrifuged at 16,000 x g for 10 min ..
0.6 volumes of propan-z-ol was added to the supemantant and centrifuged at 2,000 x
g for 15 min.. The resulting pellet was washed with 2 m! of 70% (v/v) ethanol and
dried in a vacuum desiccator. The pellet was resuspended in 4.3 m! ofTNE, 4.85 g of
CsCI and 320 ~l of 10 mg/ml ethidium bromide. This solution was centrifuged at
300,000 x g for 18 - 20 hours at 20°C, and the purified plasmid band recovered from
the gradient with the aid of a hypodermic needle and syringe. The ethidium bromide
was removed from the sample by repeated extraction with CsCI-saturated propan-2-ol.
The DNA was then precipitated by diluting the final aqueous phase with three volumes
of TNE and 10 volumes of ethanol and placing it at -70°C for 1 hour The DNA
precipitate was subsequently pelleted by centrifugation at 10,000 x g and the resulting
pellet resuspended in 0.5 - 1.0 m1 ofTE buffer or water.
2.3.3. M13 Phage Techniques
The bacterial strain used as a host strain for M13 phage vectors (Messing et al., 1977)
was the F+ bacterial strain TOI (Gibson, 1984~ Sambrook et al., 1989).
2.3.3.1. Transformation procedure
Preparation of competent E. coli
'I'Gls (supE hsda5 thia(lac-proAB) F,[traD36 proAB+ /acIq /acZi\MIS]) were made
competent as per the method described in 2.3.2.2.
Transformation
DNA «25 JlI) was mixed with 150 JlI of competent TO 1 bacteria in a round bottom
15 m! tube and left on ice for 30 min.. The mixture of DNA and competent cells was
then placed at 42°C for exactly 2 min. and subsequently placed back on ice for a
further 30 min.. Afterwards, 89%, 10%, and 1% volume aliquots of the suspension
were mixed with 3 m! of top agar at 46°C supplemented with 20 ~l of 100 mM IPTO,
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30 ~l 2% (v/v) Xgal and 200 ~l of TOI cells grown to saturation. This was then
poured on to a pre-warmed (about 40°C) LB plate and, when set, incubated at 37°C
overnight. Plaques were picked the next day for either small scale replicative form
(RF) DNA purification or single strand preparations for sequencing.
2.3.3.2. Culturing M13 clones
3 ml of a TO 1 culture in stationary phase was used to seed 50 ml of 2YT medium.
This culture was incubated at 37°C, 250 rpm for one hour after which 3 ml aliquots
were placed in universals. Positive plaques were identified in the TO 1 lawn, following
transformation, by the absence of the blue colouration indicative of B-galactosidase
activity. These plaques were picked using a sterile tooth pick and innoculated into the
TOI aliquots. These TOIIM13 cultures were then incubated for either 5 hours (for
ssDNA preparations) or 7 hours (for RF preparations) at 37°C, 300 rpm.
2.3.3.3. Preparation of RF DNA from M13 cultures
RF M13 DNA was prepared as in 2.3.2.3. except 1.5 ml of a TOIIM13 culture was
used as starting material.
The supernatant from the first centrifugation step (2.3.2.3.) was recentrifuged at
16,000 x g for 10 min. to clear any residual bacterial cells. The pellet from this second
centrifugation was discarded and the supernatant stored at 4 °C as a recombinant M13
phage stock.
2.3.3.4. Preparation of single strand DNA from M13 plaques
Single stranded M13 DNA was prepared by centrifuging 1.2 ml of TGIIM13 culture
at 16,000 x g for 5 min. and removing the supernatant to a clean tube. The
supernatant was then centrifuged again as before and transfered to a clean tube. 300
~l ofPEOlNaCl solution (20% polyethylene glycol600, 2.5 M NaC) was added to the
supernatant and inverted 3 times to mix. The solution was then left to stand at room
temperature. After 15 min. the solution was centrifuged at 16,000 x g for 5 min. to
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pellet the PEG-phage complexes which had formed. The supernatant was discarded
and the pellet recentrifuged as before. Again, any supernatant was discarded and the
pellet resuspended in 120 ul of Tfi, 50 III ofphenollTNE was added and vortexed for
30 seconds. The resulting two phases were separated by centrifugation at 16,000 x g
for 5 min. and 100 III of the aqueous phase removed to a clean tube. To this was
added 50 III of chloroform/isoamyl alcohol and the two phases mixed by vortexing for
30 seconds. The solution was then centrifuged at 16,000 x g for 5 min. and 80 ul of
the aqueous phase placed in a clean tube. The single stranded M13 DNA was ethanol
precipitated, dried (2.3.1.1.) and resuspended in 30 III TE. 5 III of this solution was
used for each subsequent sequencing reaction.
2.3.4. Tissue culture and virus techniques
2.3.4.1. Maintenance and passage of cell lines
HeLa, W162 (Weinberg and Ketner, 1983) and HEK-293 (Graham et al., 1977) cell
lines were passaged routinely in 90 mm tissue culture dishes containing DMEMlI0%
CS. All cells were grown at 37°C in a 5% C02 humidified atmosphere. When
passaged, cells were washed with TD and then soaked in TDE/trypsin (TD
supplemented with EDTA at a final concentration of 0.5 mM and trypsin at a final
concentration of 0.25 gil) for 1 to 2 min.. Excess CS was then added to 20% volume
and the cells centrifuged at 2,000 x g for 3 min.. The resulting pellet was resuspended
in DMEMlIO% CS and placed into tissue culture dishes at the required density. HeLa
and WI62 cells were passaged at a ratio of 1:10 while HEK-293 cells were split at a
ratio ofl:4.
2.3.4.2. Maintenance and passage of non-transformed cells
The non-transformed cell lines used in this work were MRCS (gift of C.R. Pringle),
HISM WI-38 and HUV-EC-C (American Type Tissue Culture collection). The,
MRCS, HISM, and WI-38 cell lines were passaged as in 2.3.4.1. except FCS was used
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instead ofCS and the maximum ratio of subcultivation was 1:4. The HUV-EC-C cell
line was grown in F12 K medium supplemented with 10% FCS, 100 ug/ml of heparin,
and endothelial cell growth supplement at 10 ug/ml. The cells were passaged as above
with a maximum subcultivation ratio of 1:3.
2.3.4.3. Freezing cell stocks
Cells were prepared for long-term storage by suspending the cells from one 90 mm
dish in 8% (v/v) dimethylsulphoxide/ 92% FCS and placed in freezing vials suitable for
storage in liquid nitrogen. The vials were slowly cooled to -70°C and then placed in
liquid nitrogen.
2.3.4.4. Recovery of cell stocks
The cells were removed from the liquid nitrogen and rapidly thawed in a 37°C
waterbath. Once thawed the cells were placed in a 90 mm dish containing prewarmed
growth medium, which was changed the following day.
2.3.4.5. Calcium phosphate transfection for the construction of adenovirus mutants
W162 cells from one 90 mm dish were passaged and divided between 3 x 60 mm
dishes 24 hours before the transfection. Three hours before the transfection the
medium was replaced with DMEMlI0% FCS. Prior to the transfection the
DNA/calcium phosphate precipitates were prepared; 10 ul of 1.25 M calcium chloride
was added slowly to 50 J.11of 2 x HEPES buffer (16 gil NaCI, 0.74 gil KCI, 2 gil
glucose, 10 gil HEPES), 3 ul 100 x phosphate solution (9.9 gil Na2HP04), 10 ~l
DNA (1 to 10 ug) and 27 ~l of water and mixed by passing air through the solution.
The precipitate was allowed to form at room temperature for 30 min. after which it
was added to 900 ~l ofDMEMlIO% FCS. The medium was removed from the dishes
of W162 cells and the cells overlayed with the 1 m1 of precipitate. The cells were
subsequently incubated at 37 °C/5% C02 for 3 hours with occasional rocking to
ensure the cells did not dry out. The media was then removed and 1 m1 of 20% (v/v)
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glycerol in TS buffer was added to each dish for 1 min.. The dishes were washed
twice with 2 m1 ofTS and overlaid with DMEM/I0% CS for 30 min.. The cells were
then overlaid with semi-solid media (4% (v/v) CS, 0.375% (w/v) NaHC03, 1% (w/v)
noble agar, in 1 x DMEM). After 3-4 days another semi-solid overlay was added (1%
(v/v) CS, 0.1875% (w/v) NaHC03, 1% (w/v) noble agar, in 1 x DMEM). When
plaques were visible (normally 6 days post-infection onwards) a third semi-solid
overlay was added (1% (v/v) CS, 0.l875% (w/v) NaHC03, 0.01% (w/v) neutral red,
1% (w/v) noble agar, in 1 x DMEM) and the plaques counted the next day. The
neutral red stained any live cells present facilitating the identification of virus plaques.
Any plaques visible were picked using a Pasteur pipette and stored at -70°C in 0.5 m1
TS/2% (v/v) CS.
2.3.4.6. Virus infection of cells monolayers
The medium overlaying the cell monolayer was aspirated off and TS/2% (v/v) CS
containing virus at a concentration to achieve the required multiplicity of infection was
added. For a 90 mm culture dish the volume of TS/2% (v/v) CS containing the virus
added was 0.5 ml; this was adjusted for other culture dishes according to their size.
The infected monolayer was incubated in a humidified incubator at 37°C, 5% C02 and
occasionally rocked to ensure the monolayer did not dry out. After approximately 1
hour prewarmed growth medium was added (10 m1 for a 90 mm plate) and the infected
monolayer retuened to the incubator.
2.3.4.7. Rapid preparation of adenovirus DNA
The cells from an infected monolayer in a 90 mm dish were harvested when cytopathic
effect could be seen. The cells were centrifuged at 2,000 x g for 10 min., the
supernatant removed and the pellet resuspended in 0.4 m1 TE (pH 9.0)/10 mM
spermine tetrahydrochloride. To this suspension 0.4 m1DOe lysis buffer (20% (v/v)
ethanol, 100 mM Tris.HCI pH 9.0, 0.4% (w/v) sodium deoxycholate) was added and
the resulting cell debris pelleted by centrifugation at 16,000 x g for 5 min.. The
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supernatant was collected and 60 ul of 10% (w/v) SDS, 20 ul 0.5 M EDTA, and 20 pl
20 mg/ml proteinase K were added. This was mixed by inversion and incubated at 37
"C for 1 hour. The solution was then extracted with phenol/chloroform and the DNA
precipitated by the addition of 30 ~l 5 M NaCI and 0.6 ml of propan-Z-ol. This was
mixed by inversion and left for 10 min. at room temperature, after which the DNA was
pelleted by centrifugation at 16,000 x g for 15 min.. The pellet was washed in ice-cold
70% (w/v) ethanol and then dried in a dessicator. The viral DNA pellet was
resuspended in 30 ~l of distilled water.
2.3.4.8. Large-scale preparation of adenovirus DNA
Infected cells were harvested on day 3 of the infection when the monolayer was
starting to lift from the surface of the dish. The cells were scraped from 10 infected 90
mm dishes and centrifuged at 2,000 x g for 10 min .. The cell pellet was resuspended in
10 ml of 0.1 M Tris.HCt pH 8.0 and sonicated on ice for 2 sets of 10 x Is pulses
separated by 30s using a Jencons GE375 ultrasonic processor and a 3 mm microtip.
The sonicated cells were then centrifuged at 3,750 x g for 10 min. at 4 "C and the
supernatant placed over a CsCI step gradient (5 x 90mm dishes per gradient) consisting
of3 ml ofCsCI in TO (density 1.25 g/ml) over 2ml ofCsCI in TD (density 1.4 g/ml).
The gradients were centrifuged at 150,000 x g for 1 hour at 15°C in a Beckman SW41
rotor. The resulting virus band was collected by puncturing the base of the tube and
collecting the required drip fraction. The collected virus was centrifuged again but in
CsClITD (density 1.35 g/ml) at 150,000 x g for 16 hours at 15°C in a Beckman
SW50.1 rotor to purify the virus further. The virus was collected as before, diluted
with two volumes of water and then the virions precipitated with two volumes of
ethanol at -70°C for 15 min.. The virions were was then pelleted by centrifugation at
5,000 x g for 20 min. at 4°C. The virion pellet was dried and resuspended in 2 ml of
TNE, 120 ~II0% (w/v) SOS, 40 ~l 0.25 M EDTA, and 20 ~11O mg/ml proteinase K.
This suspension was incubated at 37°C for 1-2 hours then extracted with 2 ml
phenol/TNE. The tube was gently inverted repeatedly over one minute when 1 ml of
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chloroform/amyl alcohol was added, and the solution mixed gently again for a further
minute. The two phases were separated by centrifugation at 2,000 x g for 10 min. at 4
°C. The aqueous phase was then phenol/chloroform extracted as before. 0.1 vol of 3
M sodium acetate and 2 volumes of ethanol were then added to the resulting aqueous
phase and the solution placed at -70°C for 30 min. to precipitate the viral DNA. The
DNA was pelleted by centrifugation at 5,000 x g for 30 min. at 4 °C after which the
pellet was washed with 70% (w/v) ethanol. The pellet was then resuspended overnight
at 4°C in 0.5 mlofTE.
2.3.4.9. Preparation of virus stocks
Infected cells were harvested when viral cytopathic effect could be clearly seen in the
monolayer. The cells were centrifuged at 2,000 x g for 10 min. and half of the
supernatant removed (so as to concentrate the virus stock). The cells were then
resuspended and subjected to four freeze-thaw cycles to lyse the cells and release
attached virions. The samples were then centrifuged again at 2,000 x g for 10 min. to
remove the cell debris and the supernatant stored in 2 to 3 rnl aliquots at -70°C.
2.3.4.10. Preparation of purified adenovirus virions
The protocol used for the purification of adenovirus virions was identical to that of the
large scale purification of viral DNA (2.3.4.8) upto the point when the virions are
purified from the second CsCI gradient. The purified virions were collected from the
gradient by the puncture of the base of the tube and then placed on ice. The
concentration of the virions was established by measuring the A260 value of virions
diluted in TNE/O.l% SDS (1 A260 unit is equivalent to 1012 virions/ml (1 pfu is equal
to 20-50 virions (Green et al, 1967)). The virion stock was stabilized by diluting 5-
fold with stabilizing buffer (0.1% BSA, 50% glycerol, 10 mM Tris (pH 8.0),100 mM
NaCI, and 2 mM MgCI2) and stored at -70°C ..
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2.3.4.11. Titration of adenovirus by plaque assay
A serial dilution of the virus stock was made from 10-1 to 10-8 in TS/2% CS. 200 III
of the appropriate dilution was used to infect duplicate HEK-293 cell monolayers in 35
mm wells in 6 well trays. The cells were then overlayed with semi-solid medium as
described in 2.3.4.5. The number of plaques were recorded after the staining of the
monolayer with neutral red (2.3.4.5.), allowing the calculation of the concentration of
the virus stock in pfu/ml.
2.3.5. Analysis of viral RNA expression
2.3.5.l. Preparation of cytoplasmic and nuclear RNA
The cells from a 150 mm dish were washed twice with 10 ml of complete PBS (PBS
supplemented with 0.1 gil CaCl2 and 0.1 gilMgCI2) and centrifuged at 2,000 x g for 3
min .. The cell pellet was resuspended in 2 ml isotonic buffer (150 mM NaCI, 10 mM
Tris.HCI pH 7.6, l.5 mM MgCI2) and vortexed with 200 III of 10% (v/v) Nonidet P40
(NP40). The suspension was then left to stand for 10 min. and the nuclei pelleted by
centrifugation at 2,000 x g for 3 min.. The supernatant was removed and the pellet
washed with 1 ml of isotonic buffer and centrifuged as before. The resulting
supernatants were combined and 60 III of 10% (w/v) SDS and 120 III 0.25 M EDTA
added. The pellet was resuspended in RSB (IOmM Tris.HCI pH 7.6, 3 mM MgCI2, 10
mM NaCl) and 2 III of 10 mg/ml DNase I (RNase-free) was added. The resuspended
nuclei were left on ice for 30 min. when 20 III of 10% (w/v) SDS and 40 III of 0.25
mM EDTA were added. Both the nuclear RNA fraction (the lysed pellet) and the
cytoplasmic RNA fraction (the supernatant) were then extracted with one volume of
phenollTNE and one volume of chloroform/amyl alcohol and centrifuged at 2,000 x g
for 10 min.. This was then repeated with one volume of phenollTNE and two volumes
of choloform/amyl alcohol. The aqueous phase was extracted repeatedly with
chloroform/amyl alcohol until it was clear. The RNA in the resulting aqueous phase
was precipitated with ethanol (-70°C) for one hour and pelleted by centrifugation at
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8,000 x g for 30 min.. The RNA pellet was dried and resuspended in 300 ~l of water.
(All manipulations were carried out at 4°C using RNase-free solutions).
2.3.5.2. Preparation of antisense RNA probes
1 ~g of linearized template was prepared by the appropriate digestion at the 3' end of
the sequence which was to be transcribed in the relevant pGEM subclone. This
template DNA was purifed by phenol/chloroform extraction and ethanol precipitation.
The purifed, linear template was then resuspended in water at a concentration of 100
ng/ul. The in vitro transcription reactions were then prepared in the order as follows:-
10 J.lCi/J.lIa_32p UTP (800 Ci/mmol)
Volume (ul)
2.5
5 x Sp6 or T7 buffer 1.25
10 x nucleotide mix (0.5 mM ATP, CTP, GTP and 0.1 mM UTP) 0.625
200mMDTT 0.3125
Water
Human placental RNase inhibitor (15 U/J.lI)
Template DNA (1OOng/~I)
Sp6 or T7 RNA polymerase
0.3125
0.25
0.7
0.5
The mixture was incubated for 1 hour at 37°C (for T7 polymerase) or 40°C (for Sp6
polymerase). The reaction was then diluted to 50 ul with water, 2 J.lIof 200 mM
vanadyl ribonucleotide complex and 1 ul of 10 mg/ml RNAse-free DNase added. The
reaction was incubated at 37°C for 10 min. when 0.5 J.lI10% (w/v) SDS was added
and the solution extracted with phenol/chloroform. The radioactive RNA probe was
purified using a Stratagene Nuctrap push column and stored at -20°C.
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2.3.5.3. Ribonucleaseprotection analysis
All the ribonuclease protection assays were carried out according to the method of
Melton et al. (1984). 5 ug of cellular RNA and 5 ~l of antisense probe were co-
precipitated by increasingthe volume to 40 ul with water and adding 1 ul of 5MNaCI,
100 ul of ethanol and placing at -20°C for 30 min.. The resulting RNA pellet was
dried and resuspended in 20 ~l of hybridisation buffer (80% (v/v) deionised
formamide,40 mM PIPES pH 6.7, 0.4 M NaCI, 1 mM EDTA). This was heated to 80
°C for 5 min. and then allowed to cool slowly overnight to 56°C. The hybridised
RNA solution was then diluted to 200 ~l in RNase solution (10 mM Tris.HCI pH 7.5,
5 mM EDTA, 300 mM NaCI, 100 units/ml RNase TI, and 5 ug/ml pancreatic RNase
A) and incubated at room temperature for 30 min.. To this 10 ~110% (v/v) SDS and 1
~1 of 20 mg/ml proteinase K was added and the solutions vortexed vigorously and
incubated at room temperature for 15 min. to ensure the complete degradation of the
RNases present. The solution was then extracted with phenol/chloroform, and the
protected RNA precipitated with 3 volumes of ethanol for 30 min. at -20°C. The
RNA was pelleted by centrifugation at 16,000 x g for 15 min., dried and resuspended
in 6 ul of formamide dye mix (80% (v/v) deionised formamide, 10 mM EDTA (pH
8.0), 0.05% (v/v) xylene cyanol and 0.05% (v/v) bromophenol blue). The sample was
heated to 90°C for 4 min. and then placed immediatelyon ice prior loading onto a 5%
polyacrylamidegel (2.3.5.4).
2.3.5.4. RNA PolyacrylamideGel Electrophoresis (PAGE)
Using Bio-Rad SequiGen gel apparatus, a 5% polyacrylamide denaturing gel was
prepared in 1 x TBE containing 4.75% acrylamide, 0.25% N,N -methylene-bis-
acrylamide, 46% (w/v) urea, 0.8 ug/ml ammonium persulphate and 0.83 ul/ml
TEMED. 2 ul of each RNA sample was loaded onto a prewarmed gel and
electrophoresised at 45 W (ca. 50°C) for 2-3 hours depending on whether the
protected fragments were large or small. The gel was then immediatelydried at 60 °C
88
under vacuum for 1-2 hours onto a piece of paper. The protected fragments were
visualised by autoradiography (2.3.12.).
2.3.6. Analysis of proteins
2.3.6.1. SDS polyacrylamide gel electrophoresis (SDS-PAGE)
SDS polacrylamide gel electrophoresis was carried out according to Laemmli (1970).
Protein samples in 100 mM DTT, 25 mM Tris.HCI pH 6.8, 10% (v/v) glycerol, 2%
(w/v) SDS and 56 ug/ml bromophenol blue were heated to 95 °C for 3 min. prior to
being loaded onto the discontinuous SDS-polyacrylamide gel. The resolving gel
contained 0.43 M Tris.HCI pH 8.8, 10 to 15% (w/v) acrylamide, 0.27 to 0.4% (w/v)
N,N-methylene-bis-acrylamide, 0.095% (w/v) SDS, 0.067% to 0.033% (w/v)
ammonium persulphate and 0.2 ul/ml TEMED. The amount of acrylamide in the
resolving gel was varied according to the size of the protein to be resolved, low
percentage acrylamide gels were run for the resolution of large proteins and vice versa.
The stacking gel contained 0.12 M Tris.HCI pH 6.8, 4.57% (w/v) acrylamide, 0.12%
(w/v) N,N-methylene-bis-acrylamide, 0.1% (w/v) SDS, 0.095% (w/v) ammonium
persulphate and 0.48 ul/ml TEMED. The gel was run in the BRL vertical gel
electrophoresis system at 240 V for about 3 hours in a buffer containing 30.3 gil Tris,
144.2 gil glycine, and 10.0 gil SDS.
2.3.6.2. Coomassie-blue staining ofSDS-polyacrylamide gels
To observe proteins present in a gel, the gel was stained and fixed for at least 1 hour in
7% (v/v) acetic acid, 25% (v/v) methanol and 0.1 rng/ml Coomassie blue. It was then
destained overnight using 7% (v/v) acetic acid and 25% (v/v) methanol and dried for
1-2 hours at 70 °C under vacuum.
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2.3.6.3. Monochromatic silver staining
If a more sensitive staining proceedure was required than coomassie blue staining the
PAGE-SDS gels with the diamine silver stain of Wray et al., (1981). The gel was
soaked in 50% methanol for at least one hour and then soaked in freshly prepared
silver stain for 15 minutes with gentle agitation. The silver stain was prepared by
adding, dropwise, 4 mls of a O.2g/ml silver nitrate solution to 22.4 ml of 0.3475%
NaOH and 0.925M ammonium hydroxide, and then made up to 100 mls with deionised
water. The gel was then washed 3 times for 5 minutes in deionised water and
developed in 500 mls of fresh developing solution (0.005% citric acid, 0.0185%
formaldehyde). When the stain was of the required intensity then the gel was washed
in deionised water and the development stopped by placing it in 50% methanol.
2.3.6.4. Preparation ofSDS-polyacrylamide gels for autoradiography
To visualise any radioactive proteins within a gel, the gel was fixed for 1 hour in 7%
(v/v) acetic acid, 25% (v/v) methanol, treated for 20 min. with Amplify (Amersham)
for fluorographic enhancement of radioactive emissions and then dried for 1-2 hours at
70°C under vacuum. Any radioactive proteins present were observed by
autoradiography (2.3.12.)
2.3.6.5. Bradford Assay (Bradford, 1978)
The amount of protein in a sample was quantified by performing a Bradford Assay on a
portion of the sample. 5 to 10 III of the protein sample was mixed with 0.15 M NaCI
to bring the volume up to 100 Ill. This was added to 1 ml of Coomassie G-250
Brilliant Blue Solution (100 ug/ml Coomassie Brilliant Blue (G-250), 0.05% (v/v)
ethanol, 8.5% (v/v) phosphoric acid) and vortexed. The colour was allowed to
develop for 2 min. and the AS9S was measured. The amount of protein present in the
sample was deduced by comparing the result of the unknown to the equivalent A595
reading on a BSA standard curve ranging from 0 to 10 ug (protein samples were
diluted to give an AS95 reading within this range).
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2.3.7. Bacterial protein expression
2.3.7.1. Protein expression and purification using the Glutathione-S-Transferase
system
Small scale protein purification
E. coli, containing the pGEX-2T plasmid with the gene to be expressed cloned in
frame in the short polylinker after the GST gene, were used to seed 2 ml of LB-Amp.
The culture was allowed to grow, at 37 °C/250 rpm, to a density of 0.5 ~OO when
IPTG was added to a concentration of 0.1 mM to induce the transcription of the
GST/gene fusion. The culture was then grown for a further 2-6 hours and then
centrifuged at 16,000 x g for 10 seconds to pellet the cells. The cells were
resuspended in 1 ml of ice-cold PBS and sonicated on ice for 30 seconds or until the
solution became translucent, using a Jencons GE37S ultrasonic processor and a 3mm
microtip. The solution was subsequently centrifuged at 16,000 x g for 5 min., to
remove the insoluble fraction (P), and 50 III of a 50% (w/v) slurry of glutathione
sepharose 4B beads (Pharmacia) added to the supernatant (SIN). The mixture was
rocked gently for 10 min. and the beads pelleted by centifugation at 16,000 x g for 10
seconds. The beads were then washed 3 times with PBS and resuspended in an equal
volume of2 x SOS/samplebuffer (200 mM OTT, 50 mM Tris.HCl pH 6.8,20% (v/v)
glycerol, 4% (w/v) SOS and 112 ug/ml bromophenol blue) if the samples were to be
analysedby SOS polyacrylamidegel electrophoresis.
Large scale protein purification.
A 500 m1 culture (as above) was allowed to grow, at 37 °C/250 rpm, to a density of
0.5 ~OO when IPTG was added to 0.1 mM. The culture was then placed at 30
°C/250rpm, left overnight and then centrifuged at 2,000 x g for 15 min. to pellet the
cells. The cell pellet was resuspended in 10 m1 of ice-cold PBS and broken using a
French Cell Pressure Press (American Instruments Company) at 1010 psi. The lysed
cellswere centrifuged at 32,500 x g for 60 min. to remove the bacterial debris and the
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supernatant removed. The supernatant was diluted to 500 m1with PBS and 2.5 m1of a
50% (w/v) slurry of glutathione sepharose 4B beads added. This mixture was rocked
gently at room temperature for 10 min. and the beads subsequently pelleted by
centrifugation at 2,000 x g for 3 min.. The beads were washed three times with 100 m1
of PBSI1% (v/v) Triton XI00, and then immobilised on a small column. The
GST/gene fusion protein was eluted off the column with 50 mM Tris.HCI pH 8.0/20
mM reduced glutathione and collected in 0.5 m1 fractions. The protein content of
these fractions was assayed by SDS-PAGE (2.3.6.l.) and Bradford analysis (2.3.6.5.).
The fractions containing the most pure protein were pooled and stored at -70 °C.
Thrombin cleavage of the GST -fusion protein
If the GST fusion protein was to be cleaved to release the pure recombinant protein
then the PBS washed beads, with the recombinant protein attached were washed with
150 mMNaCl, 50 mM Tris pH7.5, and then with 150 mM NaCI, 50 mM Tris pH7.5,
2.S mM CaCI2. The GST fusion protein was then cleaved by digestion with the
required amount of thrombin at 30 °C in 150 mM NaCI, SOmM Tris pH7.S, 2.S mM
CaCl2 (40 ~l ofbuffer/l0 ~l of 50% (w/v) glutathione sepharose beads).
2.3.7.2. Inclusion body purification ofpGEX fusion proteins
The recombinant protein was expressed in a 2 m1 culture under standard conditions
(2.3.7. I). The cells were then pelleted by centrifugation at 16,000 x g for 10 seconds
and resuspended in 200 ul ofTEN (SOmM Tris.HCl pH 7.5, 0.5 mM EDTA, 0.3M
NaCI, 1 mg/m1lysozyme). This was incubated on ice for 15 min. when NP40 was
added to 0.2% and left for a further 10 min .. 300 ul of I.5M NaCl, 12 mM MgCI2,
3.3 ug/ml DNase was added and the mixture left at 4 °C overnight. The mixture was
then centrifuged at 1,000 x g for S min. to remove any intact cells, the supernatant
removed and centrifuged again at 5,000 x g for 20 min. to pellet the inclusion bodies.
These were then washed three times with 100 ul 6M urea and then three times with
100 ~1TEN (without the lysozyme). The method was scaled up when required.
92
2.3.7.3. Protein expression and purification using the histidine tag system
The pTrcHis expression system (Invitrogen)
Expression and purification of recombinant proteins using this system was
accomplished as per the instructions provided by the manufacturer.
The pQE expression system (Qiagen)
E. coli containing the pQE-30 (Qiagen) plasmid, with the gene to be expressed cloned
in frame in the short polylinker after the 6 histidine residues, were used to seed 50 ml
ofLB containing suitable antibiotics. The culture was allowed to grow, at 37 °C/250
rpm, to a density of O.SAQoo when IPTG was added to 2mM. The culture was then
incubated for a further 5 hours at 37°C and centrifuged at 2,000 x g for 15 min. to
pellet the cells. The cells were then lysed in 10 ml of 6M guanidine.HCI, 0.1 M
NaH2P04, 0.01 M Tris.HCI, pH 8.0 and left for 1 hr at room temperature. The
resulting lysate was centrifuged at 10,000 x g for 15 min. at 4°C and mixed with 4 ml
of nickel-resin (ProBond, Invitrogen), previously equilibrated with 6M guanidine.HCl,
0.1 M NaH2P04, 0.01 M Tris.HCI, pH 8.0, for 1 hour at room temperature. The
resin was then immobilised on a small column and washed with 10 volumes of 6M
guanidine.HCI, 0.1 M NaH2P04, 0.01 M Tris.HCl, pH 8.0 and then 5 volumes of 8M
urea, 0.1 M NaH2P04, 0.01 M Tris.HCI, pH S.Ountil the eluate had an A2S0 of less
than 0.01. The column was then washed with a high stringency wash (SM urea, 0.1 M
Na2P04, 0.01 M Tris.HCl, pH 6.8) until the eluate had an A2S0 of less than 0.01.
The recombinant protein was eluted from the column with SM urea, 0.1 M Na2P04,
0.01 M Tris.HCI, pH 4.5) in 0.5 ml fractions. The protein content of the fractions was
determined by SDS-PAGE (2.3.6.1.) and Bradford analysis (2.3.6.5.).
2.3.8. Production of mono-specific polyclonal antibodies
500 J.lIof purified recombinant fusion protein (from either the GST or Histidine tag
system, 200 to 500 ug/ml) was mixed with an equal volume of Freund's adjuvant
(complete adjuvant was used in the first injection, subsequent boosts used incomplete
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adjuvant) by vortexing for 30 min. or until the mixture was glutinous. The Freund's
adjuvant prevents the rapid catabolism of the antigen when in the animal by forming a
deposit and also stimulates the animals immune response non-specifically by increasing
the lymphokine level of the animal so stimulating the activity of the antigen processing
cells. The mixture was then innoculated into a virgin rabbit by subcutaneous injection
into the scruf of the neck. The rabbit was boosted with antigen every 2-3 weeks.
Blood samples were taken by bleeding the rabbit from the marginal ear vein at 6 weeks
after the first inoculation and then every 2-3 weeks. The blood was allowed to clot
overnight at 4 QC. The clot was then detached from the container and allowed to
shrink for 24 hours at 4 QC. The clot was then removed by two 15 min. centrifugations
at 2,000 x g and the supernatant (the serum) stored as 500 J.llaliquots at -20 QC.
The immunisation and bleeding of rabbits was kindly performed by Mrs. Carol Hill.
2.3.9. Immunochemical techniques for the detection of proteins
2.3.9.l. Western blot analysis (Towbin et al., 1979)
Protein transfer
The SDS-polyacrylamide gel was soaked in transfer buffer (3.03 gil ofTris base, 14.4
gil of glycine, 20% (v/v) methanol) for 30 min. along with 6 pieces of What man 3MM
filter paper, 2 nylon pads and one piece of nitrocellulose (Hybond C, Amersham). The
pads, gel, filter paper and nitrocellulose were then sandwiched together, placed in a
BioRad Trans-Blot Cell and a potential difference of 70V placed across the sandwich
so that the negatively charged proteins were transfered onto the nitrocellulose. The
proteins were allowed to transfer for 3-4 hours at 4 QC. To see if the proteins had
transfered, the nitrocellulose was soaked in Ponceau S solution (0.5% (w/v) Ponceau
S, 1% (v/v) acetic acid) for 5 min., and subsequently washed with water to allow the
visualisation of the transfered proteins.
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Detection of antigen present on the nitrocellulose
The nitrocellulose was soaked for at least 1 hour in PBS/5% (w/v) low fat dried milk
(Marvel), and then washed for 5 x 5 min. with PBS/0.1% (v/v) Tween 20. The
primary antibody (diluted to the required concentration) was then added to the
nitrocellulose in PBS/5% (w/v) marvel for 2 hours at room temperature. The
nitrocellulose was then washed for 5 x 5 min. with PBS/0.1 % (v/v) Tween 20 and the
secondary antibody conjugate added (anti-rabbit immunoglobulin, biotinylated species-
specific whole antibody, Amersham) at a dilution of I in 400 in PBS/1 % (w/v) Marvel.
This was incubated with the nitrocellulose for 1 hour at room temperature when the
nitrocellulose was washed for 5 x 5 min. with PBS/0.1 % (v/v) Tween 20. Then a
streptavidin-biotinylated horseradish peroxidase complex (Amersham) was added to
the nitrocellulose at a dilution of 1 in 300 in PBS/1 % (w/v) Marvel and left at room
temperature for 25 min.. The nitrocellulose was subsequently washed for 5 x 5 min.
with PBS/0.1% (v/v) Tween 20 and then twice with PBS. Any antigen present was
visualised by the addition of the development solution (16.7% (v/v) methanol, 0.5
mg/ml 4-chloro-1-naphthol, 0.015% hydrogen peroxide in PBS). The developed
nitrocellulose membrane was then air-dried on Whatman 3MM paper at 37°C in the
dark.
2.3.9.2. Immunoprecipitation of proteins using polyclonal antibodies
Most immunoprecipitations were carried out with 1 ml RIPA buffer (150 mM NaCI,
50 mM Tris.HCI pH 8.0, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 100 IlM
PMSF) lysates of 107 HeLa cells. Sometimes the buffer conditions and the amount of
antigen present were different, in which case the amount of antibody used was varied
accordingly; the wash buffer used was always of the same composition as the lysis
buffer. If the lysates were labelled with 35S-met then an equal number of incorporated
counts (see section 2.3.10.2.) was assayed ensuring that the same amount of labelled
protein entered the assay.
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5 ~l of preimmune sera was added to the lysate and incubated at room temperature for
15 min. when 50 ~l of Immuno-precipitin (formalin-fixed Staphylococcus aureus cells
(10% w/v» were added for a further 15 min. to pre-adsorb any background protein.
The mixture was then centrifuged twice at 16,000 x g for 30 seconds to remove the S.
aureus cells. To the supernatant 2-3 ~l of antibody was added and the mixture
allowed to shake gently at 4 °C overnight. To this 25 ~l Immuno-precipitin was added
and shaken gently for a further 30 min.. The Immuno-precipitin/antibody complex was
then pelleted by centrifugation at 16,000 x g for 30 seconds and the pellet washed
thoroughly 3 times to remove any nonspecifically bound proteins. The pellet was then
resuspended in 30 ~l of SDS gel loading buffer (100 mM DTT, 25 mM Tris.HC} pH
6.8, 10% (v/v) glycerol, 2% (w/v) SDS and 56 ug/ml bromophenol blue) and the
sample run on a SDS-polyacrylamide gel (2.3.6.1)
2.3.9.3. Enzyme linked immunoadsorbent assay (ELISA)
0.5 ug of antigen in 100 ~l of coating buffer (0.1 M Na2C03, 0.1 M NaHC03) was
placed into the required wells of an Immulon 2 ELISA plate and left overnight at 4 °C.
The liquid was then removed and the wells washed three times with PBS/0.05% (v/v)
Tween 20. 200 ul of 5% (w/v) Marvel was added to each well, left for 1 hour at 37
°C and again washed three times with PBS/0.05% (v/v) Tween 20. The test antisera
were then added in 100 pl of 0.1% (w/v) BSAlO.OS% (v/v) Tween 20IPBS as a
dilution series. This was left for 1 hour at 37 °C when the wells were washed three
times with PBS/O.OS% (v/v) Tween 20. Bound antibody was then detected by the
addition of 100 ~l of a 1 in 400 dilution of a biotinylated species-specific whole
antibody preparation of anti-rabbit immunoglobulin to each well in 0.1% (w/v)
BSAlO.05% (v/v) Tween 201PBS. After one hour at 37 °C the wells were washed
three times with PBS/O.OS% (v/v) Tween 20 and 100 ul of a 1 in 3,000 dilution of a
streptavidin-biotinylated horseradish peroxidase complex added in 0.1% (w/v)
BSAlO.05% (v/v) Tween 201PBS. This was left for 15 min. at room temperature and
washed three times with PBS/0.05% (v/v) Tween 20. 100~} of substrate (35 mM
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citric acid, 67 mM Na2HP04, 670 mg/ml 1,2-phenylenediamene (OPD, Dako) and
l.25 x 10-4% (v/v) H202) was then added and left for 5 to 10 min.. The resulting
colour change was stabilized by the addition of 50 ~l of 2.5 M sulphuric acid. The
1\492 was then measured for each well using an ELISA plate reader (Titertek
Multiskan Plus MkII). The titre of a sample was taken as the dilution required to give
an 1\49250% of that of the plateau 1\492,
2.3.10. Analysis of viral protein expression
2.3.10.l. 35S-methionine labelling of proteins in tissue culture
Cell monolayers on 90 mm dishes (107 HeLa cells, labelling experiments carried out
using different size dishes used amounts of reagents that were scaled accordingly) were
incubated with 2 ml of methionine-free GMEM for 30 min.. This was replaced with 1
ml of methionine free GMEM supplemented with 100 ~Ci of35S methionine (specific
activity >800 ~Cilmmol, Amersham) and the dish incubated for a further 1 to 3 hours
and then placed on ice. The cells were then washed with ice cold TD and lysed in the
required lysis buffer. In most instances the cells were lysed in RIPA buffer (150 mM
NaCl, 10 mM Tris.HCI pH 7.6, 1% (v/v) Triton X-lOO, 1% (w/v) sodium
deoxycholate, 0.1% (w/v) SDS, 100 ~M PM SF) but sometimes the cells were
fractionated by lysis in alternative buffers (2.3.10.3,2.3.10.4). RIPA buffer lysates to
be immunoprecipitated were then sonicated on ice, at low power, using a Jencons
GE375 ultrasonic processor and a 3 mm microtip to disipate the released DNA. The
samples were then centrifuged at 16,000 x g for 10 min. to remove any debris,
quantified (2.3.10.2.) and the supernatant immunoprecipitated (2.3.9.2).
2.3.10.2. Quantification of 35S-methionine incorporation into protein
10 ~l of labelled cell extract was diluted to 0.5 ml with ice cold water and mixed with
100 ul of 100% (v/v) TCA in water. This was allowed to stand for 15 min. and the
resulting precipitate collected on a 2.5 cm Whatman GF/C glass microfibre filter. The
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filter was then washed twice with 1 ml of S% (v/v) TCA (4°C) and twice with 1 ml of
ethanol. The filter was then air-dried and placed in S ml of Optiphase Safe scintillation
fluid. The radioactivity present on the filter was measured using a LKB Wallac 1219
Rackbeta scintillation counter.
2.3.10.3. Subcellular fractionation using hypotonic buffer
The washed tissue culture cells were scraped off the 90 mm dish into S ml of ID.
They were then centrifuged at 2,000 x g for 5 min., resuspended in 1 ml of hypotonic
buffer (10 mM Tris.HCI pH 7.5, 10 mM NaCI, I.S mM MgCI2, 100 ~M PMSF), and
allowed to stand on ice for 20 min.. The swollen cells were lysed with 25 strokes in a
Dounce homogeniser and the lysate was centrifuged at SOOx g for S min. to pellet the
nuclei (PO.S, >236600 Svedberg Units). The supernatant (SO.S) was then either
fractionated further or made up to RIPA conditions for analysis. To fractionate the
supernatant further it was centrifuged at SO,OOOx g for 20 min. to produce a pellet
(PSO, >1,113 Svedberg Units (cell membrane fraction» and a supernatant (SSO). The
supernatant was then centrifuged at 200,000 x g for 60 min. to produce a pellet (P200,
>59 Svedberg Units) which contained polysomes, ribosomes and smaller microsomes
found within the cytoplasm. The resulting supernatant (S200) contained proteins
which were in complexes of less than 59 Svedberg Units This final supernatant was
made up to RIPA conditions and the pellets were resuspended in Iml ofRIPA buffer.
All the fractions were then sonicated on ice for 10 seconds, at low power, using a
Jencons GE37S ultrasonic processor and a 3 mm microtip. The fractions were then
centrifuged at 16,000 x g for 10 min. to remove any debris and anlaysed by immuno-
precipitation (2.3.9.2)
2.3.10.4. Sucrose gradient analysis
The monolayer from a 90 mm dish of cells (107 cells) was lysed by hypotonic lysis
2.3.10.3. The supernatant fraction (SO.S) was then placed on a S ml sucrose step
gradient (S to 20% (wt/wt) gradient in 6 steps, with a 60% fraction at the base, all in
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hypotonic buffer (10 mM Tris.HCI pH 7.5, 10 mM NaCI, 1.5 mM MgCI2, 100 JlM
PMSF» which had previously been allowed to stand for 2 hours at 4 "C. The gradient
was then centrifuged at 240,000 x g for 6 hours at 6°C. 0.5 m1 fractions were then
collected from the gradient by bottom puncture. The protein content of each fraction
was examined by immunoprecipitation.
2.3.11. In vitro protein expression
2.3.11.1. In vitro protein expression
The expression of proteins in vitro was accomplished using the Promega TnT Coupled
Transcription-Translation Reticulocyte Lysate System and used according to the
manufacturers instructions.
2.3.11.2. Quantitation of protein produced using rabbit reticulocyte lysate
2 JlI of a 50 JlI translation reaction (2.3.11.1.) was mixed with 98 JlI of 1 M NaOHl2%
(v/v) H202 and incubated for 10 min. at 37°C. Subsequently 900 JlI of ice cold 25%
(v/v) TCAl2% (w/v) casamino acids was added and allowed to stand on ice for 30
min.. The resulting precipitate was collected on a 2.5 cm Whatman GF/C glass
microfibre filter and processed as 2.3.10.2 .. Total counts were measured by adding 5
JlI of the TCA reaction directly onto a filter and measuring the radioactivity present.
This allowed the determination of the percent incorporation into high molecular weight
material in the reaction.
2.3.12 Autoradiography
Radiolabelled protein, RNA or DNA on dried, radioactive, polyacrylamide gels was
visualised by placing the gel in close contact with preflashed Fuji Rx X-ray film in a
light-fast autoradiography cassette at -70°C. The appropriate preflash distance was
determined by measuring the absorbance of test film at 545 nm and comparing it to
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that of unflashed film. The flash distance was set so that the ratio of absorbance of
preflashed to unflashed film was in the order of 0.1 to 0.2. This allowed the film to
respond in a linear fashion to the radioactivity in the gel. The film was then developed
after the required period oftime (normally the next day).
2.3.13. Densitometry
The bands on autoradiographs which corresponded to radioactivity in the gels were
quantified on a Molecular Dynamics laser densitometer, using Image Quant 3 analysis
software. Only autoradiiographs which were 'pre-flashed' (2.3.14.) and not over
exposed were quantified by densitometry ..
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Chapter 3.
The Sequence of ORFI and 2 of AdS early region 4
3.1 Introduction
ORFI and ORF2 of AdS E4 region were originally sequenced by Steenbergh and
Sussenbach (1979) using the Maxim-Gilbert chemical degradation technique; this
sequence was subsequently used by Chroboczek et al. (1992) in compiling the
complete AdS genome sequence. However, comparison of the published Ad2 and AdS
sequences (Roberts et al., 1984, Chroboczek et al., 1992) showed a number of
differences in the E4 region, including disrupted ORFs 1 and 2 in AdS. The high ratio
of frameshift to point mutations in these putative coding regions, together with the
high degree of sequence conservation as compared with adjacent non-coding regions,
suggested that the frame-shifts might be sequencing artefacts. To determine whether
or not AdS could potentially encode E4 ORFI and ORF2 products, the region of AdS
between nucleotides 34790 and 35615 was resequenced.
3.2 Cloning of the AdS DNA to be sequenced
All adenovirus numbering in this chapter refers to the published sequence of
Chroboczek et al., 1992 (Gen Bank ace, no. M73260) amended by Dix and Leppard,
1992 (Gen Bank ace. no. D12587) unless otherwise stated.
The relevant pieces of the AdS strain wt300 KpnI-G genomic fragment were subcloned
into plasmids and then the M13 vectors mp18 and mpl9: the SmaI (35354) - HaeIII
(35615) fragment was cloned into the SmaI site of pGEM4, to give the subclone
pID13, and then into the polylinker ofmpI8 and 19 using the HindIII and EcoRI sites
of pGEM4~ the HindIII (34930) - SmaI (35354) fragment was cloned into the
polylinker of pGEM4, to give the subclone pID 11, and then into the polylinker of
mp 18 and 19 using the HindIII and EcoRI sites of pGEM4. Single stranded DNA was
prepared from the M13 clones and sequenced with the -40 M13 universal primer. The
sequence from 34790 to 34930 was determined by sequencing directly a plasmid
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subclone (pID9) containing the AdS wt300 BglII (3411S) to HindIII (34930) fragment
using an SP6 specific primer; IDB (see section 2.1.2.).
3.3 Results
In each of the four regions where the published AdS sequence contained frameshifts in
ORFI and ORF2 (positions 34934, 3S320/21, 3SS09/10 and 3S522/23), the sequence
obtained showed the ORFs to be intact, as in Ad2 (see fig. 3.1., and table 3.1.). All
except one of the other differences between Ad2 and AdS expected on the basis of
previously published data were confirmed (see table 3.1.) discounting the possibility
that the DNA sequenced was of Ad2 origin. The exception was the ORF2 missense
mutation at nucleotide 34860 (AdS) where this data indicates that the AdS wt300
strain ORF2 encodes the same amino acid as that of Ad2 at this position (met78). The
data presented here would suggest a revised length of 3S938 bp for the AdS strain
wt300 genome as opposed to the previously published length of 35935 bp
(Chroboczek et al., 1992). The revised sequences ofORFl and ORF2, together with
the differences as compared to Ad2 (Roberts et al., 1984) and AdS (Chroboczek et al.,
1992), are displayed in Fig. 3.2 and 3.3, respectively.
3.4. Discussion
The above results demonstrate that both ORFI and ORF2 are intact in AdS. The AdS
nucleotide sequences of both ORFI and ORF2 are over 99% identical with their Ad2
counterparts, with 3 nucleotides varying in each ORF (see Table 3.1.). However,
while the predicted 128 amino acid AdS ORFI is identical in protein sequence with the
Ad2 ORFI sequence, the predicted 130 amino acid AdS ORF2 has a single amino acid
difference compared to the Ad2 protein (AdS = Ser30, Ad2 = AlaJO) (Table 3.2.).
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Figure 3.1. ORFI and ORF2 sequence data depicting regions of variation
between published Ad2, Ad5 and revised Ad5 sequences. AdS wt300 DNA was
sequenced using the dideoxynuc1eotide chain termination method (2.3 .1.13.). The
arrow indicates the 5' to 3' direction of the L-strand while an * indicates a nucleotide
different to that found in either the Ad2 (Roberts et aI., 1984) and/or the published
AdS (Chroboczek et aI., 1992) sequence (see Fig. 3.2 and 3.3 and table 3.1.). All gels
are loaded G, A, T and C.
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Figure 3.2. The comparison of the revised sequence of Ad5 E4 ORFI with Ad5
(Chroboczek et al., 1992) and Ad2 (Roberts et al., 1984) 35526·35143 (Lestrand).
'.' indicates an absent nucleotide.
ATGGCTGCCGCTGTGGAAGCGCTGTATGTTGTTCTGGAGCGGGAGGGTGCTATTTTGCCTAGGCAGGAGGGTTTTTCAGGTGTTTA
TGTGTTTTTCTCTCCTATTAATTTTGTTATACCTCCTATGGGGGCTGTAATGTTGTCTCTACGCCTGCGGGTATGTATTCCCCCGG
GCTATTTCGGTCGCTTTTTAGCACTGACCGATGTGAATCAACCTGATGTGTTTACCGAGTCTTACATTATGACTCCGGACATGACC
T C
GAGGAGCTGTCGGTGGTGCTTTTTAATCACGGTGACCAGTTTTTTTACGGTCACGCCGGCATGGCCGTAGTCCGTCTTATGCTTAT
A
AAGGGTTGTTTTTCCTGTTGTAAGACAGGCTTCTAATGTT AdS (Dix and Leppard)
Ad5 (Chroboczek et al.)
Ad2 (Roberts et al.)
Figure 3.3. The comparison of the revised sequence of Ad5 E4 ORF2 with Ad5
(Chroboczek et al., 1992) and Ad2 (Roberts et al., 1984) 35092·34704 (L-strand).
'.' indicates an absent nucleotide.
ATGTTTGAGAGAAAAATGGTGTCTTTTTCTGTGGTGGTTCCGGAGCTTACCTGCCTTTATCTGCATGAGCATGACTACGATGTGCT
A
TTCTTTTTTGCGCGAGGCTTTGCCTGATTTTTTGAGCAGCACCTTGCATTTTATATCGCCGCCCATGCAACAA-GCTTACATCGGG
A
G A
GCTACGCTGGTTAGCATAGCTCCGAGTATGCGTGTCATAATCAGTGTGGGTTCTTTTGTCATGGTTCCTGGCGGGGAAGTGGCCGC
A
GCTGGTCCGTGCAGACCTGCACGATTATGTTCAGCTGGCCCTGCGAAGGGACCTACGGGATCGCGGTATTTTTGTTAATGTTCCGC
TTTTGAATCTTATACAGGTCTGTGAGGAACCTGAATTTTTGCAATCA AdS (Dix and Leppard)
AdS (Chroboczek et al.)
Ad2 (Roberts et al.)
lOS
Table 3.1. The DNA sequence variations of the E4 ORFI and ORF2 regions of
AdS (Dix and Leppard, 1992), AdS (Chroboczek et al., 1992) and Ad2 (Roberts
et al., 1992) (sequence changes indicated are to the L-strand)
Ad5 (Chroboczek) Ad5 (Dix and Leppard) Ad2 (Roberts)
34860 A 34860 T 34863 T
34925 C 34925 C 34928 A
34934 A 34933/34 - 34936/37 -
35005 T 35006 T 35008 G
35049 G 35048 G 35051 A
35264 G 35263 G 35269 A
35318 T 35317 T 35323 C
35320/21 - 35320+21 TG 35326+7 TT
35509/10 - 35511 G 35517 G
35522/23 - 35525 T 35531 T
Table 3.2. Amino acid changes due to the nucleotide differences between Ad2
and AdS ORFI and ORF2. Ad5 sequence is from Dix and Leppard (1992) while the
Ad2 sequence is from Roberts et al. (1984), sequence is taken from the L-strand.
Adenovirus 5 (Dix and Leppard) Adenovirus 2 (Roberts)
Nucleotide Amino acid Nucleotide Amino acid
34925 C ORF2 Ile 56 34928 A ORF2 ne 56
35006 T ORF2 Ser 30 35008 G ORF2 Ata30
35048 G ORF2 Glu 15 35051 A ORF2 Glu 15
35263 G ORFI Glu 88 35269 A ORFI Glu 88
35317 T ORFI Asn 69 35323 C ORFI Asn69
35320 G ORFI Val68 35326 T ORFI Val68
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3.5. Computer prediction and homology studies of ORFI and ORF2
3.5.1. Introduction
The AdS ORFI and ORF2 protein sequences deduced from the DNA sequences have
been subject to computer analysis to predict protein structure, using both the
University of Wisconsin Genetics Computer Group sequence analysis software
package (GCG) and the Microgenie sequence analysis program (Queen and Korn,
1984). Two different algorithms were used for secondary structure predictions, that of
Garnier et at. (1978) and Chou and Fasman (1974, 1977), and two algorithms were
also used to determine the hydrophobicity/ hydrophilicity of the proteins, that of Hopp
and Woods (1981) and Kyte and Doolittle (1982). Where possible, the consensus of
the results of alternative prediction methods was used in subsequent dicussions.
Homology searches were also carried out for these proteins, screening the EMBL data
base and the SwissProt data base, using the GCG Fasta and Tfasta programs at default
settings.
In the following sections the results from these analyses are discussed.
3.5.2. ORFI structure predictions
Analysis of the amino acid content of the 128 residue AdS E4 ORFI protein indicates
that it is hydrophobic (see figs 3.4 and 3.6) and has a negative overall charge at neutral
pH with a pI of 5.12.
The sequences of a number of different adenovirus ORFI proteins have been
published. Using the Pileup and Pretty programs on the GCG package, ORFI proteins
representative of 4 adenovirus subgroups were analysed for homology: the subgroup A
virus Ad12, 52% identity to AdS (Sprengel et al., 1994)~ the subgroup B virus Ad34,
29% identity to AdS (Chen and Horwitz, 1990)~ the subgroup C virus AdS (Dix and
Leppard, 1992), the subgroup D viruses Ad9, 45% identity to AdS (Javier and Shenk,
1992), (see Fig. 3.5.). The E4 sequence of Ad40, a subgroup F
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Figure 3.4a. AdS ORFI
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Figure 3.4b. ADS ORF2
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Figure 3.4. The structure of AdS ORFI and ORF2 as predicted by the Microgenie
Sequence Analysis Program (Queen and Korn, 1984). Displayed are one
dimensional, multi-paneled plots with the protein residues on the x axis and the
attributes represented as continuous curves on several different panels. All structure
was determined using the algorithm of Garnier et al. (1978), while hydrophobicity
was determined using the algorithm of Hopp and Woods (1981). Values above the
dashed line indicate an increased probability of the protein containing either an alpha
helix (Alpha), beta sheet (Beta) and/or a hydrophilic region (Hyd) at this point and
vice versa for values below the dashed line. 'Charg' indicates the predicted net charge
at this point; values above the norm indicate a positive charge while values below the
norm indicate a negative charge.
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virus, has been published by Davison et al. (1993) and does not contain any region
capable of encoding an ORFI-related protein. This would indicate that Ad40, which
causes infantile gastro-enteritis, does not require the ORFI product for efficient
replication within the gut. The other viruses sequenced, which all retain the ORFI
protein, are not primarily associated with gut infections, suggesting the protein is
necessary for viral replication only in certain cells of the host.
From Fig. 3.5 it can be seen that there is one distinct region of homology between all
of the ORFI proteins, between residues 53 and 68 (Ad5)~ VxIPxGYxGxFLxLxD. This
may signify a functionally important region of the protein. As a result of this sequence
conservation, the predicted secondary structure of the region, a tum - p-strand - tum,
is conserved in all of the ORFI proteins at this point. The lack of any other distinctive
regions of homology between all four ORFI proteins can be attributed to the
divergence of the Ad34 ORFI protein. On closer inspection of the Ad34 right end
DNA sequence, a good homology to the other Ad ORFI's from about residue 70
onwards to the C terminus was identified in the +1 reading frame, suggesting that there
has been a frame-shifting sequencing error in this region of E4 in the data of Chen and
Horwitz (1990), (Figure 3.5.). Presuming this to be the case, the Ad34 protein is
probably about 124 amino acids in length as opposed to the 108 amino acids of the
current sequence.
Assuming that the C terminus of the Ad34 ORFI protein has the alternative sequence
discussed previously, all the Ad ORFI proteins have a second conserved region
between residues 88 to 96 (Ad5)~ ELxVxLFNH. This region is also close to a
potential N-linked glycosylation site in the Ad9 (NHT, residues 92 to 94) and Adl2
(NHS, residues 94 to 96) ORFI proteins. However this site is not conserved in the
Ad5 and Ad34 sequences suggesting that it may not be of significance. Apart from
conserved sequence motifs, the ORF 1 proteins also show similarities in their predicted
secondary structure and distribution of hydrophobic residues that are not readily
detectable detectable from the primary sequence. A distinct hydrophilic
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1 50
ad50rfl MAAAVEALYV VLEREGAILP RQEGFSGVYV FFSPINFVIP PMGAVMLSLR
ad90rfl MA ...ESLYA FIDSPGGIAP VQEGTSNRYT FFCPESFHIP PHGWLLHLK
ad120rfl MA.AFETLYV YFTGPGAMLP KQEGDSNAYV LFSAANFVIP PHGVVLLYLH
ad340rfl M ...IEALYV YLEGPGATLP EQQQ.RNNYI FYSPVPFTLY SRGVALLYLR
Conserved (4)
Conserved (3)
M----E-LY- -----G---P -Q------Y- **----F--- --G--*L-L-
M*---E-LYV Y**-PGA-LP -QEG-SN-Y* FFSP--F-IP P-GWLL-L-
51 100
ad50rfl LRVCIPPGYF GRFLALTDVN QPDVFTESYI MTPDMTEELS VVLFNHGDQF
ad So r f I VSVLVPTGYQ GRFMALNDYH ARDILTQSDV IFAGRRQELT VLLFNHTDRF
ad120rfl IAVDIPPGYL GTLFSLCDMN ARGVFVGAET LYPGSRMELS VLLFNHSCVF
ad340rfl LSI IIPKGYV GCFFSLTDAN SLDCMLHQEL FMLVTARNFR CCCLITMTGF
ad340rfl (alt) LYASSRI IHAGHREELS VLLFNHHDRF
Conserved (4) --*-*P-GY- G-**-L-D-- ----*----- --------*- ---*-----F
Conserved (3) --V-IP-GY- G-F*-L-D-N --D**---*- -------EL- V-LFNH---F
101 128
ad So r f I FYGHAGMAW RLMLIRWFP WRQASNV
ad l z o r f I CDVRAKQPVA RLLLSRVVFP PVCQASLI
ad90rfl LYVRKGHPVG TLLLERVIFP SVKIATLV
ad340rfl ..TRSSWRPC GLVL ...... .. . . . .. .
Ad340rfl (alt) YEVELETLWA CLVMERLIYP PVRQATMI
Conserved (4) ---------- -L-L------ --------
Conserved (3) ---R----V- -L*L-RV*FP -V--A--*
Figure 3.5. Alignment of the predicted AdS, Ad9, Ad12 and Ad34 E4 ORFI
protein sequences, prepared using the GCG PileUp and Pretty programs. Displayed
are the points of identity in the sequences and any conserved amino acids present in
all four of the sequences (Conserved (4» and three of the sequences (Conserved (3».
An * denotes where there is a conservative constitution in a114 of the proteins (in 3 of
the proteins with Conserved (3». The AdS, Ad9, Ad12 and Ad34 E4 ORF1 proteins
are 128, 125, 127 and 108 amino acids respectively. The Ad340RFl (alt) is the
alternative Ad34 ORFI C-terminal sequence, corrected for the presumed sequence
error in the DNA (see text).
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Figure 3.6. Predicted secondary structures of the AdS, Ad9, Ad12 and Ad34
ORFI proteins as determined using the Plotstructure and Peptidestructure commands
of the Genetics Computer Group Sequence Analysis Software (version 3.1, 1991).
KD Hydrophobicity = hydrophobicity as determined using the algorithm of Kyte and
Doolittle (1982). CF = secondary protein structure as determined by the algorithm of
Chou and Fasman (1978). GOR = secondary protein structure as predicted by the
algorithm of Gamier et al. (1978). See page 111a for an extended legend.
Figure 3.6a. AdS ORFI
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Figure 3.6b. Ad90RFl
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Figure 3.6c. Ad12 ORFI
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Figure 3.6d. Ad34 ORFI
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Extended legend for Figures 3.6 and 3.9. Figures 3.6a-d and 3.9a-d are one
dimensional, multi-paneled plots with the protein residues numbered on the x-axis and
the attributes represented as continuous curves in each of several different panels.
Values above the horizontal line across the KD Hydrophilicity panel indicate
hydrophilic residues at this point in the protein while values below the line indicate
hydrophobic residues. The horizontal line across the surface probability (surface
prob.) panel at position 1.0 on the y-axis indicates the expected surface probability
calculated for a random sequence. Values above this line indicate an increased
probability of this region being found on the protein surface as determined by Emini et
al. (1985). Flexibility is an indication of the flexibility of the 'backbone' of the protein
with high values indicating a high flexibilty. The antigenic index (AI) is a measure of
the probability that a region is antigenic. It is calculated by summing several weighted
measures of secondary structure (Jameson and Wolf, 1988). The higher the value the
on the y-axis the higher the probability that the region is antigenic. The secondary
structure motifs (turns, alpha helices, beta sheets) were predicted using the either 1)
the method of Chou and Fasman (1978) modified by Nishikawa (1983) to resolve
overlapping regions of alpha helices and beta sheets and to locate turns that are not in
conflict with other secondary structures (CF) or 2) the method of Garnier et al. (1978)
(GOR). The higher the value on the y-axis the higher the probability of the relevant
secondary structure at this point. Glycosylation sites are predicted for sites where the
residues have the composition NxT or NxS.
IlIa
region at about residue 23 and other, less distinct hydrophilic regions at about residues
70 and 85 are present in all four proteins. Turns in the predicted structure can be
identified in all of the sequences at about residues 23, 57 and 97. Predicted alpha helix
at the amino-terminus and p-sheet structures between residues 45 to 55 and from
about residue 110 to 125 are also seen in all the ORF1 protein sequences.
3.5.3 ORFI homology searches
A data base search (EMBL and SwissProt) for homology of AdS ORFI to any other
known protein sequence, using the GCG Fasta and Tfasta programs, revealed that the
ORFI protein has homology to a 147 amino acid deoxyuridine 5'-triphosphate
pyrophosphatase protein (dUTPase) found in Saccharomyces cerevisiae (SwissProt
acc.no. P33317), (see Fig. 3.7.). This protein has 26.9% sequence identity with ORFI
over 119 amino acids and the significance of this homology is strengthened by the
observation that 15 of the 30 amino acids conserved between all four adenovirus ORFI
proteins are conserved between AdS ORFI and the dUTPase protein (Fig. 3.7). The
homology is particularly evident over the conserved motifELxVxLFNH at residues 88
to 96 in the ORFI protein (AdS). ORFI was also found to have homology to a similar
dUTPase protein of Vaccinia virus (SwissProt acc.no. P17374) although there is only
17.5% identity over 120 amino acids. However, ORFI only has poor homology with
other viral dUTPase enzymes (McGeoch, 1990) and it does not have strong homology
with the 5 recognised protein motifs characteristic of dUTPases (Fig. 3.7.) (McGeoch,
1990; McIntosh et al., 1992; Gadsden et al., 1993). ORFI is actually truncated
compared to most dUTPases, lacking the C-terminus 'P-Ioop' structure thought to be
important in the binding of nucleotides (McIntosh et al., 1992). dUTPases ensure the
cellular dUTP level is kept low by catalysing dUTP hydrolysis, creating dUMP, and
thereby effectively excludes dUTP as a substrate for DNA polymerase. Extensive
uracil incorporation into DNA is potentially lethal for the cell as it induces extensive
exicision repair which IS believed to lead to DNA fragmentation.
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Figure 3.7. Sequence alignment over 119 amino acids of AdS ORFI and the
Saccharomyces cerevisiae deoxyuridine 5'-triphosphate nucleotidohydrolase
(dUTPase) using the GCG fasta program. A I denotes identity between the two
proteins while : denotes conservation. Indicated below the alignment are the
conserved amino acids found in all four of the Ad ORFI proteins (the alternative
Ad34 ORFI was sequence was used to generate this data). The five conserved motifs
characterisitic of dUTPase enzymes are underlined in the dUTPase sequence
(McGeoch, 1990;McIntosh et al., 1992)
adfio r f l,
50
M.AAAVEALYVVLEREGAILP.RQEGFSGVYVFFSPINFVIPPMGAVMLSLRLR
I I:: ::1: I :::1::1 : :: :: I:::: :::11:11: 1:1 ....
dUTPase MTATSDKVLNIQLRSASATVPTKGSATAAGYDIYASQDITIPAMGQGMVSTDIS
Identity(orf1) M ----E-LY------G---P -Q------Y-------F-----G---L-L---
ad50rfl
100
VCIPPGYFGRFLALTDVN.QPDVFTESYIMTPDMTEELSVVLFNHGDQFFYGHA
:1 1:11: : :::: : :: I:: ::::11:1::111111::: I
dUTPase
Identity(orf1) ---P-GY-G----L-D-- -----------------EL-V-LFNH---F-----
ad So r f I
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GMAVVRLMLIRVVFPVVRQASNV
1 1::1:1 ::1 147
GDRVAQLILEKIVDDAQIVVVDSLEESARGAGGFGSTGNdUTPase
Identity(orf1) ------L-------P-V--A---
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A more restricted data base search (SwissProt), for homologies with the two ORFI
regions which are conserved in all the adenovirus ORFI proteins (residue 53 to 68 and
residue 88 to 96 (AdS», was also carried out using the GCG Fasta program. The
VxIPxGYxGxFLxLxD motif (AdS ORF1, residues 53 to 68), was found to have 60%
identity with a sequence found in the Marburg virus RNA dependent RNA polymerase
(SwissProt acc.no. P313S2). The ELxVxLFNH motif (AdS ORF1, residues 88 to 96),
which was found to be conserved with the yeast dUTPase, has good homology (86%
identity) to the BMRFI protein of the early antigen-D complex of Epstein-Barr Virus
(EBV). Only Glu88 ofORFI was not identical with the BMRFI motif having another
acidic amino acid, aspartate at this point. Even the less well conserved amino acids of
this motif in ORF1, i.e. Ser90 and Va190, are conserved, with BMRFI having serine
and isoleucine respectively at these positions. The SOkDa BMRFI protein is thought
to be a activator of transcription in virus-infected cells (reviewed by Kieff and
Liebowitz, 1990~Miller, 1990) and also to be involved in DNA synthesis, interacting
with the EBV DNA polymerase. What role the VxIPxGYxGxFLxLxD and
ELxVxLFNH motifs play in the function of these proteins is as yet unclear.
A search for known protein motifs within the ORFI protein sequence, using the GCG
Motif program, was unsuccessful.
3.5.4. ORF2 structure predictions
Analysis of the amino acid content of the 130 residue AdS E4 ORF2 protein indicates
that it is hydrophobic (Figs. 3.4 and 3.9) and has a negative overall charge at neutral
pH with a pI of 4.91.
The sequence of a number of other adenovirus ORF2 sequences have been published.
Using the Pileup and Pretty programs on the GCG package, ORF2 proteins
representative of 4 adenovirus subgroups were analysed for homology: the subgroup A
virus Ad12, 48% identity to AdS ORF2 (Sprengel et al., 1994), the subgroup C virus
AdS (Dix and Leppard, 1992), the subgroup D virus Ad9, 31% identity to AdS
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1 50
ad50rf2 MFERKMVSFS VWPELTCLY LHEHDYDVLS FLREALPDFL SSTLHFISPP
ad90rf2 MLQRRGVSYH IWPGVLVTY LE ..DFSITQ MIKEKLPRFI THILEGITGD
ad12orf2 MFQRSLVHYS VLFPESLRNY LHGLDFEVVT FLKDVLPEFW LLVMHYLTPP
ad40orf2 MYLLRPVFIS VWPEPLMFY LNNMDISWD FLKTNMSEFL LHILHCVTPV
Conserved (4) M*----V--- *--P-----Y L---D--*-- -----*--F- ---*------
Conserved (3) M*-R--V-*S VWPE-*--Y L---D*-V-- FLK*-LP*F- --*LH-*TP-
ad50rf2
ad90rf2
ad12orf2
ad40orf2
51 100
MQQAYIGATL VSIA.PSMRV IISVGSFVMV PGGEVAALVR ADLHDYVQLA
TKRAYSSMQF LGASFGALKF SLTLASPTLS PGSELSAWA QDLSDFLQLT
MRDVYVGATL TNMG.PFVQV VCSVGTPELV PGGELSLLLA SDLYDFIQLA
LQAAYCGFTL TSLA.PTLEM ICCVASPELL PDSELTELIC NDLDDFVQLM
Conserved (4)
Conserved (3)
----Y----* ---------- --------*- P--E------ -DL-D*-QL-
*--AY-G-TL -----P-*-- *--V-SP-L- PG-EL--L*- -DL-DF*QL-
101 133
ad50rf2 LRRDLRDRG. IFVNVPLLNL IQVCEEPEFL QS.
ad90rf2 LRRELRAEGR TLLNLVVLNT LQWEQQDLF LL.
ad12orf2 LRCQLRDQG. VEPNVNLLNL LQVFEDPDFF QQI
ad40orf2 LRMEIRDRG. FEPNVNLLNE LQVTREPDLF QP.
Conserved (4) LR---R--G- ---N---LN- -QV----*-*
Conserved (3) LR-ELRD-G- ---NV-LLN- LQV-E*PD-F Q--
Figure 3.8. Alignment of the predicted AdS, Ad9, Ad12 and Ad40 E4 ORF2
protein sequences, prepared using the GCG PileUp and Pretty programs. Displayed
are the points of identity in the sequences and any conserved amino acids present in
all four of the sequences (Conserved (4» and three of the sequences (Conserved (3».
An * denotes where there is a conservative substitution in all 4 of the proteins (in 3 of
the proteins with Conserved (3». The AdS, Ad9, Ad12 and Ad40 E4 ORF2 proteins
are 130, 130, 131 and 130 amino acids respectively.
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ORF2 (Javier and Shenk, 1992), and the subgroup F virus Ad40, 42% identity to AdS
ORF2 (Davison et al., 1993), (Fig. 3.8). As yet it is unclear whether Ad34 has an
ORF2 reading frame as only a small region of the Ad34 genome has been sequenced.
The AdS, 9 and 12 ORF2 proteins lack any potential N-linked glycosylation sites; the
Ad40 ORF2 protein however has one such site at residue 35. This difference in
potential glycosylation coincides with a different predicted pattern in hydrophobicity/
hydrophilicity in the N terminal half of the proteins. The AdS, 9 and 12 ORF2 proteins
have a hydrophilic peak around residue 50 while Ad40 ORF2 lacks this peak but has
an alternative peak at residue 3S, the predicted glycosylation site. All the ORF2
proteins have a well conserved hydrophilic peak between residues 100 and 110.
The ORF2 proteins have few regions where conserved residues are concentrated, one
that does stand out is the DLxDxxQLxLR motif between residues 91 and 102. This
motif of charged amino acids has no distinct predicted secondary structure element
associated with it, but its conservation is suggestive that it is important in function.
A search for known protein motifs, using the GCG Motif program, within the ORF2
protein was unsuccessful.
3.5.5 ORF2 homology searches
When the protein sequence data base (EMBL and SwissProt) was searched for
homologies to AdS ORF2 no distinctive homology to any other known protein was
found, apart from other adenovirus E4 ORF2 proteins. However, a search for the
conserved ORF2 motif of DLxDxxQLxLR at residues 92 to 102 found good
homologies in three other proteins: a rat peptidylarginine deiminase (SwissProt acc.no.
P20217), a putative adenylate cyclase regulatory protein (SwissProt acc.no. P23799)
and a diphtheria toxin repressor protein (SwissProt acc.no. P33120). The significance
of these homologies, if any, in the function of the ORF2 protein is unclear.
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Figure 3.9. Predicted secondary structures of the AdS, Ad9, Ad12 and Ad40
ORF2 proteins as determined using the Plotstructure and Peptidestructure commands
of the Genetics Computer Group Sequence Analysis Software (version 3.1, 1991).
KD Hydrophobicity = hydrophobicity as determined using the algorithm of Kyte and
Doolittle (1982). CF = secondary protein structure as determined by the algorithm of
Chou and Fasman (1978). GOR = secondary protein structure as predicted by the
algorithm of Gamier et al. (1978). See page 111a for an extended legend.
Figure 3.9a. AdS ORF2
100
I
KOHyoropnillcity
10.0
Surfacl PrOD.
1.2
FIlS IDlllty
0 .•
1.1
JAM.on-NoIf
(Antigenic I_xl
-1.1
CF Turn.
CF AlpN .. lIces
CF BaU 91Hts
~T~ ==~~========~nJ\~ ~====~~~ _
&ell Al_ .. Hces
6QA BaU Shalts
61ycoayl. SittS
100
Figure 3.9b. Ad9 ORF2
s.O
100
I
to.O
Sur',c, PrOD.
t.l
FluiDlllty
0.'
1.7
J,lIuon-.olf -""\ .\ /~.-------..., __i\I'. r-- ~I /'-.
(Antlg.nlc Inanl '.___/'u V '-.._.,.J ,_,- __ / \ j I".._.' \ ~._
'1.7
CF Turns
CF A1DII, Hellen
. , ....,=-----;=====-__ - _.-....___,-'--...J -: "' _
GOA Turns - ~\_--- -'.
-,V '__ ___,
'---------,_/--------
CF Beta SlIeets
GOAAIDII' Helices ___r-.'-- ___'
r+: ,-\ r+r:'------ ~' .'--------------- -----GOA Beta $lints ~.
Glycosy). SltlS --- _
100
Figure 3.9c. Ad12 ORF2
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Figure 3.9d. Ad40 ORF2
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3.5.6. Conclusion
The analyses presented here do not allow the prediction, with any certainty, the
functions for either ORFI or ORF2. However, the ORFI protein displays some
homology to a number of different proteins involved in nucleic acid metabolism. The
fact that ORFI has homology over almost its entire region with a dUTPase, together
with the fact that many of the conserved ORFI residues are also present in the yeast
dUTPase, would suggest that ORFI has dUTPase activty. However it sould be noted
that AdS ORFI does not have homology with the conserved motifs found in dUTPases
indicating that, while ORF 1 may not be a classical dUTPase, it may have a related
function. Despite this, it may still proove productive to examine the role of ORFI in
dUMP and dUTP metabolism in infected cells. How this possible function in nucleic
acid metabolism is related to the phenotype associated with the ORFI protein of Ad9,
i.e. that of cellular transformation (see section l.4.2.2.), is unclear.
Despite the absence of an obvious function for these proteins, they clearly are required
for the virus infection of its host organism as they are well conserved across widely
divergent adenoviruses. Viruses, in general, do not carry genetic information that is
not important in their propagation, as carrying extra, nonessential nucleic acid is a
drain on the virus's resources, making replication less efficient. On this premise one
can conclude that both ORFI and ORF2, found in most serotypes of adenovirus, are
necessary for viral replication in the host organism, even if they have no discernible
function in tissue culture.
118
Chapter 4.
The Expression of the AdS E4 mRNAs.
4.1 Introduction
As discussed in the introduction, the lytic infectious cycle of AdS is divided by
convention into early and late phases, separated by the initiation of viral DNA
replication. The E4 region is designated an early region as it is first expressed before
the initiation of DNA replication. However like many of the other early regions, the
expression of E4 is not confined to the early phase, with expression continuing into the
late phase of the infection, although E4 transcription is reduced late in the infection.
A number of studies have explored the pattern of Ad2 E4 mRNA expression. In this
section E4 mRNAs A-L are as referred to in Virtanen et al. (1984), with mRNAs M, N
and 0 inferred from the cDNA clones (pGY7, pGY4 and pGY9 respectively) of Freyer
et al. (1984). Initial studies of the E4 region identified 3 differentially spliced E4
mRNAs which had identical 5' and 3' termini (mRNAs C, D and G, see Fig. 4.l.),
(Berk and Sharp, 1978). Berk and Sharp (1978) identified these RNAs by performing
endonuclease SI and exonuclease VII assays on cytoplasmic RNA preparations of
cytosine arabinoside-treated cells, 8 hours post-infection. Chow et al. (1979), using
electron microscopy of heteroduplexes of viral mRNA and single-stranded Ad2 DNA,
identified 6 E4 mRNAs, believed to be the A,D,E,G,H and L mRNAs ofVirtanen et al.
(1984). Virtanen et al. (1984) used a number of different techniques to examine the
E4 transcripts. As well as using northern blot and SI nuclease analysis they
constructed a cDNA library from mRNA prepared from Ad2 infected cells treated with
cycloheximide, at 2 to 10 hours post-infection. They identified 11 mRNAs in the
cytoplasm of cycloheximide treated cells, mRNAs A-L. From these studies they
concluded that there were 4 splice donor sites (Dl, D2a, D2b and D3) and 6 splice
acceptor sites (Ala, Alb, Ale, AId, Ale, and A3), (Fig 4.1.). Two other studies
conducted at the same time as the Virtanen study (Freyer et al., 1984~ Tigges and
Raskas, 1984) largely confirmed these results, but with some detailed differences.
Freyer et al. (1984) constructed a eDNA library from mRNA prepared from
anisomycin treated cells at 7 or 8 hours post infection. They identified 5 intact eDNA
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clones, corresponding to mRNAs D,F,K and L of Virtanen et al. (1984) and a novel
mRNA referred to here as mRNA M. mRNA M is constructed using a novel splice
acceptor site referred to as A4. Freyer et al. (1984) also isolated a number of partial
cDNA clones, two of which implied the existence of novel mRNAs, referred to here as
mRNAs Nand O. mRNA 0 is formed by the utilisation of a 3' acceptor site close to
the A3 site ofVirtanen et al. (1984) referred to as AS in this study. It is unclear if the
use of this alternative splice site AS affects an ORF or if it just alters an UTR. Tigges
and Raskas (1984) used SI nuclease and exonuclease VII analysis to identify E4
transcripts in the cytoplasm of cycloheximide- and cytosine arabinoside-treated cells at
5 hand 7 h post-infection respectively. They identified a novel full length, unspliced
transcript and a number of mRNAs akin to mRNA L identified by Virtanen et al
(1984). These mRNA L-like mRNAs were formed by the utilisation of alternative DJ
sites and A3 sites, including the AS site identified by Freyer et al. (1984). These
mRNA L-like mRNAs are not included in Fig. 4.1. (except mRNA 0 also identified by
Freyer et al. (1984» as no evidence for the use of these novel splice sites has been
indicated in any other studies. To conclude, the primary transcript from the E4 region
is differentially spliced, producing a set of mRNAs which have a common 5' terminus
(see 1.4.1.) and polyadenylation site (Fig. 4.1.).
It should be noted that only in the study of Chow et al. (1979) (and a limited study
included in Tigges and Raskas,(1984» were virus infections conducted in the absence
of translation or DNA replication inhibitors. Chow et al. (1979) demonstrated that the
inhibition of translation or DNA replication during an infection, which prevents the
early to late transition, increases the relative abundance of the early mRNAs, including
the E4 mRNAs, in the cytoplasm. This increased abundance of E4 mRNAs facilitated
the studies of the pattern of E4 expression. However, it cannot be discounted that
some mRNAs observed by studies which utilised inhibitors, may be artefacts of the
,
experiments since it is unclear how the inhibition of protein synthesis or DNA
replication affects the splicing ofE4 transcripts.
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Chow et al. (1979) and Tigges and Raskas (1984) both conducted limited experiments
examining the pattern of expression of the E4 mRNAs over the course of the infection,
in the absence of inhibitors. Both groups concluded that early in the infection a long
mRNA predominated, probably mRNA D, while after DNA replication a short mRNA
accumulates, probably mRNA L. These observations were confirmed by Ross and Ziff
(1992) while comparing E4 expression in abortive and non-abortive infections. All of
these experiments suggest that the pattern of mRNA expression from the E4 region is
temporally regulated.
The results of all these experiments has led to some confusion as to the precise
expression pattern for the E4 mRNAs over the course of a lytic infection in the
absence of translation or DNA replication inhibitors. To characterise the pattern of
expression of the known and putative E4 products in more detail, a systematic study of
the levels of individual mRNAs during the AdS infectious cycle was undertaken. In
parallel with this study, the role of the E1b-SSK and E4 ORF6-34K proteins in
regulating the cytoplasmic accumulation of the E4 mRNAs was also examined, as it
had been demonstrated that cytoplasmic accumulation of late viral messages was
dependent on the E1blE4 heterodimer (see introduction). The approach used to
~ investigate the expression of the E4 mRNAs was to probe cytoplasmic and nuclear
RNA samples, prepared from infected cells at different times post infection, for the E4
mRNAs by RNase protection analysis. This allowed the quantification of splice site
utilisation in the production of the E4 mRNAs over the course of the infection.
4.2. Methods
4.2.1. Cells and Viruses.
dl309 was used as a wild-type virus for the purposes of these studies (d1309 was
generated from wt300 and retains only one of the four XbaI cleavage sites (Jones and
Shenk, 1978». It displays a wild-type phenotype and is the parental virus of all the
mutant viruses employed in these experiments. Mutant viruses were used in this study
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to examine the expression of the E4 region in the absence of the Elb-55K protein
and/or E4 ORF6-34K proteins. dl338 carries a deletion of 524 bp in the Elb coding
region located between 2805 and 3329 bp, preventing the synthesis if the Elb-55K and
EIB-17K (156R, Fig. 1.4.) proteins (Logan and Shenk, 1984). However, Pilder et al.
(1986b) demonstrated that the phenotype associated with this mutant, i.e. the
reduction in the accumulation oflate viral mRNAs in the cytoplasm of the infected cell,
was due to the lack of the Elb-55K protein; Pilder et al. constructed a variant, pm380,
which has a base pair change at position 3275, which destroys the 3' acceptor site
required for the synthesis of the El B-17K mRNA. pm380 grew as a wild-type virus
suggesting that the El b-17K protein has no effect in virus replication in tissue culture
and that the phenotype associated with the d1338 virus is due to the absence of the
Elb-55K protein. A virus only lacking the intact Elb-55K protein (pm381), was also
constructed by Leppard et al. (1987). This virus displayed identical growth properties
to the d1338 suggesting that the observed phenotype is due exclusively to the Elb-55K
protein. The data of Mont ell et a1. (1984) supported this conclusion, as they observed
that a virus mutated in the 5' donor site of the E IB-17K mRNA also grew as wild-
type. d1355 (Halbert et al., 1985) has a 14 base pair deletion in the E4 ORF6-34K
reading frame, resulting potentially in the production of a 188 aa truncated protein but
this was not detectable in infected cells (Cutt et al., 1987). Finally, dl367 (Cutt et al.,
1987), contains the deletions present in both dl338 and d13S5 in a single virus.
Virus stocks were grown on HeLa (dI309), HEK-293 (d1338, dI367), and W162 cells
(d13S5). HEK-293 cells are a human embryonic kidney cell line transformed with a
DNA fragment carrying the left 11% of the AdS genome (Graham et al., 1977) and
support the growth ofElb-deficient viruses such as d1338. The W162 cell line is Vero
line carrying an integrated copy of the AdS E4 region (Weinberg and Ketner, 1983)
and support the growth of E4 defective viruses such as d135S. Virus was quantified
either by plaque assay on 293 cells or, as purified virus, by the measurement of optical
density of lysed virions, at 260 run, using a conversion factor of 1 A260 unit = 1012
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virions/mI. All infections were carried out using HeLa cells at a MOl of 10 pfu/cell or
500 virions/cell.
4.2.2. The antisense RNA probes (see appendix 3)
A series of antisense E4 RNA probes was constructed for use in quantitative RNase
protection assays (Figure 4. I). These probes were designed to allow the identification
and quantitation of each of the E4 mRNAs as described previously. They were
constructed by cloning the relevant pieces of d1309 KpnI-G genomic fragment into
either pGEM3 or pGEM4. plD7 was constructed by first cloning the Kpnl (33594) -
Bgnl (34115) fragment into the modified pUC19 MCS (the Pstl site is substituted for
a Bgnl site) of pEXP5 (a gift of K. Leppard) using the Kpnl and Bgfll sites of the
MCS. The Bgnl (34115) - Bgnl (34387) fragment was then inserted into this plasmid
and the orientation checked to ensure the Ad5 sequence was contiguous across both
fragments using HinfJ. digestion. The Kpnl (33594) - Bgnl (34387) fragment was then
moved into pGEM3 using HindlII and EcoRi sites of the MCS to create pID7. pID9
was constructed in a similar manner, beginning with the BgnI (34387) - HindlII
(34930) fragment. plD11 was constructed by subcloning the HindIII (34930) - Smal
(35354) fragment into pGEM4 between the HindlII and SmaI sites. pID13 was
constructed by subcloning the Smal (35354) - HaelII (35616) fragment into the Smal
site of pGEM4. A clone was then selected which allowed the production of anti-sense
E4 RNA when using the T7 promoter. pID 16 was constructed by excising the Kpnl
(33594) - Pstl (33875) fragment from pID7. plD52 was constructed by subcloning the
SmaI (33091) - KpnI (33594) fragment into pGEM4 cut with Kpnl and HincII. The
two other probes used in the course of this study, an E1a probe (Pvull (455) - Pstl
(1838» and a J3-actinprobe, were both gifts ofK. Leppard.
All the above constructs were purified by large scale plasmid DNA preparations and
then linearised so allowing the optimal production of antisense E4 RNA; pID7, -9, and
-16 were linearised with HindIII, while pID11, -13, -52 were linearised with
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Figure 4.1. The E4 transcription map showing the location of the RNA probes.
The right terminal portion of the AdS genome (bp 32500 to 32598) is shown as a line
scale. Below the line is the E4 transcription map inferred from studies of the closely
related virus, Ad2. The positions on the genome map of the cloned fragments from
which the RNA probes were derived are shown at the top of the diagram (pID7, -9, -
11, etc.).
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EcoRI. These linearised plasmids were then transcribed using either T7 polymerase or
SP6 polymerase to produce radiolabelled, antisense RNA probes for use in RNase
protection assays.
4.3. Results
4.3.1. The temporal classes ofE4 mRNA
To examine the temporal control of AdS E4 splicing, the cytoplasmic level of each E4
mRNA was determined at various times after infection with wild-type AdS (d1309).
Each RNA probe used (see 4.2.2.) gave protected fragments of characteristic length,
allowing the identification and quantitation of individual mRNAs, or in some cases of
pairs ofmRNAs predicted to encode the same translation product. The levels ofEla
and ~-actin mRNA were also quantified in parallel with the E4 mRNA to control for
differences in either infection multiplicities or RNA inputs into the assays.
Results of representative assays are shown in Fig. 4.2. The probes used to identify
mRNAs A, B and full length (pIDll and pID13) did not distinguish between these
mRNAs. However, experiments conducted using pID9 showed no protection by the
Alb to D2a fragment, characteristic of mRNAs B and N, suggesting that these
mRNAs were absent in the infection. The pID 11113 signal is thus attributed to mRNA
A and full length mRNA. Similarly, the pID9 probe did not distinguish between
mRNAs D and E, nor between mRNAs G and H. However, from results with pID7,
which protected a fragment from mRNAs A, E, and H, it could be deduced that both
mRNAs E and H were significantly less abundant than mRNAs D and G, respectively.
and were expressed with different kinetics (see below). The major component of the
protected fragments DIE and G/H shown in Fig. 4.2 is therefore attributable to
mRNAs D and G respectively.
The quantification of ~-actin confirmed that the levels of RNA put into the experiment
were comparable (the RNA was quantified using a spectrophotometer) as ~-actin
mRNA is an abundant cellular message. The decrease observed in the 24
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Figure 4.2. Analysis of cytoplasmic levels of Eta, p-actin and E4 mRNAs during
infection of HeLa cells by wild-type virus, d1309, by RNase protection assay
(2.3.5.). HeLa cells were infected at an MOl of 10 and total cytoplasmic RNA was
isolated at the time p.i. indicated above each lane. Five micrograms of RNA was
probed for specific E4, E1a 3' common exon and ~-actin E4 mRNAs, indicated to the
left. A doublet was routinely isolated using the ~-actin probe. Fragments shown (the
predicted size from the Ad5 sequence is shown in brackets): E1a, 404 nucleotides; ~-
actin, (-532 nucleotides); DIE, pID9 (-382 nucleotides); C, pIDll (174 nucleotides);
L, pID7 (178 nucleotides); K, pID7 (426 nuc1eotides, arrow indicates lower band); A,
pID13 (258 nucleotides). It should be noted that any fragment indicated as mRNA A
could also be due to protection of full length mRNA.
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hour sample probably reflects the increase of MLTU messages in the cytoplasm so
reducing the relative level of 13-actinmessage.
Two distinct classes of E4 mRNAs were identified by this analysis, early and late.
mRNAs belonging to the early class (mRNAs C, D, G and J (C and D are shown in
Fig. 4.2» were first detected in the cytoplasm 9 hours post-infection with levels
remaining almost constant throughout the infection. The low levels of Ela mRNA
detected at 5 h p.i. in this experiment (this is not observable in figure 4.2. due to the
poor reproduction of the photograph) may explain why little or no E4 mRNA of any
type was detected at this time point as the El a products are involved in the activation
of the E4 promoter (see section 1.4.1.). The small increase in the level ofmRNAs D
and E that was observed between 9 and 16 h p.i. is consistent with estimates ofmRNA
E synthesis from pID7 experiments (data not shown). No increase in the levels of
mRNAs G and H was observed between 9 and 16 h p.i. possibly indicating that mRNA
H is not present (or present at low levels) late in the infection (data not shown).
mRNAs of the late class (A, EIH, K, L) were first detectable at significant levels at 16
h p.i.. However, mRNA Nfull length mRNA was only observed in low amounts at
16h p.i., with its levels not peaking until 20 h p.i. while the other mRNAs with late
kinetics (i.e. mRNA K and L in Fig. 4.2) reached maximum, or near-maximum, levels
at 16 hours p.i..
mRNA-probe duplexes covering the region around position 34250 consistently showed
sensitivity to RNase that resulted in 50 to 80% cleavage of the probe. Fragment
lengths were in each case consistent with an mRNA-probe RNA discontinuity at this
position, although no splice donor or acceptor sequence was present. Inspection of the
sequence revealed a stretch of 11 A residues in the E4 mRNA. Stuttering of RNA
polymerase on this sequence, either in the cell or, in the antisense during probe
synthesis in vitro, could explain this observation.
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4.3.2. The D3 to A3 intron is excised late in the infection.
The expression pattern of E4 mRNA, reveals two distinct temporal classes.
Correlation of these data with the transcription map reveals that members of the early
class all retain sequences distal to the between splice site D3 in the 3' half of the E4
unit, while this donor site is utilised late in the infection, presumptively in combination
with the AJ or AS acceptor sites, to produce a family of shorter mRNAs. Using
pIDS2, these acceptor sites were found to be utilised at 24 h p.i. but not 9 h p.i.,
confirming that the D3-AJ intron is only excised late in the infection and indicating that
the D3-AS intron is also only excised late in the infection (Fig. 4.3.). The efficiency of
usage of the AJ splice site is 40 fold greater than the AS site. There is no evidence for
the use of other alternative splice sites proposed by Tigges and Raskas (1984) to
produce the family ofO.8kb mRNAs encoding the series ofORF6/0RF7 fusions. The
only splice sites utilised in this region, in these experiments, were the D3 donor site
(Freyer et al., 1984~ Tigges and Raskas, 1984~ Virtanen et al., 1984) and the AJ and
A5 acceptor sites (Freyer et al., 1984~Tigges and Raskas, 1984~Virtanen et al., 1984).
4.3.3. Relative abundance of E4 mRNAs
The accurate determination of the relative amounts of the different E4 mRNAs is
complicated by the need to assume that different probe RNAs were labelled to the
same specific activity. This assumption is reasonable only for probes prepared in
parallel from the same mixture of a-32P-Iabelled and unlabelled UTP. For such probe
sets, protected fragments were quantified using laser scanning densitometry and the
data corrected to take into account the number of uridine residues in the protected
fragment to give a measure of relative mRNA levels. A full data set was obtained by
linking the results for groups of mRNAs having one or more members in common.
These estimates of relative E4 mRNA levels are shown in Table 4.1. with mRNA L
being the most abundant RNA species detected. mRNAs E and H have not been
identified individually; however neither is found in significant amounts at 9 h p.i., and
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Figure 4.3. Analysis of
cytoplasmic levels of E4
mRNAs in Hela cells infected
by wild type dl309 or
El b-55K mutant dl338 at the
times p.i. indicated. 5 ug of
cytoplasmic RNA was probed
for the use of the A3 and AS by
RNase protection analysis
(2.3.5,3.) using pIDS2. The
predicted protected fragments
are: 503 nt - unspliced at A3 or
AS; A5 (189nt) - spliced at A5;
A3 (99nt) - spliced at A3. The
547nt fragment is probably due
to protection of undigested
template DNA, including the
pGEM sequences.
8-actin
547nt _
503nt -
A5 -
A3 -
dl309 dl338
9 24 9 24
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Table 4.1. Classification of E4 mRNAs. mRNAs were quantified using laser
scanning densitometry and the data corrected to take into account the number of
uridine residues in each protected fragment. The semi-quantitative amounts displayed
are all relative to the levels of mRNA L at late times. * = The amounts shown for
mRNAs E and H are shown collectively. See appendix 4.
E4RNA Relative amount Relative amount Kinetic Class
9 h p.i. 20 h p.i,
Afull length - ++ Late
B - -
C + + Early
D +++ +++ Early
E* - ++ Late
F - -
G ++ ++ Early
H* - ++ Late
I - -
J + + Early
K - ++ Late
L (+) ++++ Late
M - + Late
N - -
0 - + Late
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their collective abundance is less than that of mRNA D. mRNAs B, F, I, and N were
not detected in any experiment.
4.3.4. Late E4 mRNAs are dependent on DNA replication for accumulation.
To determine whether expression of the late class of E4 mRNAs was dependent on
viral DNA synthesis, their levels in cells infected in the presence of the DNA synthesis
inhibitor hydroxyurea (IOmM) were assayed. As shown in Fig. 4.4., expression of
mRNA D (early class) in a wild-type infection was unaffected by the inhibitor, whereas
the accumulation of the late E4 mRNAs L and Nfull length mRNA was largely and
completely prevented, respectively (the low level of mRNA L at 24 h p.i. in the
presence ofHU is not visible due to the poor reproduction of the photo in Fig. 4.4.).
Thus, these late E4 mRNAs, like other viral late rnRNAs, depend on DNA replication
for their expression. The dependence of the expression of the minor late rnRNAs (i.e.
mRNAs EIH, K and M) was not determined, however their expression pattern was
identical to that ofrnRNA L, in the absence of any DNA replication inhibitors (see Fig.
4.2.), possibly suggesting that these mRNAs are also dependent on DNA replication.
4.3.5. Dependence of late E4 mRNA expression on the El b-55K protein.
As mentioned in section 1.3., cytoplasmic mRNA accumulation for genes expressed
from the Ad5 genome at late times is dependent on a function provided by the EI b-
55K protein. The possible dependence of the late class of E4 mRNAs, as defined
above, on this Elb function was therefore examined using a mutant virus, d1338, which
is unable to express the Elb-55K protein.
The E4 mRNAs present during a d1338 infection were quantified in a comparative
analysis with wild-type virus. Representative analyses are shown in Fig. 4.5a. with
quantitation of these data shown in Fig. 4.Sb. The Ela mRNA levels were comparable
in the two infections demonstrating that the multiplicity of infection of the two viruses
were similar. As expected, the early class of E4 mRNA (represented
132
Figure 4.4. Analysis of late E4 mRNA expression in the presence and absence of
an inhibitor of DNA replication. HeLa cells infected by wild-type virus, dl309 at the
times p.i. indicated, in either the absence (-) or presence (+) of hydroxyurea, added at
10 mM to the culture medium. 5 ug of unselected, cytoplasmic RNA was probed for
specific mRNAs indicated at the left; other details as Fig. 4.2.
9 h p.i. 24 h p.i.
HU
RNA DIE
+ +
RNAL
RNAA
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Figure 4.Sb. Quantitation of data shown in Fig. 4.Sa. Results of laser scanning
densitometry (2.3.12., 2.3.13) are shown in arbitrary units plotted against time p.i. for
dI309 (.) and d1338 (.). These data are not corrected for protected fragment length
and specific activity differences; therefore, amounts are not comparable between
panels.
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Figure 4.5a. Analysis of cytoplasmic levels of Ela and E4 mRNAs during
infection of BeLa cells by wild-type virus dl309 or Elb-5SK mutant virus d1338,
as indicated. Details are as for Fig. 4.2.
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by mRNA D) accumulated in the cytoplasm of wild-type- and d1338-infected cells with
identical kinetics. The peak observed for this mRNA in d1338 infection is an artefact
of the experiment as it was not reproducible. More surprisingly, most of the late class
ofE4 mRNAs (represented by mRNA L) displayed only minimal dependence ofElb-
55K protein function. The one exception was mRNA Nfulliength mRNA, which had
shown a unique delayed late kinetic profile in a wild-type infection (Fig. 4.2.).
Accumulation of this mRNA was found to be strongly dependent on Elb function,
with cytoplasmic levels in dl338-infected cells only 5 to 10% of the wild-type level at
20 to 24 h p.i.
It is also of note that the levels of mRNAs utilising the A3 site (and AS site) are
comparable in the cytoplasm of wild- type- and d1338- infected cells at 24 h p.i. (Fig.
4.3.). One would have expected that ifmRNA A is dependent on the Elb-55K protein
then the level of the A3-SmaI fragment would be lower in the d1338 fraction. It may
be that the other mRNAs (E,H,K,L and M) dilute the difference so making it
impossible to observe in the infections using this probe. However there is a distinct
difference in the level of full length protected mRNA (using pID52) between the wild-
type-infected 24 h p.i. RNA sample and the dl338-infected 24h p.i. sample (Fig. 4.3)
suggesting that the full length mRNA exists and is dependent on the Elb-55K mRNA
for optimal cytoplasmic accumulation. However the existence of the full length mRNA
cannot however be proved conclusively using the probes shown in Fig. 4.1., only
inferred, as no one probe protects full length mRNA in such a way to yield a fragment
of a unique size. The additional 547 nt band present in all the lanes, especially in the
d1338/24 hr p.i. lane, can only be the complete probe with the pGEM4 MCS sequences
intact. This cannot be protected by the viral mRNA and is probably an artefact of the
probe, possibly due to secondary structure, although it is unclear why it is not even in
each sample.
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4.3.6. E4 mRNA Alfulliength mRNA is dependent on E4 ORF6-34K for optimal
cytoplasmic accumulation.
As mentioned in section l.3., the Elb-55K protein exists as a molecular complex with
the E4 ORF6-34K protein in infected cells. In previous studies, virus d1355 (lacking
E4 ORF6) and d1367 (lacking E4 ORF6 and Elb-55K) showed phenotypes very
similar to that of the Elb-55K mutant d1338 in respect to the cytoplasmic accumulation
oflate viral mRNA (Halbert et al., 1985~Cutt et al., 1987). To confirm that the effect
of the EI b mutation on the levels of E4 mRNA Nfulllength mRNA was due directly
to the absence of the EI b mRNA transport regulatory function, the levels of mRNA
Nfull length mRNA in E4 ORF6 mutant infections were examined (Fig. 4.6.).
Cytoplasmic levels of mRNA D (early class) were unaffected at 9 h p.i. in these
infections and only marginally at 24 h p.i.; mRNA L showed a similar pattern at 24 h
p.i. These marginal reductions at late times may be due to the slight reduction in the
rate of DNA replication previously noted for these mutants (Halbert et al., 1985~ Cutt
et al., 1987). In contrast, cytoplasmic levels of mRNA Nfull length mRNA were
severely depressed in both E4 mutant infections, as they were in d1338 infections.
4.3.7. E4 mRNA Alfull length mRNA dependence on Elb-55K is at a post
processing level.
Since all E4 mRNAs derive from the same primary transcript, the selective depression
of cytoplasmic mRNA Nfulliength mRNA levels seen in the d1338 infection must be
due to a post-transcriptional effect. mRNA Nfulliength mRNA results from the non-
usage of the E4 5' splice donor site DI (Fig 4.1.). To determine whether the absence
of Elb-55K protein resulted in increased usage of this site, the relative abundance of
RNA spliced and unspliced at this site in nuclear RNA was assessed for cells infected
with either wild-type or dl338 virus. The results of this analysis are shown in Fig. 4.7.
Levels of a control E4 mRNA (mRNA L) in both nucleus and cytoplasm were
unaffected by the absence ofElb-55K protein. Levels ofmRNA Nfulliength mRNA
in the cytoplasm were, as before, greatly reduced in the mutant infection.
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Figure 4.6. Analysis of cytoplasmic levels of E4 mRNAs in BeLa cells infected by
wild-type d1309, E4 ORF6 mutant d1355, or Elb-55K1E4 ORF6 mutant dl367 at
the times p.i. indicated. Virus stocks were CsC} gradient-purified particle preparations
used at 500 particles per cell. 5 ug of unselected RNA was probed for specific
mRNAs indicated at the left; other details are as for Fig. 4.2.
9 h p.i. 24 h p.i.
virus
RNA DIE
RNAL
RNAA
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Figure 4.7. Analysis of cytoplasmic and nuclear levels of E4 mRNAs during
infection of BeLa cells by wild-type dl309 or Elb-55K mutant virus d1338. Total
cytoplasmic (Cyto) and total nuclear (Nuc) RNAs were isolated at the times p.i.
indicated, and 5 ug samples analysed. The virus used and E4 RNA detected are
indicated at the left. Other details are as for Fig.4.2.
Cyto Nuc
hrs p.1. 8 12 16 22
309
8 12 16 22
A
338
L
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338
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However, no similar reduction in nuclear levels of mRNA Alfulllength mRNA was
seen. This result shows that, as for other mRNAs which depend on E1b-55K protein
for accumulation, E4 mRNA Alfulllength mRNA requires this function for its efficient
movement out of the nucleus or for cytoplasmic stabilisation rather than to modulate
its splicing. No probe fragment protected by mRNAs spliced at site D 1 could be
detected in either wild-type- or dl338-infected cell nuclear RNA. Also the
cytoplasmic/nuclear ratio for mRNA L was very much greater than that for mRNA
Alfull length mRNA. These findings suggest that, once spliced at the D 1 site, E4
mRNA is rapidly exported to the cytoplasm. A similar conclusion was reached
previously regarding E2 mRNA expression (Leppard and Shenk, 1989).
4.4. Discussion.
4.4.1. Classes ofE4 mRNA
The various Ad5 E4 mRNAs have been divided into two temporal classes based on a
detailed analysis of RNA levels over the time course of a wild-type infection. mRNAs
C, D, G, and I form an early class, while mRNAs Alfulliength, E, H, K, L, M, and 0
mRNA form a late class, dependent on viral DNA replication for cytoplasmic
expression. Previously described mRNAs B, F, I, and N could not be detected, nor
was any evidence found for the utilisation of the splicing sites for the O.8kb mRNA
family described by Tigges and Raskas (1984). Within the late class, mRNA A and/or
full length mRNA are unique, both in the late time p.i. at which their accumulation
peaks and in their dependence on the E1b-S5K and E4 ORF6-34K proteins for optimal
cytoplasmic accumulation.
When members of these E4 classes are compared with one another, structural
relationships can be identified. All the mRNAs expressed at early times retain the D3
to A3/A5 intron suggesting that the usage of these sites is temporally regulated during
the course of the AdS infection. The regulation may be due to the action of the E2a
DBP as described by Ross and Ziff (1992). Like other examples of regulated
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adenovirus splicing, such as in the expression of the El a, Elb, and LI genes (Spector
et al., 1978; Esche et at, 1980; Lewis and Mathews, 1980; Akusjarvi and Persson,
1981; Mantell et al., 1984), processing in E4 moves toward more heavily spliced,
shorter mRNAs in the late phase of the infection. These results are in agreement with
the observations of Chow et al. (1979) and Tigges and Raskas (1984) who also
observed the predominance of shorter mRNA late in the infection. The exception is
the full length mRNA which possibly appears very late in the infection, with kinetics
distinct from the other late mRNAs (apart from possibly mRNA A), which is not
spliced (Fig. 4.2. and Fig. 4.3.).
The undetected mRNAs B, F, I, and N are also related, being formed by the use of
donor sites D2a or D2b in conjunction with an acceptor site. The lack of usage of
these sites may be sequence related, as they are more divergent from the consensus
sequence (Mount, 1982) than are sites DI and D3, where splicing was observed (Fig.
4.8.). Given the detection of mRNAs spliced at these sites by other workers, their
absence in these experiments may indicate that usage of D2a and D2b is regulated and
apparent only under certain circumstances, such as in the presence of translation
inhibitors, or only in the Ad2 infection. Similar analysis of the predicted splice sites of
the 0.8kb family ofmRNA found by Tigges and Raskas (1984) was prevented by the
imprecise location of the splice sites given in the paper.
Why the late E4 mRNAs are dependent on DNA replication for expression is not clear.
As mentioned in section 1.2.4., the shift in the splicing of other adenovirus transcripts
late in the infection has been attributed to a number of factors. Ross and Ziff (1992)
examined E4 expression in abortive CV-I infections where DNA replication is delayed
and E4 and MLTU RNA processing is defective (see 1.4.1.). They did not attribute
the failure of the early to late shift in E4 mRNA splicing simply to the absence of DNA
replication as they noted that at 50 h p.i., when DNA replication was near normal, the
early E4 splicing pattern was retained. Instead they attributed the defect in E4 RNA
processing in abortive infections, to the absence of a functional DBP since a missense
mutation in this protein could alleviate the splicing defect. The failure to produce late
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Figure 4.8. The E4 donor splice sites as compared to the eukaryotic consensus
sequence of Mount (1982). The percentages given are the percent occurrence of the
nucleotide shown at that site. The slash indicates the position of RNA cleavage. The
bold nucleotides of the E4 donor sequences (Dl, D2a, D2b, D3) indicate bases present
which are different to those found in the consensus sequence
Donor Sequence
M ('II
"f ootO
Percentage O"fM OOOl«)~M"ftO ..... ,... .... ('11 to«)tO
Consensus RAG/GT~AGT
Site
01 CTG/GTAAGG
02a AAG/GTGGCG
02b TAG/GTTGGC
03 AAC/GTGAGT
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E4 mRNAs in infections of HeLa cells in the absence of DNA replication may also be
due to the effect of the DBP; late in the infection, after DNA replication, the E2-L
promoter is active resulting in the production of high levels ofDBP, the absence of this
increased level of DBP may restrict E4 expression to the early pattern. So, while it
would appear that the microenvironment of the DNA template is not directly involved
in the late shift in E4 splicing, it may be involved indirectly, regulating the activation of
the E2-L promoter and so production of the DBP.
4.4.2. The expression of the E4 ORF products
The observed temporal pattern of mRNA expression from the E4 region suggests that
ORF2, ORF3, ORF4, and ORF6 products are synthesised initially during the early
phase of infection, while the products ofORFl and ORF617 are synthesised later in the
infection.
The ORFI-14K protein, involved in the formation of mammary tumours of rats inAd9
(see section 1.4.2.2.), is encoded by mRNA A and full length mRNA, which are
possibly expressed with late kinetics (it is unclear if both or just one of these mRNAs is
expressed). The role of the ORFI product in the AdS infection is unknown (see
chapters 3 and 6) but the data from these studies suggests that it is required late in the
infection. These results are in agreement with the observations of Javier (1994) who
found Ad9 E4 ORFI-14K in infected AS49 cells (a human lung carcinoma cell line
permissive for viral replication) 20 hpj. No function has yet been assigned to the
ORF2-14K protein although this data would suggest that it is expressed early in the
infection, as mRNA C (encoding ORF2) is present early in the infection.
The early expression ofORF3 and ORF6 mRNA is in agreement with the role of their
products in facilitating viral gene expression from the onset of the late phase (see
section 1.4.2.3.) (data for mRNA D (ORF3) can be seen in Fig. 4.2.; the data for
mRNA J (ORF6) is not shown due to difficulty with photography, however mRNA J
was first seen in the cytoplasm at 9 h p.i. and remained at a constant level until at least
24 h p.i.). It is not clear how translation of the ORF6 from mRNA J occurs (mRNA I
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was not found in these experiments) as three AUG codons exist upstream of the initial
AUG ofORF6 (although Virtanen et al. (1984) noted that only one of these upstream,
potential translational start sites is favourable according to the rules of Kozak (1981».
The obvious mRNA to encode the ORF6 protein is an mRNA lacking the DI-Ale
intron but retaining the potential D3-A3 intron, but this mRNA has never been
identified, a result confirmed in this study. The early expression of the E4 ORF4
mRNA is also in agreement with previous data as the E4 ORF4-13K protein was first
observed to mediate the down-regulation ofEla phosphorylation in HeLa cells early in
the infection (Muller et al., 1992).
The absence of mRNAs F and N in these studies suggests that the ORF3/4-7K and the
ORF3/12aa fusion products do not exist in the infected cell, in the absence of
cycloheximide. Similarly no evidence was found for the use of potential splice sites
between ORFsl and 2 or a potential donor site within ORF2 as predicted by Herisse et
al. (1981) confirming the results of Freyer et al. (1984), Tigges and Raskas (1984) and
Virtanen et al. (1984).
The late expression of the ORF617 mRNA is surprising, given its role in the activation
of the E2 early promoter (see section 1.4.2.6.). Hardyet al. (1989) observed that the
formation of an infection-specific, E4-dependent complex on an E2 promoter fragment
first occurred in HeLa cells at 6 h p.i. This complex has been shown subsequently to
contain the E4 ORF617 protein (Huang and Hearing, 1989b~ Reichel et al., 1989~
Marton et al., 1990~Neill et al., 1990~Raychaudhuri et al., 1990). However, amounts
of this complex increased dramatically between 6 and 12 h pi in these experiments.
Given the differences in experimental protocol used (multiplicity of infection and cell
type), this delayed-early increase in activity observed by Hardy et al. (1989), now
attributed to the E4 ORF617, is in reasonable agreement the expression of ORF617
mRNA. Similar experiments by Marton et al. (1990) are harder to rationalise with the
kinetics of the ORF617 mRNA expression in this study as they observed that E4
ORF617 dependent E2F complexes formed on E2 promoter fragments in nuclear
fractions from 3 h p.i. while extracts prepared late in the infection (18h and 35h) failed
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to produce infection-specific complexes. All the ORF617 mRNAs (K, L, and M)
displayed late kinetics, first being observed 16 h p.i. suggesting that the protein does
not occur until late in the infection.
4.4.3. Regulation of the expression of mRNA A and/or full length mRNA
Of all the E4 mRNAs detected in this study, only mRNA A and/or full length mRNA
are dependent on the Elb-SSKlE4 ORF6-34K complex for optimal cytoplasmic
accumulation. Additionally, these two mRNAs are expressed with later kinetics than
the other mRNAs, reaching maximal cytoplasmic levels at 20 h p.i. Among the E4
rnRNAs detected in this study, these mRNAs are the only rnRNAs to retain splice
donor site D I unused. Furthermore, these rnRNAs also retain a number of acceptor
sites (Ala to Ale) that can be used, with DI, to form other detectable E4 mRNAs.
Thus, E4 mRNA A and full length mRNA are incompletely spliced mRNAs which
contain a readily removable intron. Although other E4 mRNAs are similarly
incompletely spliced, through retention of either the D2a1Ale, D2b/Ale or D3/AJ
intron, these mRNAs either are synthesised in the early phase of infection or else carry
introns whose removal was not detected in our experiments. In a previous study,
strong dependence on EI b function for accumulation oflate viral mRNA was shown to
correlate with the presence in the mRNA of unused splice acceptor sites and/or intron
sequences (Leppard, 1993). It was argued that this result was due to viral mRNAs, in
the absence of the Elb-SSK protein, being held on the nuclear matrix by host cell
mechanisms whose function was to prevent the effiux of immature RNA from the
nucleus. Therefore the presence of such sequences in mRNA A and full length mRNA
may explain the unique dependence of these RNAs, among the E4 population, on the
Elb-SSK protein for optimal cytoplasmic accumulation.
Alternatively, the accumulation ofrnRNA A and/or full length mRNA in the cytoplasm
of wild-type infected cells may be a secondary effect of the Elb-SSKlE4 ORF6-34K
protein complex. This would explain the late kinetics observed for mRNA A and/or
full length mRNA. Fig. 4.7. demonstrates that mRNA Nfulllength mRNA is present
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at a significant level in the nucleus of the wild-type infected cell at 16 h p.i. but is not
observed in the cytoplasm at this time point implying it is restricted to the nucleus.
However other studies have shown that E 1b is active in the export of MLTU messages
at 16 h p.i. (Pilder et al., 1986a,b)~ E4 mRNA Alfull length mRNA does not
accumulate in the cytoplasm until 22 h p.i. It is conceivable that partially and/or
unspliced E4 mRNA, which is normally retained in the nucleus, is released into the
cytoplasm in a wild-type infection because of the general restructuring of the viral
nucleus observed late in the infection (Zhonghe et al., 1986) due to the activities of the
late viral proteins encoded by the MLTU which can only be expressed in the presence
of the ElblE4 complex and not because of the direct action ofElb and E4 proteins.
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Chapter 5.
The construction and analysis of a virus containing a
mutated E4 Dl donor site.
5.1. Introduction
The work described in chapter 4 demonstrates that of all the E4 mRNAs only mRNA
A and/or full length mRNA is dependent on the Elb-55K1E4 ORF6-34K complex for
optimal cytoplasmic accumulation. These data, combined with the results of Leppard
(1993), led to the hypothesis that these mRNAs displayed a strong dependence on the
Elb-55K1E4 ORF6-34K complex because of the presence of intact splice sites/introns
within their sequence (see section 1.3.5.). Intact introns present in an RNA molecule
have been shown to act as nuclear retention signals, blocking efficient RNA export
(Ciejek, 1982; Legrain and Rosbash, 1989; Chang and Sharp, 1989; Hamm and Mattaj,
1990). If this hypothesis is correct the action of the Elb-55K1E4 ORF6-34K complex
is similar to that of the Hlv l Rev protein in overcoming the retention of incompletely
spliced mRNAs in the nucleus of infected cells.
As mentioned, mRNA A and full length mRNA differ from the other late mRNAs of
the E4 region in that the DI-Ala1Alb/Alc/Ald/Ale intron is intact in these mRNAs.
As late mRNAs identical to mRNA A but lacking this intron, are independent of the
Elb-55K1E4 ORF6-34K complex, it is possible that these splice sites or intronic
sequences are the reason for the dependence of mRNA A and/or full length mRNA on
the complex for optimal cytoplasmic accumulation. However since mRNA A and full
length mRNA have not been distinguished, a role for the D3/A3 intron, removed from
all late E4 RNAs except 'full length' cannot be excluded. As an initial step in
evaluating these possibilities, the role of the major donor site, D 1, in conferring El b-
55K1E4 ORF6-34K dependence was explored: According to this hypothesis E4
transcripts lacking the D 1 site will not be so tightly associated with the nuclear matrix
and/or splicing machinery and therefore not so dependent on the El b-55K1E4 ORF6-
34K complex for release into the cytoplasm.
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5.2. Experimental strategy
In order to explore the role of the Dl donor site in conferring Elb-55K1E4 ORF6-34K
dependence on an mRNA, a virus was built which lacked the Dl donor site. If this site
were important then the E4 mRNA A and/or full length mRNA, containing the
mutated D I site, would be able to accumulate in the cytoplasm in the absence of the
Elb-55K and/or the E4 ORF6-34K proteins. If it were unimportant then mutant
mRNA Alfulllength mRNA would fail to accumulate in the absence of these proteins.
To acheive a comparison of mRNA Alfulllength mRNA accumulation from the Dl
mutant in the presence and absence of RNA transport functions, Dl was mutated in an
RNA transport- background, and Elb-55K1E4 ORF6 functions supplied in trans from
a co-infected, wild-type virus (or as a control, an E4 ORF6- virus). Since the deletion
of the D I site would probably disrupt the expression of the whole E4 region, it was
decided that it would be easier to build the Dl mutation in the context of an E4 ORF6
lesion, rather than an Elb-55K lesion. An alternative strategy was the construction of
two mutant viruses, both with mutated D 1 sites but with only one lacking the E4
ORF6-34K protein. However, this strategy was not pursued as a number of attempts
to construct a virus lacking just the D 1 site failed.
The strategy behind the analysis of the mRNAs produced from this mutated E4 region
involved the co-infection of HeLa cells with the mutant virus and either wild-type (so
providing the E4 ORF6-34K protein in trans) or d1355 (lacking the E4 ORF6-34K
protein), the purification of the cytoplasmic RNA and analysis of the RNA by RNase
protection. The antisense RNA probe, to be used in the RNase protection assays, was
designed so that it could distinguish between mRNA Alfulllength mRNA from the D 1
mutated virus and the D 1 wild-type virus, being complementary to the mutant mRNA
from the SmaI site (35354) to the HindIII site, created in the mutagenesis of the DI
site, at 35537 bp (see Fig. 5.1.). Wild-type Dl mRNA Alfull length mRNA would
therefore protect a fragment of 175 nt while the Dl mutant mRNA Alfull length
mRNA would protect a fragment of 182 nt.
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Figure 5.1. The strategy for the detection of the mRNA A derived from the Dl
and E4 ORF6 mutated virus vDl. In vDl the E4 Dl splice site is mutated to a
HindIII site. Therefore, using a probe transcribed from pID50, E4 mRNA derived
from vDl will protect a fragment 7 nucleotides larger than mRNA from dl309 (wild-
type).
d1309 RNA
...CTTTTTTACTGGTAAGGCTGACTGTTATG ...
~Dl
mutant vD1 RNA
...CTTTTTTACTAAGCTTGCTGACTGTTATG ...
HindIII
pID50 anti-sense RNA probe
...AGTAGCGCTATTCGAACGACTGACAATAC ...
pBR322 HindIII 1 E4 seq.
1
I
1175 nt protected fragment
: from the wild-type vi~:..
182 nt protected fragment
from the mutant virus~------------
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5.3. Construction of the Dl and ORF6 mutant virus.
The central plasmid involved in the construction of the E4 mutant virus was pRC6.
pRC6 is a pBR322 based plasmid containing the righthand 8,607 bp of d1309, from the
EcoRI site at 27331 to the end at 35938, including all the E4 region. The 2348 bp
EcoRV fragment was removed from pRC6 and cloned into pBR322C (pBR322 with
the Clal site removed by cutting with Clal, end filling the 5' overhang and ligating) to
create pID26. Using pRC6 as a template, the D 1 site was mutagenised, using a PCR
protocol (see section 2.3.12., RSI = SmaI (pRC6, 8023), RS2 = ClaI (pRC6, 8609),
the primers used were J, K, L, and M (2.1.2.», creating a HindIII site and destroying
the D 1 donor site sequence. The resulting PCR cDNA was subcloned into pID26
using ClaI and SmaI and the resulting clones screened for the presence of the HindIII
site at the E4 D 1 site by HindIII digestion. The region amplified during the PCR (the
SmaI (pRC6, 8023) to ClaI (pRC6, 8609) fragment) was then subcloned, from a
number of the positive clones, into the SmaI site of M 13 mp 19 and sequenced using
the -40 M13 universal primer. A number of the positive clones (i.e. having a mutated
D 1 site) had point mutations in the amplified region in addition to the D 1 mutation,
probably due to the PCR, but one was selected, pID30, which was wild-type in
sequence apart from the Dl mutation (this mutation at the Dl site in pID30 can be
seen in Fig. 5.2.). The mutated 2348 bp EcoRV fragment from pID30 was then
returned to pRC6 to create pRC61D 1x.
The E4 ORF6-34K reading frame was mutated as follows. The 4637 bp NheI
fragment was removed from pRC61Dlx and subcloned into pBR322 to create pID39.
pID39 was subsequently linearised with Acc65I, which cuts within the E4 ORF6-34K
reading frame at the KpnI site, Klenow repaired and self-ligated to create pID41.
These manipulations resulted in the addition of 4 bp in the ORF6-34K reading frame
causing a shift to the -1 reading frame so destroying the ability to produce intact
ORF6-34K protein. dl355 (Halbert et al., 1985), which is phenotypically ORF6-34K
minus, carries a similar frame shift at this position. The 4644 bp Nhe 1 fragment from
pID41 was then returned to pRC61Dlx to create pRC61DIxlORF6x.
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Figure 5.2. The sequence of the Dl site of dl309 at 35542 bp, the HindIll site in
vDl at 35543 bp ( the location of the Dl site in d1309) and the mutated Kpnl site
in the ORF6 reading frame ofvDl at 35599 bp (sequence numbered as AdS wt300).
The DNA was sequenced using the dideoxynuc1eotide chain termination method
(2.3.1.13.). The arrow indicates the 5' to 3' direction of the L strand. The samples
were loaded as indicated.
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The EcoRI-Clal fragment of pRC6ID1x10RF6x, comprising of the righthand end of
the AdS genome, was then purified and ligated to the lefthand end EcoRI fragment of
the Ad5 genome from d1309. This ligated product was subsequently transfected into
W162 cells (Weinberg and Ketner, 1983), which are able to support the growth ofE4
mutant viruses. Six potential mutant plaques were identified (the plaqing efficiency of
W162s is 100 fold lower than HEK-293 cells (Halbert et al., 1984», however only two
of these contained virus, of which one (D) was mutated in the E4 region when the viral
DNA was analysed by digestion with KpnI and HindIII. This virus was subsequently
plaque-purified to create the E4 mutant virus vD 1 which lacked both the D 1 splice site
and an intact E4 ORF6 reading frame, as analysed by restriction mapping (Fig. 5.3.).
5.4. Analysis of mRNA A/fulllength RNA expression from the vD. virus.
vD 1 virus particles were purified on a CsCI gradient and used to co-infect HeLa cells
at 500 particles/cell of vD1 virus along with 100 particles/cell of either d1309 (wild-
type) or d1355 (E4 ORF6 mutant virus). dl309 provided the E4 ORF6-34K protein in
trans to the vD 1 virus to simulate a E4 ORF6-34K wild-type infection in which E4
vD1 mutant RNA was expressed, while the dl355 plus vD1 co-infection provided the
E4 ORF6-34K minus situation for comparison. In parallel d1309 and dl3S5 infections
(at 100 particles/cell) were carried out as controls.
Cytoplasmic RNA was harvested at 24 hr p.i. and analysed for the presence of the
mutant E4 mRNA using a T7 probe generated from pID50. pIDSO was constructed by
subcloning the 181 bp Smal-HindIII fragment ofplD30 into pBR322 to create pID48.
The 260 bp Nhe 1-EcoR 1 fragment of pID48 was then subcloned between the Xbal and
EcoRI sites of pGEM4. The resulting T7 transcribed RNA probe contained 182
contiguous nucleotides complementary to the mutant E4 mRNA and 175 contiguous
nucleotides complementary to the wild-type E4 mRNA (with an intact Dl site). This 7
nucleotide difference in the length of the protected fragments in an
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Figure 5.l. Restriction digest analysis of the Dl mutant virus vDl and dl109 as
analysed on a 0.8% agarose gel. The purified virus DNA was digested with either
KpnI or HindIII as indicated above the gel. Also shown are the fragments which vary
in size between the dl309 and vD 1 viruses due to the removal of a restriction site
(KpnI, vD 1) or the addition of a restriction site (Hindm, vD 1). All figures are in base
pairs. The marker shown (in bp) is the '1 kb ladder' (Gibco BRL).
Indicated below are the restriction maps of AdS wt300 virus as reviewed by Tooze
(1982). It should be noted that d1309 lacks the 72.8 map unit Hindill restriction site,
fusing the HindIII fragments A and B together. Also the KpnI F fragment is slightly
smaller in dl309 than in wt300 due to a substitution in the E3 region. The 1008 bp
Hindill I fragment is cleaved by HindfII in vD 1 as the splice donor site D 1 was
mutated to a Hindill site. Also in vD 1 the KpnI 4811 bp D and 2340 bp G fragments
are fused due to the mutation of the KpnI site at 93.5 map units in the ORF6 reading
frame to create a 7151 bp fragment.
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RNase protection assay was sufficient to allow the resolution of the RNA species on a
6% acrylamide gel.
The results of such RNase protection analysis can be seen in Fig. 5.4. mRNA Alfull
length mRNA from the mutant vD I virus accumulates to levels in the cytoplasm in the
dl355 co-infection akin to those found the in the dl309 co-infection while wild-type
mRNA Alfulllength mRNA does not accumulate to such high levels in the cytoplasm
in the dl355 co-infection. This would suggest that the D I site is involved in conferring
dependence on the RNA on the E4 ORF6-34K protein, and probably the Elb-S5K
protein, for optimal cytoplasmic accumulation. However, the levels of mutant mRNA
Alfull length mRNA in the dl355 infection are still lower than those in the dl309
infection indicating that, although the removal of the D I site does alleviate some of the
dependence ofmRNA Alfulllength mRNA on the Elb-55K1E4 ORF6-34K complex it
does not alleviate it completely. This may indicate that sequences in the mRNA other
than DI contribute to the Elb-5SKlE4 ORF6-34K dependence of an mRNA such as
the other splice sites unique to these two late mRNAs (Ala and, for full length only,
D3, A3 and AS) or undefined intronic regions.
It should be noted, however, that the results obtained when conducting this series of
RNase protection assays were not as expected. For some unexplained reason the
difference in the level of mRNA Alfull length mRNA in wild-type and E4 ORF6
mutant infections was not as great as observed in multiple experiments conducted
before (see chapter 4). Also the overall levels of the E4 mRNA detected were low in
all experiments and the RNA not of good quality, resulting in a lot of degradation in
the assays. To evaluate conclusively the role of the DI donor site in Elb-55K1E4
ORF6-34K dependence more studies need to be conducted with this virus.
154
Figure 5.4. RNase protection analysis of d1309, d1355, and vm mRNA A/full
length mRNA using a probe made from pID50 (2.3.5.). HeLa cells were infected
with 500 particles/cell of vDl and/or 100 particles/cell of d1309 or d13SS. 5 ug of
unselected cytoplasmic RNA was analysed 24 hr p.i. for the presence of mRNA Nfull
length rnRNA and ~-actin (not shown).
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Chapter 6.
The generation of a polyclonal antiserum to E4 ORFI
6.1. Introduction
The sequencing of Ad5 E4 DNA (see chapter 3) indicated that the predicted ORFI
protein is a hydrophobic protein of 128 aa. Three mRNAs potentially encode the
ORFI protein, mRNAs A, B and full length mRNA. Studies of the E4 mRNAs
(chapter 4) demonstrated that while mRNA B does not exist in the cytoplasm of
infected cells in the absence of translation inhibitors, mRNA Nfulliength mRNA has
late expression kinetics, first appearing in the cytoplasm at 16 hr p.i. This result
suggests that the ORFI protein is made, and is presumably required, late in the
infection, after DNA replication. However the AdS ORFI protein has not yet been
shown to exist in infected cells and no role for it has been established in the AdS lytic
cycle, although recently, Javier (1994) found the Ad9 ORFI protein and demonstrated
that it was involved in the induction of mammary tumours in rats (section 1.4.2.2.).
This chapter describes attempts to identify the ORFI protein in AdS infected cells.
The strategy employed involved the expression and purification of ORFI-related
proteins and the subsequent generation of mono-specific polyclonal antisera to the
purified protein in out-bred half-lop rabbits. These animals were chosen as they yield a
large amount of serum through the course of an immunisation regime and because their
out-bred character makes it more likely that they will respond effectively to the
immunogen. The resulting polyclonal antisera were then used to search for the ORFI
protein in infected cells using a number of different immunochemical techniques.
6.2. Viruses and cells used.
Four different viruses were used in this series of experiments; wt300, dll-3, dl327 and
d1351. wt300 is a plaque-purified stock of wild-type virus (Jones and Shenk, 1978).
The dll-J mutant virus carries a deletion in the E4 region from the SmaI (35354) to
the BgnI (34387) in a wt300 background which results in the loss of ORFs I, 2 and 3
(Huang and Hearing, 1989a). dl327 lacks the 78.5- to 84.3-map-unit XbaI fragment
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from early region 3 and is phenotypically wild-type for growth in tissue culture. This
deletion was described originally in virus dl324 (Thimmappaya et al., 1982). dl351
contains a 5 bp insertion at the BstEII site (35222) causing the disruption of the E4
ORFI reading frame in a d1327 background (Halbert et al., 1985). HeLa cells were
used for virus growth throughout this study.
6.3. Expression of the ORFI protein using the pGEX vector
The commercially available pGEX system (pharmacia) was selected to express the
ORFI-14K protein as it had been reported that it allowed the simple, high level
expression and purification of the recombinant proteins in E. coli (Smith and Johnson,
1988). The foreign polypeptide is expressed as a fusion with the glutathione S-
transferase (GST) protein, which can be easily purified from lysed cells by affinity
chromatography with glutathione-sepharose beads, followed by elution in the presence
of free glutathione. The pGEX vectors contain the ptac promoter which promotes the
transcription of the GST open reading frame, followed by a MCS containing three
unique restriction sites; Bamlfl, SmaI, and EcoRI, followed in tum by termination
codons in all three frames (see Fig. 6.1.). The vector which was selected, pGEX-2T
(Smith and Johnson, 1988), also encoded a thrombin cleavage site between the GST
gene and the MCS, into which the foreign polypeptide can be cloned, allowing the
cleavage of the fusion protein to release the foreign polypeptide. The GST moiety can
then be removed using glutathione sepharose beads leaving the purified heterologous
polypeptide in solution.
A cDNA fragment suitable for the expression of the ORFI protein was generated using
PCR. The template DNA used was the AdS wt300 genomic DNA while the two
primers used were IDC and IDD (see section 2.1.2.). The 3' terminus of IDC
contained 16 nucleotides complementary to the DNA of the 5' terminus of ORFI and
DNA immediately upstream. In the 5' terminus of IDC was a Bamlfl site positioned
so that when the resulting ORFI cDNA was cloned into the pGEX-2T vector using
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Figure 6.1. The pGEX-2T expression vector
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Figure 6.2. peR amplification of the ORFI eDNA using primers IDC and IDD
(2.3 .1.11.). All of the 413bp peR product was run on a 1.2% agarose gel. See Fig.
S.3. for marker details.
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the Bamlll site it was in frame with the GST gene reading frame. Similarly the 3'
terminus of IDD contained 18 nucleotides complementary to the DNA of the 3'
terminus of ORFI and DNA immediately downstream. In the 5' terminus of IDD was
an EcoRI site to facilitate the cloning of the ORF cDNA into the pGEX vector. The
resulting ORFI cDNA product can be seen in Fig. 6.2.
The cloning of this 413 bp ORFI cDNA product was not as easy as expected. The
direct cloning of the cDNA into the pGEX vector using the Bamlfl and EcoRI sites
failed, as did the cloning of the cDNA into SmaI site after end repair of the cDNA.
On self ligation of the ORFI cDNA, after incubation with BamHI and EcoRI, it was
noted that only monomers and dimers of the cDNA formed, with no evidence of any
higher order moieties suggesting that one of the restriction sites was non-functional
(data not shown). As a result, blunt-ended cloning of the end-filled ORFI cDNA into
a series of different vectors was attempted. Eventually 6 positive plaques were
identified after blunt-end ligation of the ORFI cDNA into SmaI site of M13 mpl9.
These six clones were sequenced using the M13 -40 universal primer; two were false
positives while the other four contained the ORFI sequence. All four positive clones
contained the same point mutation in the Bamlll site rendering it non-functional,
indicating that the primer sequence was incorrect. The 4 positive clones also contained
point mutations in the ORFI reading frame (although in different locations) due to the
high error rate of Taq polymerase. It was decided to use a clone with just one point
mutation, a Val to Ala substitution at position 128 (the last amino acid), as this was
unlikely to affect the specificity of polyc1onal antisera generated to it. Using the San.
site of the mp 19 MCS and the EcoRI site directly downstream of the ORF 1 cDNA, the
cDNA was cloned between the EcoRI and San sites ofpBR322 to create p1017, for
ease of handling. pID17 was then cut with Sau3AI, the 714 bp fragment (which
contains the ORFI cDNA) purified and end-filled. This fragment was subsequently cut
with EcoRI and the resulting ORFI fragment cloned into the SmaI and EcoRI sites of
pGEX-2T (pI022), ensuring ORFI was in the same translational reading frame as that
ofGST (see Fig. 6.3.).
161
Fig 6.3. Construction of the pGEX-2T/ORFl cDNA expression vector pID22.
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To establish if pID22 was able to express the expected 358aa fusion protein, cells
containing the construct were harvested and analysed after various periods of induction
at 37°C with IPTG. At each time point, 2 ml of sample was prepared as section
2.3.7.1., and amounts of the insoluble fraction and supernatant equivalent to 0.1 ml of
the culture were loaded onto an SDS-PAGE gel (Fig. 6.4a.). In parallel, the
expression GST from cells containing pGEX-2T was examined as a positive control
(Fig. 6.4b.) Fig. 6.4a. demonstrates that a 40K protein, presumptively GST/ORFI
(GST is a 26K protein (Smith et al., 1986) while ORFI is predicted to be 14K in size,
to give a 40K fusion protein), is induced in the cultures by IPTG but is largely
insoluble. Also shown in Fig. 6.4a. (6 hr, pure), attempts to purify the GST/ORFI
protein from the 6 hr induced supernatant were not successful. In comparison, the
induced GST protein in Fig. 6.4b. is present largely in the soluble fraction and was
easily purified on the affinity matrix.
Although insoluble fusions can be made soluble in denaturing conditions (such as 8M
urea) they cannot be purified using the GST interaction with glutathione as this
interaction is dependent on the native conformation of the GST protein. A number of
attempts were therefore made to produce soluble GST/ORFI fusion protein. Initially
the lysis conditions of the bacteria were altered, adding 0.03% SDS, 1% Tween 20 or
1% Triton-XIOO after sonication, as it had been reported that purification using
glutathione was still possible after such detergent treatment (Smith and Corcoran,
1992), but purification still failed (data not shown). The growth conditions of the
bacteria were also altered in an attempt to produce soluble fusion protein: the bacteria
were induced at a lower temperature and for longer (30°C for 16 hours) as it had been
reported by Schein and Noteborn (1988) that a number recombinant proteins, that
were insoluble in E. coli grown at 37°C, were soluble when the bacteria were grown at
30°C. However this was not the case for the GST/ORFI protein (Fig. 6.4a. and data
not shown). Blackwell and Horgan (1991) also demonstrated that the growth of
bacteria in LB supplemented with 660 mM sorbitol and 2.5 mM betaine facilitated the
production of soluble proteins. However when pID22 was induced at either 30°C or
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Figure 6.4. Protein expression from the pGEX constructs. Panel A: The
expression of the GST/ORFl fusion protein from pID22 at 30°C and 37°C
assayed by SDS-PAGE. The times post induction (hrs) and the sample fraction are
indicated above the gel. All samples are the equivalent of 0.1 ml of the culture,
except the purified fraction which is equivalent to 2 mls of culture. Visualised by
coomassie blue staining. SIN=supernatant; P=pellet; Pure=glutathione sepharose
beads. Figure 6.4 Panel B: The expression of the GST protein from pGEX-2T at
30°C and 37°C assayed by SDS-PAGE. All other details as Fig.6.4a.
Markers (Amersham): 97 kDa : Phosphorylase B
69 kDa : Bovine Serum Albumin
46 kDa : Ovalbumin
30 kDa: Carbonic Anhydrase
21.5 kDa : Trypsin Inhibitor
14.3 kDa: Lysozyme
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37°C in this supplemented LB medium, little or no increase in solubility or efficiency of
purification was observed (data not shown).
Finally, the pGEX-2T/ORFI construct was modified to produce separate GST fusions
with Nand C terminal fragments of ORFI in an attempt to allow the purification of at
least part of the ORFI protein. pID22 was cut with SmaI and EcoR! to remove DNA
encoding the C terminus of ORFI and re-ligated to produce pID22N. pID22 was also
cut with BamID and SmaI to remove DNA encoding the N terminus of ORFI and re-
ligated to produce pID22C. Both of these new constructs were sequenced across the
GST/ORFI junction, using the primer IDG (section 2.1.2.), to ensure the reading
frame was intact. After induction at 37°C for 4 hours both the resulting fusion
proteins, the 291aa GST/ORFIN and the 297aa GST/ORFIC, could be readily
identified in the bacterial total cell protein samples. However, neither could be purified
using glutathione sepharose (Fig.6.S.).
Since native, soluble GST/ORFI fusion could not be produced and so purified, it was
decided to purify the fusion protein as an insoluble inclusion body preparation.
GST/ORFI expression was induced from pID22 for 3 hours at 37°C in all culture
and the GST/ORFI inclusion bodies purified as in section 2.3.7.2. This preparation
gave a yield of about 6 mg/l (the GST/ORFI band intensity on a SDS-PAGE gel was
compared to that of known amounts of BSA to give an estimation of the amount of
protein present). This preparation was resuspended in 6 ml of PBS, and 10 III analysed
by SDS-PAGE (Fig. 6.6.). Although the preparation was not 100% pure it was
decided to use it for the production of a polyclonal antisera as the contaminating
proteins were of bacterial origin and of a relatively low concentration compared to the
GST/ORFI fusion.
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Figure 6.5. The expression of the GST/ORFIN and GST/ORFIC fusion proteins
from 3 clones of pID22N and pID22C respectively at 37°C for 4 hours assayed by
SDS-PAGE. The total samples are the equivalent of 0.1 ml of culture while the
purified samples (2.3.7.1.) are equivalent to 2 mls of culture. Visualised by coomassie
blue staining. See Fig. 6.4. for the details of the markers.
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Figure 6.6. The GST/ORFI inclusion body preparation used in the generation of
the first ORFI polyclonal antiserum assayed by SDS-PAGE. 10 III of the
GST/ORFI preparation was assayed on the gel along with 1 and 5 ug of BSA.
Visualised by coomassie blue staining. See text for details of the preparation. See Fig.
6.4. for marker details.
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6.4. The generation of an ORFI antiserum using the GST/ORFI inclusion body
preparation.
A half-lop rabbit was inoculated subcutaneously three times with 500 Ilg of the ORFI
inclusion body preparation and Freund's adjuvant (1: 1 volume ratio was vortexed for
30 minutes so the emulsion was viscous), over 65 days. The rabbit was bled three
times, 42, 56, and 81 days post first inoculation, giving serum samples A, Band C
respectively, before it had to be put down due to self-inflicted injury. The three sera
were analysed by ELISA and western blot analysis.
Ideally the ELISA should have been carried out against pure ORFI protein or
GST/ORFI protein but as no soluble forms of these proteins were available, GST (0.5
Ilg per well) was used (expressed as in section 2.3.7.1. from the pGEX-2T vector). In
parallel with this analysis a GST/ORF2 antisera generated at a similar time post-initial
inoculum was also tested (see chapter 7). This allowed the comparison of the titres of
the two antisera. The results can be seen in Fig. 6.7. The estimated titre of the
GST/ORFI antisera is 1,800, about 40 fold higher than the pre-immune sera, while the
titre of the GST/ORF2 antisera is about lOO times greater at 325,000, about 4,000 fold
above pre-immune. Although this assay does not give an idea of the level of antibodies
against the ORFI protein it is a guide as to how effective the immunogen is at eliciting
an antibody response. It is evident from this that the soluble GST/ORF2 fusion
generated a high titre of antibodies in the rabbit against GST (a good titre against the
ORF2 moiety was also generated, see section 7.4.) while the insoluble GST/ORFI
inoculum only elicited a low antibody titre against GST, and presumably therefore
against ORF I also. The titre however was rising when the animal had to be put down.
Western blot analysis was carried out using the anti GST/ORFI-C sera collected 81
days post the first inoculation. About 0.5 pg of the bacterially expressed GST/ORFI
fusion inclusion body protein was loaded onto a SDS-P AGE gel and transferred for
probing with this serum (Fig. 6.8.). This western blot clearly demonstrates that the
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Figure 6.7. Titration of the anti-GST/ORFI activity in serum samples by ELISA
(2.3.9.3.). Serial dilutions of anti-GST/ORFI sera taken in successive bleeds from a
rabbit inoculated with the GST/ORFI inclusion body preparation were tested against
0.5 Jig ofGST protein. See text for details of the GST/ORFI samples. Also shown is
the serial dilution of the GST/ORF2 antisera from an equivalent time post inoculation
(77 days) as the last GST/ORFI antisera (see section 7.4.).
Figure 6.S. Western blot analysis of the GST/ORFI polyclonal antisera (2.3.9.1.).
A 11500 dilution of the sera sample GST/ORFI-C was used in the detection ofO.25 JII
of the inoculum (- 0.5 ug). See Fig. 6.4. for marker details.
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antiserum has activity against the fusion protein as it recognises the 40K fusion protein
while the pre-immune serum fails to do so. It is unclear if this activity was against just
the GST moiety or to both the GST and ORFI components of the fusion.
Attempts to identify the ORFI protein using this antiserum in infected HeLa cells by
immunoprecipitation assay and western blot analysis failed; no proteins present in the
wild-type infected cell but absent in an ORF1 mutant (d1351 or dll-3) infected cell
could be identified (data not shown). The most likely reason for this failure to identify
the ORF1 protein is the low titre of the antisera. As a result, a fresh attempt to
generate a high titre ORF1 antiserum was made.
6.5. The expression of ORFI using the XPRESS expression system.
The XPRESS system (Invitrogen) allows the purification of bacterially expressed
proteins by exploiting the metal binding activity of six contiguous histidine residues.
The pUC-derived pTrcHisA vector (see Fig. 6.9) contains an IPTG inducible promoter
(pTrc) which is repressed by the LacN gene product, encoded by the vector, ensuring
that expression of the recombinant protein only occurs upon induction. Downstream
of the promoter is a transcription anti-termination region (E. coli rrnB) followed by the
bacteriophage T7, gene 10 RBS. Translation of the recombinant protein is enhanced
by the presence of an 8 aa mini-cistron following the RBS which efficiently restarts
translation at the following ATG. Immediately following the mini-cistron is the ATG
translation initiation site for the recombinant protein followed by a region that encodes
6 contiguous histidine residues and a MCS enabling the fusion of the histidine residues
to the N terminus of the recombinant protein. This N-terminal metal binding domain
(the 6 histidine residues) allows the simple one-step purification of recombinant
proteins by immobilised metal affinity chromatography using the nickel ion resin
ProBond (Invitrogen). Positioned between the histidine residues and the MCS is an
enterokinase cleavage site allowing the removal of the histidine residues from the
recombinant protein after expression and purification. The
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Figure 6.9. The pTrcHis vector of the Invitrogen Xpress bacterial expression
system (from commercial literature oflnvitrogen).
pTrcHisA,B,C
4.4 kb
rES> -35 (UpS), -10 (/acUY5) hybrid promoter for high level transcription initiation.~.c01 The lac repressor (encoded by laclQ gene on vector) binding site for repression of
transcription. High level transcription can be induced with IPTG.
~
~
The Sequence from e. cali rrnS (ribosomal RNA gene) which reduces the level of
premature transcription termination.
~ The ribosome binding site from bacteriophage ngene 10 which has been shown to
optimize translation initiation.
E3 A short open reading frame containing nucleotide sequences that are efficiently
~ translated in prokaryotic cells. A ribosome binding site (RSS) is present within the
coding sequence 5' to the translation termination codon. This RSS and termination
codon are positioned in frame and three nucleotides upstream from the translation
initiation codon to be used to express the fusion protein of interest Following
translation of the open reading frame of the mini cistron, ribosomes efficiently
reinitiate translation at the second initiation site.
cm The translation initiation site for the fusion protein of interest.
C The sequence encoding 6 tandem histidine residues which have a high affinity for
Ni- charged ProBond™ resin.
El The sequence encoding an enterokinase specific cleavage site
(asp-asp-asp-asp-lys-asp).
C5l The multiple clQning site, positioned in three different reading frames in versions A.
S, and C relative to the poly-histidine containing leader peptide open reading frame.
8 Transcription termination sequences from e. coli rrna gene.
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advantage of this system over the pGEX system is that the recombinant protein can be
isolated under strong denaturing conditions as the interaction of the histidine residues
with the nickel ions is not dependent on protein secondary structure. Insoluble
proteins can therefore be solubilised in 8M urea or 6M guanidine hydrochloride and
still be purified.
The ORFI cDNA from pID22 was cloned into the pTrcHisA vector at the Bamlll and
EcoRI sites. A positive clone (pID35) was then expressed as per the manufacturers
instructions. 1110 of the resulting pellet and supernatant fractions (from 2 ml of
culture) were then assayed on an SDS-PAGE gel for the presence of the His/ORFI
fusion protein (Fig. 6.10.). A faint band of about 18K (estimated size of ORFI with
the histidine residues attached), which increased in intensity as the length of induction
increased, was observed in the insoluble pellet fraction. This is probably the His/ORFI
fusion.
The HislORF 1 fusion protein was subsequently purified from a 50 ml culture induced
as above for 6 hours. The insoluble protein was solubilised in 6M guanidine
hydrochloride and the fusion protein purified under denaturing conditions using the
ProBond nickel resin and denaturing elution buffer (see manufacturers instructions) at
pm.8 to elute the purified protein from the column in O.Sml fractions. 1125 th of each
of these fractions was then assayed on an SDS-PAGE gel for the presence of the
HislORFl fusion protein (Fig. 6.11.). The His-ORFI protein was successfully purified
using this system, eluting off the column in fractions 3-S. However the estimated
purity (by SDS-PAGE analysis) of the His/ORFI fusion was only 75% as the fractions
also contained contaminating higher molecular weight bands. By quantitating the
amount of protein present in each sample using the Bradford assay it was estimated
that this 50 ml culture was only producing about 50 J.1gof His-ORFI protein, i.e. a
yield of 1 mg/l. Neither yield nor the purity of the sample could be improved in
subsequent purification experiments. As a result, this system was not exploited
further.
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Figure 6.10. The expression of the His/ORFI fusion at 37°C from pID35 assayed
by SDS-PAGE. A 25 ml culture of bacteria containing pID35 was induced at ~OO
0.5 with 1 mM IPTG and samples taken at the times post induction (hr) indicated
above the gel. Samples were lysed in PBS by three rounds of freeze/thawing and
centrifuged at 16,000 x g for 10 minutes to separate the insoluble (P) and soluble
(SIN) fractions. All samples are equivalent to 0.2 ml of culture. Visualised by
coomassie blue staining. SIN = supernatant; P = pellet. See Fig. 6.4. for marker
details.
Figure 6.11. SDS-PAGE analysis of samples of 0.5 ml fractions from the nickel
resin column used in the purification of the His/ORFI fusion expressed from
pID35. 1125 th of each fraction was assayed on the gel. Visualised by coomassie blue
staining. See Fig. 6.4. for marker details.
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6.6. The expression of ORFI using the OIAexpress expression system.
The QIAexpress expression system (Qiagen), like the Xpress system of Invitrogen,
allows the purification of bacterially expressed proteins by exploiting the metal binding
activity of six contiguous histidines, and like the Xpress system allows the purification
of recombinant proteins under strong denaturing conditions. However, the plasmids
used in the QIAexpress system are considerably different from the pTrcHis series of
plasmids of Invitrogen. In the QIAexpress system two plasmids are used, pREP4 and
pQE. The pQE plasmid (selected by ampicillin) is the vector which contains the
expression cassette for the recombinant protein while the pREP4 plasmid (selected by
kanamycin) encodes the lac repressor (see Fig. 6.12). The expression cassette of the
pQE-30 plasmid contains: the E. coli phage T5 promoter and two lac operator
sequences, ensuring a high level of protein expression on IPTG induction; a synthetic
RBS; a 6 histidine affinity tag coding sequence; a MCS; translation stop codons in all
three reading frames and the transcription terminator 'to' from phage lambda. The
presence of the strong phage TS promoter requires the presence of high levels of the
lac repressor protein to repress unwanted transcription prior to induction. Therefore
the second, high copy number, plasmid pREP4 is used, which carries the lac! gene
ensuring high levels of the lac repressor in the cell. The presence of a strong promoter
made the pQE vector attractive for the expression of the ORFI protein as it was clear
from the Xpress system that reasonable purification was possible if adequate
expression could be achieved. Also, if the levels of protein expression were to be
increased by using the QIAexpress system then the purified heterologous protein
product should be of a higher purity, due to the increased concentration of the ORFI
fusion in the cell lysate.
The ORFI eDNA from pID22 was cloned into the pQE-30 vector using the Bamill
and EcoRI sites, ensuring the ORFI sequence was in the same reading frame as the
6xHis peptide, to produce pID38. Bacteria containing pID38 and pREP4 were then
grown in a 25 rnl culture until ~OO 0.5, induced with 2 mM IPTG and 1 rnl
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Figure 6.12. The pQE-30 and pREP4 plasmids of the Qiagen QIAexpress bacterial
expression system.
T5 promoter
/lac operator RBS
Sphl Kpnl Sail Hindlll TIn
6xHis BamHI Sacl SmaI Pstl Stop to
pQE-30
3462 bp
Xbal
ORI
Xba1 HindIII
pREP4
3740 bp
Smal
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samples taken after 0, 1, 2 and 4 hours of induction at 37°C. The I m1 samples were
processed and assayed as in section 6.5. The results of this assay can be seen in Fig.
6.13. It can be clearly seen from Fig. 6.11 and 6.13 that the expression of the
HislORFl fusion protein is more efficient in the QIAexpress system with a distinct
band of about 15K being visible in the induced samples.
The expression was then scaled up to SOmIs and the HislORFI protein purified as in
section 2.3.7.3. 1I100th of the 0.5 m1 fractions eluted from the column were then
assayed on an SDS-PAGE gel for the presence of the HislORFI fusion (Fig. 6.14).
The results shown in Fig. 6.14 indicates that the His/ORFI fusion protein eluted from
the column in fractions 3-6 with a purity of greater than 90 % (estimated from the
SDS-PAGE gel). The total amount of His/ORFI protein purified, as quantified by a
Bradford assay, was estimated at 1.6 mg, giving a yield of 32 mg/l. The QIAexpress
system therefore allowed the purification of the His/ORFI protein to a higher purity
and in larger amounts than the Xpress system.
This preparation was subsequently used as an antigen to produce a mono-specific
polyclonal antiserum in rabbits. The concentration of the HislORFl protein was 800
ug/ml in 8M urea. This was diluted 2 fold to give a 4M urea solution containing 400
JIg HislORFl fusion/mI. 500 JlI of this was then mixed with either complete or
incomplete Freund's adjuvant (see section 2.3.8) and used as the inoculum for the
generation of the polyclonal sera.
All subsequent studies using His/ORFI fusion used this preparation of protein.
6.7. Attempts to detect ORFI in infected cells.
The rabbit was inoculated with antigen at 3 week intervals until 112 days the first
inoculation (see section 6.4.) and bled at 0, 43, 58, 84, 103, 117, 133 and 152 days
post-first inoculum, to give serum samples pre, A, B, C, D, E, F and G respectively.
The specific ORFI reactivity of the serum samples was analysed by ELISA,
immunofluoresence, immunoprecipitation and western blot analysis.
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Figure 6.13. The expression of the His/ORFI fusion at 37°C from pID38 assayed
by SDS-PAGE. A 25 ml culture of bacteria containing pID38 and pREP4 was induced
at A(joo 0.5 with 2 mM !PIG and samples taken at the times post induction (hr)
indicated above the gel. Samples were lysed in PBS by three rounds of freeze/thawing
and centrifuged at 16,000 x g for 10 minutes to separate the insoluble (P) and soluble
(SIN) fractions. All samples are equivalent to 0.2 ml of culture. Visualised by
coomassie blue staining. SIN = supernatant; P = pellet. See Fig. 6.4. for marker
details.
Figure 6.14. SDS·PAGE analysis of samples of 0.5 ml fractions from the nickel
resin column used in the purification of the His/ORFl fusion expressed from
pID38 (2.3.7.3.). 11100 th of each fraction was assayed on the gel. Visualised by
coomassie blue staining. See Fig. 6.4. for marker details.
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The results of the ELISA assays, using 0.5 JIg of purified His/ORFI protein per well,
can be seen in Fig. 6.15. These results suggest that the specific antibody titres
achieved are relatively low, with the peak specific titre being only 200 fold over the
pre-immune titre (as compared to the GST/ORF2 antisera titre which is 4,000 fold
greater than the pre-immune, chapter 7).
The Western blot analysis was carried out using 111000 dilution of each serum sample
against an estimated (by Bradford analysis) 400 ng of the bacterially expressed
His/ORFl protein. The results of this analysis can be seen in Fig. 6.16. This analysis
of the sera confirms the results of the ELISA~ the titre increases over the first two
samples and then reaches a plateau. The western blot analysis also indicates that the
titre of the antibody is relatively low; similar analysis with an anti-ORF2 polyclonal
serum only required 111Oth of the amount of antigen to produce the same intensity of
band when carried out in parallel with this experiment (Fig. 7.7.).
No evidence of the ORFI protein in virally infected HeLa cells could be found by
immunoprecipitation analysis (Fig. 6.17). wt300- or dll-3-infected HeLa cells (MOl
of 10) were labelled for 3 hours (100 JICi 35S-Met/I07 cells) and harvested at 24 hr
p.i. The resulting RIPA buffer lysates were then immunoprecipitated using 4 JII of
antiserum in the overnight step. This assay revealed a protein slightly smaller than 14K
which was present in the wt300 infected cells and absent in the E4 mutant virus, dll-3
(lacks ORFs 1-3). Further studies (data not shown) also suggested that this protein
was made with late kinetics as expected for the ORFI protein (the mRNA that encodes
ORFI is expressed with late kinetics (see chapter 4)). However this band was also
present in pre-immune immunoprecipitation analysis (Fig. 6.17) and in cells infected
with the ORFI mutant d1351 (the band is faint in dl327 and dl35l as the labelling
conditions were altered, see below) (Fig. 6.17.) indicating that this protein is not
ORFI. It is unknown why this protein does not appear in the dl l-J mutant.
Similar negative results were obtained for western blot analysis and indirect
immunofluoresence assays with virally infected cells; no difference could be
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Figure 6.15. Titration of the anti-His/ORFI activity in serum samples by ELISA
(2.3.9.3.). Serial dilutions of anti-His/ORFI sera taken from successive bleeds from a
rabbit inoculated with the HislORFI fusion protein, were tested against 0.5 ug of
HislORFI fusion protein. See text for details of serum samples A-G.
Figure 6.16. Western blot analysis employing sequential anti-His/ORFl antisera
to detect 400 ng of purified recombinant ORFI (2.3.9.l.). A 111000 dilution of
each antiserum (A-G, pre-immune) was used.
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ascertained between wild-type and dll-3 infected cells or between pre-immune or
immune antisera. Western blots were set up using 2.5 x 106 HeLa cells (infected and
non-infected) lysed in RIPA buffer. A number of different detection conditions and
antiserum concentrations were used in an attempt to detect the ORFI protein but these
were all unsuccessful (data not shown). Similarly, a number of different fixation
techniques (acetone/methanol, formaldehydeffXl00, methanol) were used for
immunofluoresence analysis, as were a number of different antibody combinations but
no specific fluorescence was detected. Control experiments conducted in parallel,
using antibodies specific for other antigens, for both these sets of experiments were
successful indicating that the techniques employed were not fundamentally flawed.
There are a number of possible reasons why the ORFI protein was not detected in
these analyses. First, the antiserum may not be reactive against the antigen when
presented in certain types of analysis. However this was not the case for western blot
analysis (see Fig. 6.19.) and the evidence in Fig. 6.18. suggests that the His/ORFI
antiserum can successfully immunoprecipitate an in vitro transcribed/translated ORFI
protein. This product was produced by cloning the ORFI cDNA of pID22 (as a
Sau3Al - EcoRI fragment) into the pT74(pA) vector (a modified pGEM4 vector
containing 30 adenylate residues at the SP6 end of the MCS), to create pID46. Radio-
labelled ORFI protein was expressed from 1 J.1gof this clone using the Promega TnT
coupled transcription-translation reticulocyte lysate system in the presence of 35S-met.
1I33rd of the total ill vitro translation was then immunopreciptitated with 2J.11of either
pre-immune serum or HisiORFI-D antiserum and assayed on an SDS-PAGE gel (Fig.
6.18.). It has not been demonstrated that the antiserum can recognise antigen in an
immunofluoresence assay.
Second, the ORFI protein may be post-translationally modified in such a way that the
antiserum generated against the bacterially expressed ORFI protein fails to recognise
it. Although this possibility was not fully addressed by the use of modification
inhibitors, when infected HeLa cells were labelled for only 20 min (400 J.1Ci35S_
metll07 cells) no ORFI protein could be immunoprecipitated (Fig. 6.17).
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Figure 6.17. Detection of ORFI in infected cells. wt300- and dll-3-infected HeLa
cells (MOl = 10) were labelled for 3 hours (lOO J.lCi35S-met1l07 cells) while d1327-
and d1351-infected cells (MOl = 10) were labelled for 20 min. (400 J.lCi35S-met1l07
cells) (2.3.10.1). Both were harvested into RIPA buffer 24 hours p.i. The lysates
were subsequently analysed for the presence of the ORFI protein by
immunoprecipitation using 2 J.lIof the GST/ORFI-E or pre-immune sera (2.3.9.2.).
Markers (Gibeo BRL): 97 kDa : Phosphorylase B
68 kDa : Serum Albumin
43 kDa : Ovalbumin
29 kDa : Carbonic Anhydrase
18.4 kDa : p-Iactoglobin
14.3 kDa : Lysozyme
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Figure 6.18. Immunoprecipitation of an in vitro transcribed/translated ORF1
product. 1/S0th of an in vitro transcription/translation of 1 Ilg of pID46 in the
presence of 3SS-met using the Promega TnT in vitro transcription/translation system
(2.3.11.1) was loaded onto a SDS-PAGE gel. Also shown is a negative control (no
DNA template) and a positive control (the TnT control template, the luciferase gene).
1/33rd of the in vitro transcribed/translated ORF1 (from pID46) was
immunoprecipitated using 2 III of His/ORF1-E or pre-immune sera and also analysed
by SDS-PAGE (2.3.9.2.). See Fig. 6.17. for marker details.
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Third, the C terminal amino acid change in the recombinant ORF1 protein may be in
the dominant antigenic site of the protein and so while the recombinant protein would
be recognised by the antiserum, the wild-type viral ORF1 protein would not.
However, western blot analysis using the His/ORF1 antiserum to detect the GSTIN
terminal half of ORF1 and C terminal half of ORF1, expressed separately, indicated
that the immune response of the rabbit was directed largely against the N terminal half
of the ORF1 protein (Fig. 6.19). This suggests that the C terminal amino acid change
makes no difference in the ability of the antiserum to recognise the wild-type ORF1
protein.
Fourth, the ORF1 protein may not actually exist; ORF1 may be only a potential
reading frame in the virus. However this is unlikely as mRNA encoding this reading
frame is produced in infected HeLa cells (see chapter 4), the reading frame is
conserved between a number of adenovirus serotypes (see chapter 3) and the Ad9
ORF1 protein has recently been identified in infected cells in tissue culture (Javier,
1994).
Fifth, and the most likely reason for the failure to detect the ORF1 protein in infected
cells, was the low titre of the antiserum, only about 200-fold above the pre-immune at
its peak as compared to an estimated titre of 3,400 above the pre-immune for the
GST/ORF2 antisera produced in chapter 7. If the ORF1 protein is present in the
infected cells at a low level then it is unlikely that a low titre antiserum would detect it.
Immunoprecipitation analysis using 25 ~l ofHiS/ORF1-E polyc1onal antisera (- 10 fold
as much as usual) and 150 ~l of immunoprecipitin still failed to detect the ORFI
protein in adenovirus infected cells (data not shown).
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Figure 6.19. Western blot analysis employing the His/ORF1 antisera. Bacteria
containing pGEX-2T, pID22, pID22N and pID22C were induced at Auoo 0.5 at 37°C
for 3 hours. A sample of the culture was then lysed by repeated freeze/thawing and the
equivalent of 50 JlI of the culture loaded onto an SDS-P AGE gel in triplicate. One set
was stained with coomassie blue to estimate of the amount of protein loaded, while the
other two sets were blotted and assayed with either a 111000 dilution of pre-immune
serum or the His/ORFI-E antiserum (2.3.9.l.). See Fig. 6.4. for marker details.
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6.8. Discussion
Attempts to identify the ORFI protein in adenovirus infected cells failed, probably due
to the poor titre of the polyclonal antibody obtained in both attempts to stimulate an
immune response to bacterially expressed ORFI protein.
Attempts to purify the ORFI protein as a GST/ORFI fusion protein using glutathione
sepharose failed as the protein was insoluble, probably forming inclusion bodies
(although this was never formally confirmed). Inclusion bodies are electron-dense
particles that consist primarily of the recombinant protein. They vary in size and can
contain additional material such as subunits of RNA polymerase, outer membrane
proteins, rRNA and plasmid DNA (reviewed by Schein, 1989) (probably the reason
why the inclusion body preparation of the GST/ORFI protein (Fig. 6.6.) was not
100% pure). It is unclear why inclusion bodies form upon over-expression of some
recombinant proteins in bacteria. It has been observed that the temperature at which
expression occurs is important, with expression at 300e often resulting in soluble
protein, whereas at 37°e is insoluble (Schein and Noteborn, 1988). However when
the expression of the pGEXlORFl fusion was attempted at lower temperatures, no
difference in solubility was observed. It has also been postulated that the rate of
production and the concentration of the recombinant protein is important in inclusion
body formation, however this was not observed by Schein and Noteborn (1988). This
is probably not the case for the ORFI protein either, with the HislORFl fusion
expressed at relatively low levels in the Xpress system still being insoluble (Fig. 6.10.).
Schein (I989) also noted that the primary sequence of the expressed protein was
possibly important in determining the solubility of a protein; stretches of acidic amino
acids, low proline content and the ability to bind metal ions all correlate with the
solubility of a protein. She also notes that stretches of hydrophobic amino acids could
lead to increased aggregation and so to inclusion bodies (ORFI is a hydrophobic
protein (chapter 3)). Other plausible reasons for the formation of inclusion bodies in
E. coli are first the lack of cellular compartmentation which causes the protein to be
18S
produced in a reducing environment, preventing the formation of disulphide bonds,
second the lack of mammalian post-translational modifying enzymes, and third the lack
of proper foldases (molecular chaperones) during production since it is believed that
the inclusion body forms when the heterologous protein cannot fold properly and so
forms an insoluble complex with other proteins of the cell (reviewed by Schein, 1989).
Using a protocol to purify inclusion bodies, the GST/ORFI protein was purified to a
degree and this was used to generate the first polyclonal antiserum. However the
rabbit had to be put down before adequate titres of specific reactivity were achieved.
It was decided not to inoculate another rabbit with the same immunogen as the
immunogen contained a number of contaminating proteins.
The ORFI protein was then successfully purified using the QIAexpress system. The
resulting denatured HislORF1 protein was used to generate a second polyclonal
antiserum. However the titre of this antiserum was again relatively low and this also
failed to identify the AdS ORFI protein in infected cells.
It is not clear why the titre of the antibody generated against the HisiORFI fusion was
so low. For a protein to elicit a good immune response it must contain epitopes
recognised by B and helper T cells. The binding of an antigen to a cell surface
antibody of a virgin B cell is critical to the immune response as this will determine the
binding site of the secreted antibodies produced by the differentiated B cell. One
possible reason for the failure to generate a good immune response to the ORF1
protein is the previous development of B cell (or T cell, see below) tolerance to the
antigen during the development of self tolerance. This may well be the case with the
ORF1 protein as the ORFI protein has good homology to a yeast protein (dUTPase)
although the homology to a mammalian homologue (human) was weaker (see chapter
3). The appropriate B cells (and/or T cells) involved in the generation of an immune
response to such a protein may have been eliminated during the development of self-
tolerance, so rendering the animal unable to elicit an immune response to the
homologous ORF1 protein.
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The second property of the molecule that allows it to be a good immunogen is the
ability to promote cell-to-cell communication between helper T cells and B cells (and
helper T cells and antigen-presenting cells). The antigen, attached to the surface
antibody of the B cell, is internalised and degraded within the B cell for presentation on
the cell surface as peptides in conjunction with the MHC class II proteins. These B
cell surface complexes are recognised by helper T cells via the interaction of T cell
receptors and T cell epitopes on the peptides. If the antigen cannot be degraded within
the B cell or the antigen does not contain a helper T cell epitope (possibly because of
the elimination of the appropriate helper T cells during development) then no immune
response can be generated.
Therefore, for a protein to be a good immunogen it must contain a B cell and T cell
epitopes and must be degradable within a B cell. It has been suggested that for a
protein to be a good immunogen it must be of more than 5kDa in size otherwise the
chance of it containing both epitopes is low (Harlow and Lane, 1988). The His/ORFI
protein is only about 15kDa in size and it is conceivable that it may not contain a
suitable T cell epitope. It is noted that the successful generation of the ORF2
antiserum (Chapter 7) was carried out using the much larger GST/ORF2 fusion, so
overcoming any possible problems posed by the size of the 14K ORF2 protein.
Similarly the titre of the antiserum raised against GST/ORFI was increasing when the
rabbit died. It may have been wise, in retrospect, to couple the ORFI protein to a
carrier protein which contained a good helper T cell epitope, such as KLH. Another
possible reason why the animal failed to generate a good immune response to the
HisiORFl fusion could be the failure ofMHC class II molecules to bind to the antigen.
The presence of urea in the inoculated sample may have affected the immune response
of the animal, although no visible effects were observed on the health of the rabbit. It
was decided to inoculate the rabbit with protein in the presence of urea as other groups
had experienced no difficulty with this procedure and had produced effective antisera
to their proteins. Also only a small sample of protein was available, and so the risks of
protein loss during dialysis due to precipitation seemed too great.
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Chapter 7.
The E4 ORF2 protein
7.1. Introduction
The predicted 130 aa ORF2 protein is potentially encoded by just one E4 mRNA,
mRNA C (Berk and Sharp, 1978; Tigges and Raskas, 1984; Virtanen et al., 1984).
Studies of the expression of the E4 region indicate that mRNA C is produced early in
the infection but only at a relatively low level (chapter 4). This would imply that the
ORF2 protein is required initially early in the infection, before the onset of DNA
replication. However attempts to identify a phenotype associated with a lack of the
ORF2 protein have failed as virus lacking just the E4 ORF2 protein grows as well as
wild-type virus in tissue culture (Halbert et al., 1985).
This chapter describes the generation of a mono-specific polyc1onal antiserum to the
ORF2 protein and the subsequent identification of the protein in the infected cell. The
strategy employed in the generation of the polyc1onal antiserum was identical to that
used in the production of the initial ORFI polyc1onal antiserum, using the pGEX
expression system and out-bred half-lop rabbits (chapter 6).
7.2. Viruses and cells used.
Four different viruses were used in this series of experiments; wt300, dll-3, dl327 and
d1352. For a description ofwt300, dll-3 and d1327 see section 6.2. d1352 contains a 4
bp insertion at the HindIII site (34930) causing the disruption of the E4 ORF2 reading
frame; this lesion is present in the dl327 background. All infections were carried out at
an MOl of 10. HeLa cells were used throughout this study.
7.3. Expression of the ORF2 protein using the pGEX vector
The pGEX expression system was selected for the bacterial expression of the ORF2
protein for the reasons indicated in chapter 6. A cDNA fragment suitable for the
expression of the ORF2 protein in the pGEX-2T vector (Fig. 6.1.) was generated using
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peR. The template DNA used was the AdS wt300 genomic DNA and the two primers
used were IDE and IDF (see section 2.1.2.). The 3' terminus of IDE contained 20
nuc1eotides complementary to the DNA at the 5' terminus of ORF2 reading frame and
DNA immediately upstream. In the 5' terminus of IDE a Bamlll site was positioned so
that when the resulting ORF2 cDNA was cloned into the pGEX-2T vector using the
Bamm site it was in frame with the GST gene reading frame. Similarly, the 3'
terminus of IDF contained 16 nucleotides complementary to the DNA immediately
downstream of the ORF2 reading frame. In the 5' terminus of IDF was an EcoRi site
to facilitate the cloning of the ORF cDNA into the pGEX vector. The resulting 433bp
ORF2 eDNA product (Fig. 7.1.) was cloned into the pGEX-2T vector using the
Bamill and EcoRI sites to create pID19. The sequence of the ORF2 cDNA and the
ORF2 cDNNGST junction was verified by directly sequencing pID 19 using primers
IDG (upstream of the MCS) and IDH (downstream of the MCS)(see section 2.1.2.).
To establish ifpID19 was able to express the 358aa fusion protein, an expression study
was undertaken where the length of induction at 37°C was varied and the expression at
300e was examined. A 25 m1 culture of pIDI9 was induced with IPTG and placed
either at 30°C or 37°C. 2 m1 samples were removed at various times post induction
and prepared as in section 2.3.7.1.. The resulting pellet and supernatant fractions were
then assayed for the presence of the GST/ORF2 fusion protein by SDS-PAGE (Fig.
7.2.). Also assayed on the gel was the purified GST/ORF2 product, from 2 m1 of
culture (purified from the 6 hour, 37°e, induction sample). In parallel, the expression
and purification of GST (from pGEX-2T) was examined as a positive control for the
expression of the fusion (Fig. 6.4b.) This experiment demonstrated that the
GST/ORF2 fusion was relatively insoluble as compared with the GST protein at 37°C,
although, unlike the GST/ORFI fusion, a substantial amount of protein was purified
from the soluble fraction on glutathione sepharose. However, expression for 20 hours
at 300e routinely resulted in the increased solubility of the GST/ORF2 protein (Schein
and Noteborn, 1988). As a result, when scaling up the expression of
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Figure 7.1. peR amplification of the ORF2 cDNA using primers IDE and IDF
(2,3,1.11,), All of the 433bp peR product was run on a 1.2% agarose gel. See Fig,
5,3, for marker details
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Figure 7.2. The expression of the GST/ORF2 fusion protein from pID22 at 30°C
and 37°C (2.3.7.1.) assayed by SDS-PAGE. The times post induction (hrs) and the
sample fraction are indicated above the gel. All samples are the equivalent of O.lrnl of
the culture, except the purified fraction which is equivalent to 2 mls of culture.
Proteins visualised using coomassie blue. SIN = supernatant; P = pellet; Pure =
glutathione sepharose purified. See Fig. 6.4. for marker details.
Figure 7.3. SDS-PAGE analysis of samples of the 0.5 ml fractions from the
glutathione-sepharose column used for the purification of the GST/ORF2 fusion
expressed from pID19 (2.3.7.1.). 1/50th of each fraction and 1/5Oth of the
glutathione-sepharose column was assayed on the gel. Proteins visualised with
coomassie blue. See Fig. 6.4. for marker details.
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GST/ORF2 to SOOml the expression conditions used were 30°C for 20 hours. This
resulted in the expression of large amounts of GSTIORF2 protein that could be easily
purified using glutathione sepharose. However only about 50% of the protein initially
bound to the glutathione sepharose could be eluted off using 20 mM reduced
glutathione (the 0.5 ml fractions 2 and 3 (Fig. 7.3.). The overall yield from the
purificationwas 1 mg of the GST/ORF2 protein, as estimated by Bradford assay (i.e.
2mg/l).
The 40K GST/ORF2 fusion protein, attached to the glutathione sepharose, could be
cleaved into the 26K GST and 14K ORF2 proteins, using the protease thrombin (see
section 2.3.7.1.). A range of thrombin concentrations were used (from 0.2% to 4.0%
total protein) to cleave 10 ug of the fusion at 30°C for one hour (Fig. 7.4.)~ it was
found that the cleavage of the fusion protein was equally efficient at both 30°C and
37°C (data not shown). For the complete cleavage of the fusion protein, at both
temperatures, large quantities of thrombin were required, but if the incubationwas left
for 8 hr at 30°C the fusion protein was cleaved to completion in the presence of just
0.5% thrombin (Fig. 7.5.). In this experiment the released ORF2 protein was further
purified from GST and uncleaved fusion protein by separating the glutathione
sepharose, with its bound protein, from the protein free in the supernatant by
centrifugation at 16,000 x g for 5 min. (compare SIN and P fractions, Fig. 7.5.). It
was found that only about 70% of the ORF2 protein was purified in the supernatant,
the rest still being associated with the pellet. Subsequent washes of this pellet with
PBS (WI-W3) failed to release any substantial amount of further ORF2 protein. The
SIN fraction, which contained the bulk of the purified ORF2 protein was also
contaminated with thrombin and uncut GST/ORF2, so it was decided to produce an
ORF2 polyclonal antiserum using the uncleaved GST/ORF2 protein. This larger
protein also had more chance of containing both B and helper T cell epitopes,
important for immune recognition, than the ORF2 protein alone (see section 6.8.).
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Figure 7.4. SDS-PAGE analysis of 10 Ilg of glutathione sepharose-bound
GST/ORF2 fusion protein cleaved with thrombin (2.3.7.l.). The percentage
(wt/wt) thrombin used is indicated above the gel. All digests were carried out at 30°C
for 1 hour. Proteins visualised with coomassie blue. For marker details see Fig. 6.4.
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Figure 7.5. Purification of the ORF2 protein cleaved from the GST/ORF2 fusion
by thrombin digestion. 10 ug of glutathione sepharose-bound GST/ORF2 fusion
protein cleaved with thrombin and assayed by SDS-PAGE analysis (2.3.7.l.). The
length of incubation with thrombin is indicated above the gel. All digests were carried
out at 300e with 0.5% (wt/wt) thrombin. Also indicated are the supernatant fraction
(SIN), the three PBS washes (W1-W3) and the resulting pellet fraction (P), all from
the 8 hr digest (see text). Proteins visualised with coomassie blue.
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7.4. The generation of an anti-ORF2 antiserum using the GST/ORF2 fusion
protein.
A half-lop rabbit was subcutaneously inoculated four times with 200 ug of the
GST/ORF2 fusion preparation in PBS and Freund's adjuvant over 58 days. The rabbit
was bled seven times, 34, 58, 77, 94, 108, 128, and 124 days after the first inoculation,
giving serum samples A, B, C, D, E, F, and G respectively which were stored as 0.5 ml
aliquots at -20°C. These sera were analysed initially by ELISA and western blot
analysis.
The ELISA used 0.5 ug of purified GST/ORF2 fusion protein per well (Fig. 7.6.).
Ideally, pure ORF2 protein should have been used, but not enough was available.
These data demonstrated that the GST/ORF2 antibody titre increased over time until it
reached a maximum at about 110 days after the first inoculum. The peak titre,
estimated by noting the dilution of the antibody when the A492 was 50% the plateau
A492, was 3,400 times higher than the pre-immune titre. Since ELISAs conducted
using GST as antigen gave a similar titre of antibody (Fig. 6.7. and data not shown), it
is not clear from this study if any of the antibodies within the serum samples have any
affinity for the ORF2 portion of the fusion protein.
Western blot analysis using all. of the serum samples at a 111000 dilution against
approximately 40 ng of the purified, cleaved ORF2 product, revealed that the antisera
generated against the GST/ORF2 fusion protein did have specific reactivity against the
ORF2 protein (Fig. 7.7.). The intensity of the ORF2 band increased over samples A
and B but then reached a plateau, while the ELISA results indicated that the titre of the
antibody carried on increasing until sample D. The difference in these results is
probably due to the lack of sensitivity of the western blot with the ORF2 antibodies
being in excess in samples B to G.
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Figure 7.6 Analysis of the GST/ORF2 antisera. Panel A. Titration of the anti-
GST/ORF2 activity in serum samples by ELISA (2.3.9.3.). Serial dilutions of anti-
GST/ORF2 sera taken in successive bleeds from a rabbit inoculated with the
GST/ORF2 fusion preparation were tested against 0.5 ug of GST/ORF2 protein. See
text for the details of the GST/ORF2 samples. Panel B. Specific anti-GST/ORF2
antibody titres in serum, samples, as estimated by ELISA (Fig. 7.6a.). The titre for a
samplewas taken as the dilution required to reduce the ~92 to 50% of the plateau
~92·
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Figure 7.7. Western blot analysis employing sequential anti-GST/ORF2 antisera
to detect 40 ng of purified recombinant ORF2 (2.3.9.l.). A 1/1000 dilution of each
antiserum (A-G, pre-immune) was used.
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7.5. Expression of E4 ORF2 during a lytic infection.
7.5.1. The ORF2 protein exists in infected cells.
To show whether the ORF2 protein was expressed during a virus infection HeLa cells,
infected with either wt300, dl352 or dll-3 virus, were labelled with 35S-methionine
and harvested at 24 hours p.i. The lysates were then subjected to immunoprecipitation
analysis with 2 J-llof either GST/ORF2-E antiserum or pre-immune serum (Fig. 7.8.).
In this experiment the GST/ORF2 antiserum precipitated a protein of just less than
14K in size that was only present in the wt300 extract, being absent in the dl352 and
dll-3 extracts. This -14K protein was not precipitated by the pre-immune serum and
thus it was concluded to be the E4 ORF2 protein.
7.5.2. The time course of expression of the ORF2 protein.
To determine the pattern of expression of the ORF2 protein during a lytic infection,
western blot and immunoprecipitation analyses was performed on samples collected
over the course of an infection. Western blot analysis was carried out on RIP A
extracts of -2.5 x 106 wt300- or dll-3-infected cells harvested at various times p.i.
using the GST/ORF2-C antiserum and the pre-immune serum as a control. Bacterially
expressed, purified ORF2 protein was also analysed as a positive control for the
experiment (Fig. 7.9.). In this analysis, ORF2 protein was present at 9 hours pi in the
wt300 infected cells, although at very low levels, and amounts subsequently increased
to an approximately constant level from 16 hours p.i. onwards. Immunoprecipitation
analysis, using 2 ul of the GST/ORF2-C antiserum, on RIPA lysates of labelled wt300-
or d1352-infected HeLa cells harvested over the course of infection revealed that the
ORF2 protein was synthesised at 8 hours pi, albeit in small amounts (this is not visible
in Fig. 7.10 as the band was very faint) with production peaking between 16 and 24
hours p.i. (Fig. 7.10.). No ORF2 protein was made at 32 hours pi, in contrast to the
levels of steady-state ORF2 protein as detected by Western blot analysis.
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Figure 7.8. Detection of ORF2 in infected cells. wt300-, d1352- and dll-3-infected
HeLa cells (MOl = 10) were labelled for 3 hours (100 Ilei 35S-metJ90mm dish) and
then harvested in RIPA buffer at 24 hours p.i. (2.3.10.1.). The lysates were
subsequently analysed for the presence of the ORF2 protein by immunoprecipitation
using 2 III of the GST/ORF2-E or pre-immune antiserum (2.3.9.2. (N.B. the lysates
were not cleared with pre-immune serum before imrnunoprecipitation)). See Fig.
6.17. for marker details.
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Figure 7.9. Steady state levels of the ORF2 protein during the course of an
infection. The amount of the ORF2 protein in wt300- and dI1-3-infected cells was
analysed by western blotting using a 111000 dilution of the GST/ORF2-C antiserum or
pre-immune serum (2.3.9.1.). RIPA extract from 2.5 x 106 infected HeLa cells (MOl
= 10) at each time point (indicated in hours p.i. above the blot) was loaded onto the
SDS-P AGE gel. As a positive control, 40 ng of the purified ORF2 protein was also
analysed (see Fig. 7.5.).
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Figure 7.10. Synthesis of the ORF2 protein during the course of an infection.
wt300- and d1352-infected Hel.a cells (moi = 10) were labelled for lhr (lOO IlCi_35S-
metll07 cells) (2.3.10.1.) and labelled ORF2 protein detected in RIPA buffer extracts
prepared at various times p.i, (indicated in hours above the gel) by
immunoprecipitation analysis, using 2 III of GST/ORF2-C antiserum (2.3.9.2.). See
Fig. 6.17. for marker details.
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7.5.3. Subcellular localisation of the ORF2 protein
To determine which compartments of the infected cell contained the ORF2 protein,
indirect immunofluoresence was attempted. However, in a series of experiments
employing various fixation and cell permeablisation techniques and different antibody
sandwiches for detection, no specific fluorescence was detected (data not shown).
Since controls conducted in parallel, using monoclonal antibodies against the Elb-SSK
protein and E2a-72K DBP, were successful in detecting their cognate antigens, it was
concluded that either the anti-ORF2 antiserum was not effective in this type of assay or
that the ORF2 protein was below the level of detection.
As an alternative approach, wt300- and dll-3-infected cells were radio-labelled for 4
hours and harvested at 18 hr p.i. The cells were then broken by Dounce
homogenisation following swelling in hypotonic buffer in the absence of detergent and
the homogenates fractionated by sequential centrifugations (see section 2.3.10.3.) ..
This resulted in a series of fractions; the PO.S fraction (>236,600 S) containing the
nuclei; the PSOfraction (> 1,113 S) containing membrane fragments and vesicles; the
P200 fraction (>S9 S) consisting of polysomes, ribosomes and some smaller
micro somes and the S200 soluble fraction (also containing any complexes of <S9 S).
The fractions were then assayed by immunoprecipitation for the presence of the ORF2
protein (Fig. 7.11.). This experiment demonstrated that most of the ORF2 protein was
in the S200 fraction indicating that the ORF2 protein is either soluble in the cytoplasm
or in a complex of less then S9 S. It is not clear whether the small amounts of the
ORF2 protein in the PO.5 and PSO fractions represent distinct populations of the
protein or whether they result from contamination of these fractions with small
amounts of the S200 fraction.
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Figure 7.11. The subcellular localisation of the ORF2 protein within the infected
cell. wt300- and dI1-3-infected HeLa cells (MOl = 10) were labelled for 4 hours (100
!-lei 35S-met1l07 cells) and harvested at 18 hours pi The cells were lysed by Dounce
homogenisation and fractionated by sequential centrifugation (2.3.10.3.). The ORF2
protein was then immunoprecipitated with the GST/ORF2-E antiserum (2.3.9.2.). P =
pellet; S = supernatant. 0.5 = 500 x g; SO = 50,000 x g; 200 = 200,000 x g. See Fig.
6.17. for marker details.
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7.5.4. Interactions of the ORF2 protein with other infected cell components.
To determine whether the ORF2 protein was part of a complex of proteins when
released from cells, radio-labelled wt300- and dll-3-infected cell extracts were
subjected to sucrose gradient analysis (2.3.10.4.). SO.Sfractions prepared at 16 hours
p.i. (similar analysislater in the infection is confused by a background 14Kband) were
loaded onto a 5 to 20% (wt/wt) sucrose gradient. The gradients were centrifuged at
240,000 x g for 6 hours, to allow the resolution of proteins from 2.6S to 16.7S, and
collected as a series of 0.5 ml fractions which were then immunoprecipitated with
GST/ORF2-E antiserum (Fig. 7.12.). The ORF2 protein was found in fractions Sand
9, at the top of the gradient (fraction 10 consisted of the buffer the samplewas loaded
in). Using the tables and equations reviewed by Griffith (1975), the sedimentation
coefficient of the ORF2 protein, immunoprecipitated in a hypotonic buffer, was no
greater than 4S suggesting that it is present in the infected cell cytoplasm either
unassociated with any other proteins (which could be detected by this kind of analysis)
or within a complex of less than 4S in size.
It was of interest to determine whether the ORF2 protein made any detectable
interactions with other infected cell components. However inspection of repeated
immunoprecipitation analyses revealed no specificallyco-precipitated, labelled protein
species, that may have indicated molecular interactions of ORF2 with other proteins.
These analyses were extended to include the use of less stringent lysis and
immunoprecipitation buffers than the standard RIPA conditions; cells were lysed in
hypotonic buffer, isotonic buffer or NP40 buffer (PBS, 2% NP40, 10mg/ml PMSF
(immunoprecipitations washed in O.SM uci, O.1M Tris pHS.S» (Fig. 7.13.).
Similarly,no co-sedimentation of labelled species with the ORF2 protein was observed
during sucrose gradient analysis(Fig. 7.12.).
Other analyses have been conducted with the ORF2 protein in an attempt to identify
any protein-protein interactions it may be involved in the infected cell. One method
was used previously to detect protein-protein interactions of the Rb105 protein
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Figure 7.12. Determination of the size of the ORF2 protein by sucrose gradient
analysis (2.3.10.4.). wt300 (Panel A)- and dll-3 (Panel B)-infected HeLa cells (MOl
= 10) were labelled for 3 hours (100 ~Ci 3SS-met/90mm dish) and harvested at 16
hours p.i. The cells were lysed by Dounce homogenisation and the supernatant of a
SOOx g centrifugation loaded onto a S to 20% (wtlwt), S m1 sucrose gradient formed
in hypotonic lysis buffer. O.S m1 fractions were then taken, and analysed for the
presence of the ORF2 protein by immunoprecipitation with 2 ~l of the GST/ORF2-E
antiserum (2.3.9.2.). See Fig. 6.17. for marker details.
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Figure 7.13. o-immunoprecipitation analysis to detect ORF2 protein-protein
interaction. wt. 00- and dll-3-infected HeLa cells were labelled for 3 hours (100 uCi
35 -rne 90 mm dish) and lysed with either isotonic buffer or PBS/2% NP40 at 16 and
24 hour p.i. (indicated above the gel) (2.3.10.1.). ORF2 protein and any associated
pr tein were immunoprecipitated using 2 III of the GST/ORF2-E antiserum, and only
2 wa hes v ith the appropriate buffer (see text)(2.3.9.2.). See Fig. 6.17. for marker
detail.
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(Kaelin et al., 1991). This involved GST/ORF2 bound to glutathione sepharose as an
affinity matrix for binding components of a labelled cell extract. The column was
subsequently washed and the bound proteins resolved by SDS-PAGE. However, while
Kaelin et al. (1991) managed to get relatively clean results, experiments with the
GST/ORF2 fusion, conducted as reported, resulted in a high background of proteins
that were present in both GST - and GST/ORF2-bound fractions, making it difficult to
identify any protein-protein interactions with certainty (data not shown). Attempts to
change the labelling conditions, wash conditions, and the amount of protein on the
column made no difference to the high background observed. No proteins could be
identified in these analyses which specifically bound the GST/ORF2 fusion.
The ORF2 protein contains 2 cysteine residues which have the potential to form
disulphide bridges with either each other or other proteins within the infected cell.
However when labelled cells were lysed in isotonic buffer (I8hrs p.i.), and the ORF2
protein immunoprecipitated with GST/ORF2-E, and assayed on a non-reducing gel
(OTT omitted from sample buffer) no difference in the migration of the ORF2 protein
was observed, suggesting that it. has no disulphide bridge interactions (Fig. 7.14.).
This result is not surprising as data from cellular fractionation experiments above
suggested that the ORF2 protein is present in the reducing environment of the
cytoplasm where the formation of disulphide bonds is unfavourable.
These results suggest that the ORF2 protein does not interact with any other infected
cell components, at least in a way which is detectable by these analyses.
7.6. Discussion
An ORF2 antiserum was successfully generated using the GST/ORF2 fusion protein
which was purified using one-step affinity chromatography with glutathione
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Figure 7.14. Immunoprecipitation analysis of the ORF2 protein und r reducing
and non-reducing conditions. wt300- and dl352-infected cells (M I = 10) were
labelled for 3 hours (lOO ~Ci 35S-metl90mrn dish) and harvested at 18 h urs p.i.
(2.3.10.1.). The ORF2 protein was then immunoprecipitated with 2 ~l or the
GST/ORF2-E antiserum (2.3.9.2.). The samples were either boiled in reducing buffer
prior to loading on the SDS-PAGE gel as normal or loaded onto the gel in n n-
reducing buffer (i.e. no DTT) without being boiled (2.3.6.1.). ee Fig. 6.17. f r
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sepharose. The titre of this antiserum increased to a plateau over 110 days following
the first immunisation. This antiserum recognised the ORF2 protein both in the
bacterially expressed, recombinant form and in virus infected cell extracts.
The experiments reported here using this antiserum demonstrate the presence of a
novel gene product, E4 ORF2, in AdS-infected cells that had been recognised
previously only as a potentially translatable open reading frame present in E4 mRNA
C. The ORFlIORF2 or ORFlIORF2/0RFS fusion proteins predicted by Herisse et aI.
(1981) were not detected, confirming the results of the E4 mRNA studies (Freyer et
al., 1984; Tigges and Raskas, 1984; Virtanen et al., 1984) that these proteins do not
exist in adenovirus-infected cells. The time course of expression of the ORF2 protein
correlates with that observed previously for E4 mRNA C (chapter 4), with the protein
appearing with early kinetics (Fig. 7.9. and 7.10.). However, while the protein is being
expressed at 16 and 24 hours p.i., as assessed by immunoprecipitation analysis (Fig.
7.10.), the steady-state levels of the ORF2 protein do not increase much beyond 16hr
p.i., as assessed by western blot analysis (Fig. 7.9.). This suggests that the ORF2
protein is being turned over, or sequestered from detection by western blot analysis, at
a significant rate between 16 hr p.i. and 24 hr pi However at 32 hr p.i. the ORF2
protein is still present in the infected cell although no new protein is being produced.
Cellular fractionation experiments revealed that the ORF2 protein was located
predominantly, if not exclusively, in the soluble cytoplasmic fraction of infected cells.
These experiments also revealed low levels of the ORF2 protein in the nuclear and
membrane fractions, although it is unclear whether these represent distinct populations
of the ORF2 protein. If distinct populations of the ORF2 protein do exist they may
reflect a multifunctional aspect of the protein, although this is unlikely as the protein is
only 14K in size. Alternatively they may reflect functional and non-functional forms of
the ORF2 protein.
As mentioned, no function has yet been ascribed to the ORF2 protein. In an attempt to
elucidate a function, it was of interest to identify any proteins within the infected cell,
whether viral or cellular, which interacted with the ORF2 protein. However, no such
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proteins were detected suggesting that either the ORF2 protein does not closely
interact, or interacts only transiently, with any other infected cell components or the
methods employed were not sensitive enough. It may be that only a small subset of the
cytoplasmic ORF2 may be active and making interactions, putting these interactions
below detection limits. Alternatively the anti-ORF2 polyc1onal antisera may have
affinity for only a limited number of epitopes on the ORF2 protein so possibly
rendering the ORF2 protein within a complex undetectable as these epitopes could be
masked. If this were the case only ORF2 protein not in a complex would be detected.
However, this is unlikely as the antiserum generated was polyclonal and should not be
directed to just one epitope of the ORF2 protein, although the polyclonal antiserum
generated to the ORFI protein, which is of a similar size to ORF2, was directed
predominantly against the N-terminus of the protein suggesting that, for the ORFI
antisera at least, the antisera may not be truly polyclonal.
One possible explanation of these results is that the ORF2 protein acts as a cytoplasmic
enzyme, interacting with its substrate (if it is a protein) for only a short period of time
or only loosely interacting with it.
212
Chapter 8.
The function of the ORFI and ORF2 proteins
8.t. Introduction.
No function has yet been assigned to either the ORFI or ORF2 proteins of AdS.
Mutant strains of Ad5 unable to make ORFI and/or ORF2 grow to virtually wild-type
levels in lIeLa cells: the dl351 and dl352 mutants, constructed by Halbert et al. (1985)
using an E3-deleted virus background, which lack intact ORFI and ORF2 respectively,
are not compromised in their growth in HeLa cells. Similar results were obtained by
Bridge and Ketner (1989) and Huang and Hearing (1989a) using viruses lacking the
entire ORFI and ORF2 reading frames (dl1005 and dll-3 respectively). Both of these
mutants displayed normal late protein synthesis and viral DNA accumulation and the
dll 005 mutant also displayed a normal plaqing efficiency (the plaqing efficiency of dll-
3 was not investigated).
However, as discussed in chapter 3, these proteins, being conserved amongst the
adenovirus serotypes (with the exception of ORFI in Ad40), almost certainly have a
function in the adenovirus infection. Adenovirus 5 normally infects quiescent. non-
transformed epithelial cells of the upper respiratory tract and other tissues and not
transformed. aneuploid HeLa cells, derived from human cervical carcinoma tissue,
which have been used in all the tissue culture studies of the AdS ORFI and ORF2
mutants. The ORFI and ORF2 proteins may therefore have important functions in the
growth of the virus in the host which are not observed in HeLa cells in tissue culture.
As examining wild-type and E4 mutant adenovirus 5 replication in the natural host
(human) was impossible, it was decided to explore the role of these proteins in
infections of non-transformed human epithelial cells in tissue culture. This and other
studies of the E4 mutant viruses will be discussed in this chapter.
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8.2. Thr growth of adenovirus in non-transformed cells
Four different human non-transformed cell types were selected to observe the growth
of adenovirus; MRC5 (human embryonic lung cells obtained from Prof C.R. Pringle),
WI-38 (human diploid lung cells), HUV-EC-C (human umbilical cord, endothelial
cells) and HISM (human intestinal smooth muscle cells), all obtained from the
American Type Tissue Culture Collection. Each cell type, along with HeLa cells as a
control, was cultured on either 60 mm or 90 mm dishes and infected at an MOl of 5
with either wt300 or dll-3, at either 30% confluence or after reaching 100%
confluence for 24 hours. Although not a rigorous control of cell growth, it was
presumed that the cells in the 30% confluent monolayer were actively dividing while
the cells of the confluent monolayer had ceased dividing due to cell contact inhibition.
The cells and tissue culture fluid were harvested at 4 days p.i. and the virus titre from
each dish determined by performing a plaque assay on HEK-293 cells. The results
from this analysis can be seen in Table 8.1.
Of all the cell types examined, the only cell type to support a reproducible variation in
yield between mutant and wild-type virus was WI-38, and only when under-confluent.
However, the result was not what was expected with the mutant dll-3 virus growing
to a 12-fold higher titre in under-confluent WI-38 than the wt300 virus. Thus,ORF1,
ORF2 and/or ORF3 appear to inhibit rather than to facilitate virus growth under these
conditions. It is unclear why the mutant grows better than the wild-type in under-
confluent WI·38 cells. It may be due to one of the deleted ORFs (1,2 or 3) repressing
virus replication in the wild-type virus or it may be a cis-effect due to the deletion of
this part of the viral genome, perhaps on the levels of expression of the other E4 gene
products.
To determine if the higher titres reached in the dll-3 mutant virus (as compared to
wt300) in under-confluent WI-38 cells were due to the ORFI or ORF2 proteins, the
titres of d1327, d1351 and dl352 were compared after 4 days growth in under-confluent
WI·38 and HeLa cells (Table 8.2.). This experiment revealed that d1351 and dl352
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Table 8.t. The titres of wt300 and dlt-3 virus, 4 days after infection of HeLa,
MRC5, \\,1-38, HUV-EC-C and HISM cellsat an MOl of5. The virus titres are not
comparable between cell types as the experiments were conducted at different times.
However. HeLa cells were infected in parallel with all the experiments conducted with
the non-transformed cell types. All experiments were conducted in duplicate (Mean
values displayed).
Cell type Virus Yield Yield Ratio
pfu/cell (dll-3/wt300)
HeLa (confluent) wt300 600
dll-3 434 0.72
HeLa (1/3 confluent) wt300 1250
dll-3 1450 1.2
MRCS (confluent) wt300 584
dll-3 638 1.1
MRCS (1/3 confluent) wt300 428
dll-3 786 1.8
WI-38 (confluent) wt300 1812
dll-3 4125 2.3
WI-38 (1/3 confluent) wt300 200
dll-3 2500 12.5
HUV-EC-C (confluent) wt300 1087
dll-3 1837 1.7
HUV-EC-C (1/3 confluent) wt300 1500
dll-3 3250 2.2
HISM (confluent) wt300 1175
dll-3 1063 0.9
HISMl_1/3 confluent) wt300 525
dll-3 1000 1.9
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Table 8.2. The titres of d1327, d1351, and d1352, 4 days after infection of HeLa
and \VI-38 cells at a MOl of5.
Cell type VIruS Yield Yield Ratio
pfu/cell (dI351or2/d1327)
HeLa (confluent) dl327 104
dl351 132 1.3
dl352 126 1.2
HeLa (1/3 confluent) dl327 97
d1351 83 0.9
d1352 112 1.2
WI-38 (confluent) dl327 29
d1351 35 1.2
dl352 46 1.6
WI-38 (1/3 confluent) d1327 69
dl351 64 0.9
d1352 66 1.0
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reach titres comparable to their wild-type parent, d1327, in confluent and under-
confluent \\'1-38 cells. This indicates that the absence of the ORFI and ORF2 proteins
in the dl l-J virus was not the reason for the increased titres observed when grown in
under-confluent WI-38 cells and points rather to a role for ORF3 in this process.
The conclusion of these studies is that the deletion of E4 ORFI and ORF2 has no
observable effect on the ability of the virus to grow in non-transformed cells, either
quiescent or dividing. However this study was not exhaustive, no attempt was made
to observe the virus yields in infections with a multiplicity below 1~ in the host it is
conceivable that the multiplicity of infection is low and maybe under such conditions
the ORFI and/or 2 proteins are important. Also experiments could be undertaken
ensuring the quiescence of the cells under study, possibly by limiting growth factors in
the growth medium. This was not undertaken here as the cells were limited in supply
and could not be repeatedly passaged.
8.3. Protein expression in ORFI and ORF2 mutant viruses.
As mentioned, both Bridge and Ketner (1989) and Huang and Hearing (l989a)
examined the expression of the late proteins in E4 ORFI and ORF2 mutant viruses and
did not observe any difference compared to wild-type. However, in their studies only
protein synthesis at either 26 or 24 hr p.i. was examined while in the study presented
here protein expression was examined over the course of the infection. dI327-, d1352-,
and dl3S l-infected cells were labelled for 1 hour with 30 Ilei 35S-metl3.3 x 106 cells
and then harvested into RIPA buffer at 8, 16, 24 or 32 hr p.i. The amount of
incorporated label in each fraction was measured and 50,000 cpm aliquots were
analysed by SDS-PAGE (Fig. 8.1.). From these results, it was observed that late
protein production in both dl3S1 and dl352 infections occurs at the same rate and to
the same level as for the wild-type dl327 virus, and host cell protein shut-off
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Figure 8.1. Analysis of the protein production of wt300, dll-3, d1327, dl351 and
d1352 during the course of an infection. Infected HeLa cells (MOl = 10) were
labelled for 1hour (30 J,lCi35S-met/3.3 x 106 cells) and harvested into RIPA buffer at
the times indicated (2.3.10.1.). The amount of incorporated label was measured and
50,000 cpm were loaded in each lane (2.3.10.2.). The arrows indicate the 32 kDa
protein unique to the d1351 infection at 24 and 32 h p.i.. See Fig. 6.17. for marker
details.
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occurs as normal, confirming the results of Bridge and Ketner (1989) and Huang and
Hearing (1989a) working with the mutants dl1005 and dll-3 respectively. In this
experiment a protein of about 32K was produced in the d135l virus infection at 24 and
32 hr p.i. which was not produced in the dl327 virus or d1352 virus infection.
Experiments conducted in parallel demonstrated that this protein was not produced (or
not produced to similar levels) in the dll-3 infection (data not shown) suggesting that
the appearance of this protein is not linked with the absence of the ORFI protein in
d13S1 infection. Its appearance may be due to a cis effect of the dll-3 mutation, for
example altering E4 expression, or the deletion of ORF2 and ORF3 in d11-3 might
affect the phenotype associated with ORFI deletion. Alternativelythe presence of this
extra protein may be due to the absence of the ORFI protein in conjunction with the
absence of the E3 region (d1351), but when an intact E3 region is present the
phenotype is lost (i.e. dll-J). As the protein was of about 32K in size it was thought
possible that it was E4 ORF6-34K being over-expressed but attempts to precipitate the
protein using an anti-ORF6 monoclonal antibody failed. No reproducible difference
was observed between the protein profiles of wild-type and d1352except for the over-
production of an 18K protein at 16 and 24 hr p.i. Again the identity of this protein is
unknown.
8.4. E4 ORFI and ORFl mutant virions.
The protein content of d1327, dl35l and d1352virions was compared to see if the
absence ofORFI or ORF2 had any effect on the composition of the virions. This was
especially relevant to ORF1, which is expected to be produced with late kinetics
(chapter 4). Virions were prepared from virus-infected HeLa cells and 5 x 1010
virions were loaded onto an SDS-PAGE gel and proteins detected by silver staining
(Fig 8.2.). No reproducible difference between the ORFI or ORF2 mutant virions and
the wild-type dl327 preparation was observed suggesting that neither the ORFI
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Figure 8.2. Analysis of the protein content of d1327,d1351and d1352virions. 5 x
1010 purified virions were loaded onto an SDS-PAGE gel as indicated (2.3.4.10.).
The proteins were visualised by monochromatic silver staining 2.3.6.3 .. It should be
noted that the l8.4K protein of the molecular weight markers failed to stain under the
conditions used. Indicated to the right of the gel are the virion proteins (see Fig. 1.1.).
See Fig. 6.4. for details of the high molecular weight markers (Mh). The low
molec1uar weignt markers (MI, Amersham) are as follows:
46 kDa : Ovalbumin
30 kDa: Carbonic Anhydrase
21.5 kDa : Trypsin Inhibitor
14.3 kDa : Lysozyme
6.5 kDa : Aprotonin
3.4 kDa: Insulin chain B
2.35 kDa: Insulin chain A
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nor ORF2 protein is present in the virion at detectable levels and that neither plays a
role in virion construction in HeLa cells.
8.5. Conclusion
The experiments above revealed little about the function of either the ORFI protein or
the ORF2 protein. These proteins do not appear to be required for the growth of the
virus in non-transformed cells in tissue culture and ORFI and ORF2 mutant viruses
produce viral late proteins and shut off host cell protein synthesis as normal. Similarly
the mutant virion protein profiles appear as wild-type.
222
Chapter 9.
General Discussion
9.t. Summary and interpretation of the results.
In this study I have examined the production of mRNA and protein from the E4 region
of Ad5. Experiments were conducted to elucidate the temporal pattern of expression
of the differentiallyspliced E4 mRNAs, both in the presence and in the absence of the
Elb-55KJE4 ORF6-34K complex which is known to be involved in the optimal
cytoplasmic accumulation of late adenoviral mRNAs. The results of these studies
demonstrated that the expression of the E4 mRNAs is regulated in a temporal manner
due to a change in the pattern of splicing. Early in the infection, long mRNAs are
produced while after DNA replication the pattern of splicing changes and shorter
mRNAs are produced, lacking the D3-A3 intron (Fig. l.5.). However, there is an
exception to this general rule with the expression of mRNA Alfull length mRNA with
kinetics later than all the other late mRNAs. From the data presented, it cannot be
determined ifboth or just one of these mRNAs exists but it is clear that the expression
of these mRNAs is distinct from the other E4 mRNAs. In addition to displaying a
unique late expression pattern, only these two mRNAs displayed significant
dependence on the Elb-55KJE4 ORF6-34K complex for optimal cytoplasmic
accumulation.
It is unclear why E4 mRNA Alfull length mRNA is solely dependent on the Elb-
55KJE4ORF6-34K complex for optimal cytoplasmic accumulationwhile the other late
E4 mRNAs show no dependence. However, this unique dependence allowed the
investigation of the mechanism by which the Elb-55K1E4 ORF6-34K complex
functions. As late E4 mRNAs which show no dependence on the Elb-55K1E4 ORF6-
34K complex differ in structure in only a few regions (DI-Alb and possiblyD3-A3) as
compared to mRNA Alfull length mRNA it was concluded that these regions
potentially hold the key to conferring Elb-SSKlE4 ORF6-34K dependence on an
mRNA. Similar conclusions were made by Leppard (1993) when observing the
expression of MLTU transcripts. In an initial attempt to prove the importance of these
regions, a virus was constructed which lacked an intact E4 D1 splice donor site. On
224
examination of the expression of mRNA Alfulllength mRNA from this mutant virus it
was found that this mRNA was no longer so strongly dependent on the E4 ORF6-34K
protein, and so presumably on the E1b-5SK protein, for optimal cytoplasmic
accumulation. Therefore, the presence of intact splice sites/potential intron sequences
in E4 late mRNAs appears to confer dependence on the E1b-SSKlE4 ORF6-34K
protein complex for cytoplasmic accumulation, supporting the hypothesis proposed by
Leppard (1993) (see section l.3.5.).
This function of the E1b-5SKlE4 ORF6-34K protein in the export of incompletely
spliced viral mRNAs from the nucleus of infected cells is akin to that of the HIV -1 Rev
protein in regulating HfV mRNA accumulation. However there is a distinct difference
between the two systems; incompletely spliced Rev-dependent mRNAs all contain a
Rev response element (RRE) with which the Rev protein interacts. No such element
has been detected in E1b-55K1E4 ORF6-34K dependent mRNAs and no RNA binding
activity has yet been demonstrated for the E1b-55K1E4 ORF6-34K complex.
However, a potential RNA binding site has been identified in the E1b-5SK sequence
(Leppard, unpublished observations). Experiments conducted by Williams (1993)
demonstrated that the RevlRRE system for exporting un spliced or partially spliced
mRNAs out of the nucleus could function in an E 1b-deficient adenovirus, partially
rescuing the El b function, so confirming the similarities in function of these two
proteins. However, the differences discussed above and the fact that no distinct
regions of homology can be detected between the two proteins, suggests that, although
both are involved in the export of partially spliced viral mRNAs from the nucleus, they
achieve this end result by different mechanisms.
It is also of note that Rev has been observed to be involved in regulating splicing and
mRNA translation. While neither the Elb-55K, nor the E4 ORF6-34K protein is
thought to be involved in mRNA translation, it has been recently observed that the E4
ORF6-34K protein does play a role in the regulation of splicing (Nordqvist et al.,
1994), although it is unclear if this is due to E4 ORF6-34K within the ElblE4
complex.
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From the E4 mRNA expression data accumulated in previous studies (Berk and Sharp,
1978~Chow et al., 1979~Freyer et al., 1984~Tigges and Raskas, 1984~Virtanen et al.,
1984) it was found that the Ad2 E4 region encoded at least 7 potential proteins; ORFs
1, 2, 3, 3/4, 4, 6, 617. In this study of AdS it was concluded that the mRNAs
encoding the ORF3/4 protein and a minor ORF3 variant, ORF3/12aa, did not exist in
wild type infections in the absence of inhibitors. Of the six E4 proteins therefore
expected in an AdS-infected cell, only two had not been identified in infected cells in
previous studies; ORFs 1 and 2. On examination of the recently published AdS E4
sequence it was discovered that the predicted ORF1 and 2 reading frames, although
largely conserved, contained a number of frame shift mutations. However when this
E4 region was resequenced it was found that these apparent mutations were
sequencing errors and that the ORF1 and 2 reading frames were intact.
In this study I attempted to identify the two proteins potentially encoded by ORFI and
ORF2 reading frames in infected cells by generating mono-specific polyclonal antisera
to these proteins expressed in bacteria. However, as discussed in chapter 6, both the
antisera specific to the ORF1 protein failed to identify the ORFI protein within
infected cells, probably due to their low titres. It is of note that Javier (1994) recently
produced a polyclonal antiserum to the Ad9 ORF1 protein, by intradermally
inoculating a New Zealand White rabbit, with which the Ad9 ORFI protein was
identified in Ad9-infected cells. The difference in the ORF1 sequences (45% identity
between Ad9 ORF1 and AdS ORF1), the route of inoculation and/or the rabbits used
may of all contributed to the successful generation of this Ad9 ORFI antisera.
The ORF2 antiserum was more successful allowing the identification of the ORF2
protein in the infected cells. It was found that the ORF2 protein is initially expressed
early in the infection but steady-state levels of ORF2 remain high in the infected cell
until at least 32 hr p.i. These data correlate well with the expression of mRNA C
which is predicted to encode the ORF2 protein.
As yet no function has been ascribed to either the AdS ORFI or ORF2 protein
although it has been demonstrated that the Ad9 E4 ORFI protein is involved in cellular
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transformation (Javier, 1994). Homology searches demonstrated that both proteins are
conserved in a number of different adenovirus serotypes, indicating significant roles for
the proteins in infections of the host organism. The ORFI protein was also found to
have homology with dUTPase of S. cerevisiae and Vaccinia virus. However, the lack
of homology ofORFI with the conserved motifs found in dUTPases, and the fact that
the Vaccinia dUTPase protein is produced early in the infection (Slabaugh and
Roseman, 1989) while ORFI is presumably produced late in the infection (see chapter
4), would suggest that ORFI may only have a related function. Homology searches
with the ORF2 protein were less revealing. However the successful generation of an
antiserum to the ORF2 protein allowed an initial characterisation of the ORF2 protein
in vivo. The ORF2 protein was identified in the cytoplasm of the infected cell and, as
no ORF2 protein-protein interactions could be identified, it was concluded that the
protein was either soluble or present in the cytoplasm in a complex of less than 4S.
Unfortunately this data does not allow any speculation as to the function of the ORF2
protein, beyond the possibility that it may be a cytoplasmic enzyme. The fact that in
AdS related functions are grouped into transcription units, suggests that the ORF2
protein may be involved in the control of gene expression or DNA replication at some
level.
9.2. Future work
The investigation of the E4 mRNAs presented here was undertaken using RNase
protection analysis as this technique was sensitive enough to identify even the low
levels of some of the E4 mRNAs. However this technique did not allow the
identification of complete E4 mRNAs and so the E4 mRNAs were deduced by
mapping the protected fragments produced from a given probe, to known mRNAs.
Therefore this form of analysis is dependent on the published structures of the E4
mRNAs being correct. Traditional methods of mRNA detection were deemed
impractical or not sensitive enough to address the question of E4 mRNA expression in
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infected cells in the absence of inhibitors. However, the relatively recently refined
technique of reverse-transcription PCR may be useful. To test this idea, primers were
designed that, when used in RT-PCR, would result in the production ofE4 cDNAs of
unique lengths, according to the mRNA from which they were amplified, so allowing
the unambiguous identification of all E4 mRNAs. Initial experiments by S. White
(undergraduate project student) identified mRNA L (the most abundant E4 mRNA)
and possibly some of the other larger E4 mRNAs by this approach. However, this
work needs to be continued and the technique optimised to allow the simultaneous
identification and quantitation of all the E4 mRNAs.
Further work also needs to be conducted investigating the role of splice sites and
potential intron regions of the E4 region in conferring Elb-55K1E4 ORF6-34K
dependence on an mRNA. This work would be a continuation of the work described
in chapter 5 with the further characterisation of E4 RNA expression from the vDl
virus (i.e. examination of nuclear levels of E4 mRNA from vDl and the use of
potential cryptic splice sites). The role of the other potentially important splice sites
(i.e. Alb, D3, A3) in mediating Elb-55K1E4 ORF6-34K dependence also needs to be
investigated, and so a series of mutants lacking either one, or a combination, of these
splice sites needs to be constructed. Other virus constructs could also be made where
the mRNA sequences unique to E4 mRNA Alfull length mRNA are duplicated at
another site in the adenovirus genome, to determine whether they can confer El b-
55K1E4 ORF6-34K dependence on the expression of a heterologous gene.
As the E4 region is relatively small, it is feasible to examine the existence of any
protein-E4 RNA interactions, especially involving the Elb-55K protein, in the light of
the identification of the potential RNA binding site within Elb-55K. Such experiments
would involve the production of labelled, sense transcripts of fragments of the E4
region and the investigation of the binding, in Vitro, of any proteins from infected and
uninfected cell extracts by band-shift analysis. The involvement of the Elb-55K or E4
ORF6-34K proteins in any specific complexes detected could be examined by using
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specific monoclonal antibodies in such experiments to cause a 'super-shift' of the
labelled RNA-protein complex on the gel.
As the production of the an ORFI antiserum was unsuccessful, there remains a large
number of uncompleted experiments involved in the identification and characterisation
of the AdS ORFI protein. A successful ORFI antiserum needs to be produced. As
antigen produced from bacteria in this study only produced a poor immune response in
the rabbit, an alternative source of antigen should be used, such as protein expressed in
yeast or from Baculovirus. These eukaryotic systems may allow the production and
purification of native ORFI protein with the correct, if any, post-translational
modifications (although this is less likely in the yeast system) increasing the possibility
of producing antigen capable of stimulating a useful immune response. Alternatively,
synthetic ORFI oligopeptides coupled to a carrier protein such as KLH or BSA, could
be used to generate an immune response. Such oligopeptides would be taken from
regions of the ORFI protein with a high probability of being surface regions, such as
the region around residue 25 and be from 10 to 15 residues in length (Harlow and
Lane, 1988). Whatever the antigen used, in any future attempts to generate an immune
response to the ORFI protein, two rabbits should be used to eliminate any animal-
specific effects. When a successful AdS ORF 1 antiserum is generated, similar
experiments to those carried out with the ORF2 antiserum shall be conducted.
No investigation of the potential function of the ORFI protein as a viral dUTPase has
been undertaken in this study as the sequence of the S. cerevisiae dUTPase was only
published recently. Such an investigation would involve the development of an assay
for dUTPase. Such an assay would exploit the catalytic activity of dUTPase (dUTP =>
dUMP + PPi), possibly by radiolabelling the substrate and assaying the production of
the products by chromatography, such as TLC. Any dUTPase activity ofORFl could
be assayed in a variety of ways; in vitro transcribed/translated ORFI (presently
available) could be assayed for dUTPase activity by incubating it with labelled dUTP in
a suitable buffer, or alternatively extracts from uninfected, wild-type and ORFI
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mutant-infected cells could be assayed in parallel. Also, when an antiserum to ORFI is
available, immunoprecipitates could be assayed for dUTPase activity.
Other work to be carried out is the construction of further ORFI and ORF2 specific
virus mutants. At present, the mutants available are dll-3, d1351 and dl352. dll-3 is
limited in its use as, although in a wt300 background, it lacks three reading frames of
the E4 region. The specific ORFI and ORF2 mutants, dl351 and d13S2, also have
shortcomings, since they lack the most of the E3 region. This may result in an altered
phenotype if the ORFI and 2 proteins are involved in interactions with E3 proteins.
Attempts were made to build the dl351 and d13S2lesions into a wt300 background in
the course of this study, but they failed. Such mutants would be useful in the
continued search for a phenotype for the ORFI and ORF2 proteins. Experiments
would include the growth of virus in non-transformed cells, as mentioned in chapter 8,
but under different conditions (e.g. serum-starved cells to induce quiescence or varying
MOl). Also, comparisons of viral protein expression and rate of viral DNA synthesis
in such infected cells may be of interest.
In conclusion, the E4 region of AdS remains of considerable interest. The further, and
more complete, understanding of its expression and role in the lytic infection are
important challenges for the future.
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Appendix 1
The figure on the facing page depicts the AdS physical maps of the viruses used in this
study. All the viruses were based on either dl309 (dI338, dll-3) or dl327 (dI351,
d1352, d13S5), (d1367 contains mutations from both viruses). Deleted regions are
depicted as filled rectangles while inserted DNA is shown as open triangles. The
deleted Xbal sites of dl309 are depicted (dIXbaI) as lines (the Xbal site at 1339 bp is
intact in d1309 and the dl309 derived viruses shown).
Appendix 2
Details of the oligonucleotides used in this study. All oligonucleotides
are written in the 5' to 3' direction.
IDB: AIArTGTCGTTAGAACGCGG
Homology to the SP6 primer
region of the pGEM plasm ids
!DC: TGAIGGATCCACTGTTAIGGCTGCCG
Homology to AdS
Homology: 3SS33-3SS17bp
BamBI
Homology to AdS
IDD: AGGTGAATTCTCAAACArTAGAAGCCTGTC
EcoRI
Homology: 3S143-3S1S9bp
Homology to AdS -
IDE: TGAIGGATCCGCAGACATGTTTGAGAGA
BamHI
Homology: 35098-35083bp
IDF: AGGTGAArTCCCTCAAGCAGCGAATC
EcoRI
Homology to AdS
Homology: 34686-34701bp
IDG: AGCAAGTATATAGCATGGCC
Homology to the region
upstream of the MCS
ofpGEX-2T
IDH: GGAGCTGCAIGTGTCAGAGG
Homology to the region
downstream of the MCS
ofpGEX-2T
IDJ: ACAGCTCCTCGGTCATGTCC
Homology to Ad5
Homology: 35259-3S278bp
Homology
to AdS Homology to AdS
10K: TTTTTACTAAGCTTGCTGACTGTTATGGC
Hindill
Homology: 3SS50-35543bp
Homology: 3SS36-35S22bp
Homology
to AdS Homology to AdS
IDL: TAGCCCTGGGGAATACATAC
Homology: 3S351-3S3S6bp
Homology: 3S358-3S370bp
10M: TTCAICCACGGTGCCTGACT Homology to pBR322
Appendix 3
A list of the important sites in this study within the Ad5 E4 region.
Site Location (bp)
HaeIII 35616
Transcription start 36614-35609
D1 35542
ORF1 start 35526
SmaI 35354
ORF1 end 35144
Ala 35104
ORF2 start 35092
HindIII 35930
Alb 34732
ORF2 end 34703
ORF3 start 34703
D2a 34602
Ale 34432
BglII 34387
ORF3 end 34356
ORF4 start 34342
AId 34329
D2b 34289
A4 34241
BglII 34115
Ale 34082
ORF6 start 34077
ORF4 end 34001
D3 33905
PstI 33875
KpnI 33594
AS 33283
A3 33192
SmaI 33091
ORF6 end 32917
pA 33803
Appendix 4 - Quantitation of the E4 mRNAs
To determine the relative levels of the E4 mRNAs in infected HeLa cells, RNA from
such cells was assayed by RNase protection analysis (see section 2.3.5. and Chapter
4.). The signals from the protected fragments characteristic of each mRNA in
question, present on an autoradiograph, were quantified using laser scanning
densitometry and the Imagequant image analysis software. This allowed the
determination of the density of each signal and so the amount of each protected
fragment present in the gel. This data had to be adjusted to take into account the
number of uridine residues in the protected fragment as this was the only labelled
nucleotide in the probe RNA; a protected fragment which contained a lot of uridine
residues due to the nature of the probe will give a stronger signal than an equimolar
protected fragment with less uridine residues. This allowed the comparison of the
levels of different protected fragments from different or the same probe. However
this was only applicable for data produced using probes made in parallel, Le. which
contain the same ratio of labelled to unlabelled uridine residues. Probes made using
the same protocol but on different occasions potentially have a different ratio of
labelled to unlabelled uridine residues due to small errors in pipetting and variations
in the specific activity of the labelled uridine used. A full data set was obtained by
linking the results for groups of mRNAs having one or more members in common. It
was decided to present this processed data semi-quantitatively (Table 4.1.) and not as
fully quantitative figures as the adjustment of the primary data to take into account the
uridine residues and the linking of mRNA data sets potentially introduced .
inaccuracies making fully quantitative data possibly misleading.
Example:
Displayed below are the unadjusted densitometry readings followed by their
adjustment according to their uridine (U) content to give comparable figures:
RNA: A c D L M
Primary data:
OD 9h p.i.
OD 20hp.i.
40
2020
217
362
3680
5000
30
11310
o
452
U residues/
protected frag. 79 34 79 45 85
Adjusted figures:
9 h p.i.
20h p.i.
0.5
25.6
6.3
10.6
46.6
63.3
0.7
251.3
o
5.3
The 9 hour data less than 0 was recorded as a negative in Table 4.1. as no protected
fragment was visible on the autoradiographs quantitated and the values shown
represent background measurements (a (+) was displayed for mRNA L at 9 hours as a
band was just visible on over exposed autoradiographs). The value of 251.3 units for
mRNA L' at 24 hours was the highest value of all the inRNAs and recorded as ++++.
All other were recorded as relative to this, e.g. mRNA C (6.3 and 10.6 units) = +;
mRNA A (25.6 units) = ++; mRNA DIE (63.3 units) = +++.
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Open reading frames 1 and 2 of adenovirus region E4 are conserved
between human serotypes 2 and 5
Ian Dix and Keith N. Leppard"
Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, U.K.
The E4 region of human adenovirus type 2 is predicted
to encode seven proteins as judged from its nucleotide
sequence and the pattern of differential splicing of its
transcript. Two of the open reading frames (ORFs),
ORFI and ORF2, had been identified as being
disrupted in the recently published sequence of the
related serotype 5 virus. These ORFs were resequenced
and found to be intact in the wt300 strain of adenovirus
type 5.
The molecular genetics of human adenovirus type S
(AdS) have been studied extensively. This work has been
underpinned by sequence data derived from the AdS
genome supplemented by data from the closely related
Ad2, for which a complete sequence has been available
for a number of years (Roberts et al., 1984). The
completion of a composite AdS sequence (Chroboczek et
al., 1992; GenBank accession no. M73260) has permitted
those studies of AdS involving previously unsequenced
regions to proceed on a more systematic basis.
The E4 region of AdS was one of those for which, until
recently, only a partial sequence was available. The Ad2
sequence, together with RNA mapping studies in Ad2
(Virtanen et al., 1984; Tigges & Raskas, 1984), predicted
the expression of seven distinct proteins from the Ad2 E4
region and, by analogy, from the AdS E4 region also.
Three of these proteins, the products of open reading
frames (ORFs) 3, 6 and 6/7, have been detected in
infected cells (Downey et al., 1983; Samow et al., 1984;
Cutt et al., 1987). The remainder, the products ofORF1,
ORF2, ORF3/4 and ORF4, appear to perform no
essential function during infections of cultured HeLa
cells because mutants unable to express these proteins
grow with virtually wild-type kinetics (Halbert et al.,
1985; Huang & Hearing, 1989).
Comparison of the published Ad2 and AdS E4 region
sequences showed two nucleotide substitutions and four
deletions in AdS ORFI, and four substitutions and one
insertion in AdS ORF2; these cause frameshifts in both
ORFI and ORF2, and two missense changes in ORF2.
However, the high ratio offrameshift to point mutations
The nucleotide sequence data reported here will appear in the
DDDJ, EMDL and GenDank databases under accession number
012587.
0001-1180 CO 1992 SGM
in these putative coding regions, together with the high
degree of sequence conservation as compared with
adjacent non-coding regions, suggested that the frame-
shifts might be sequencing artefacts. To determine
whether AdS could encode E4 ORFI and ORF2
products, the region of AdS DNA between nucleotides
34790 and 3S61S was resequenced.
Relevant pieces of the AdS strain wt300 KpnI G
genomic DNA fragment were subcloned into plasmids
and then MI3 vectors mpl8 and mpl9. Sequencing was:
carried out by the dideoxynucleotide chain termination
method using the Sequenase II system (U .S. Biochemi-
cals). As shown in Fig. I, in each of the four regions
where the published AdS sequence contained frameshifts
in ORFI or ORF2, the sequence obtained showed the
ORFs to be open as in Ad2, with the exception of a silent
base change at one of the insertion positions. All except
one of the other expected differences between Ad2 and
AdS, including all those in the non-coding regions
sequenced, were confirmed by our data, discounting the
possibility that the DNA sequenced was of Ad2 origin.
The exception was the ORF2 missense mutation at AdS
nucleotide 34860; our data indicate that strain wt300
ORF2 encodes the same amino acid as that of Ad2 at this
position. These changes to the database sequence of AdS
are summarized in Table I.
ORFI and ORF2 of the AdS E4 region were originally
sequenced by Steenbergh & Sussenbach (I979) using the
chemical degradation technique; this sequence was used
by Chroboczek et al. (I992)when compiling the complete
AdS sequence. Our data suggest a revised length of 3S938
bp for the AdS strain wt300 genome with potentially
functional E4 ORFI and ORF2 regions encoding
products identical to, or differing in only one amino acid
from, their Ad2 counterparts.
2976 Short communication
(a)
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(b)
GG T A
(c)
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Fig. I. Sequence data for regions of difference between published AdS and Ad2 sequences. The regions around (a) nucleotides 35523/22
and 35511/10, (b) nucleotides 35321/20 and (c) nucleotide 34936 are shown. The sequence of the rightward strand deduced from these
data is shown to the left of each panel, with the differences from the published Ad5 sequence indicated by arrows.
Table I. Summary of changes to the published Ad5
sequence
Published Ad5 Published Ad5 Revised Ad5
nucleotide position sequence" sequence"
34860 T A
34936 T
35320/21 CA
35510/11 C
35522/23 A
• Sequence changes indicated are to the leftward strand.
The conservation of ORFI and ORF2 in two, albeit
closely related, serotypes supports the argument that they
encode proteins having some function in Ad infections.
Since they are not needed for successful infection of
HeLa cells, they may be important only in infection of
certain cell types or alternatively may be necessary only
for infections of the whole organism. Very few of the
potential coding regions of Ad5 lack an assigned
function; furthering the molecular understanding of this
virus by determining those remaining functions is an
interesting and important objective for the future.
Ian Dix is the recipient of an SERC research studentship. This work
was supported in part by a grant from the MRC.
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The E4 gene of human type C adenoviruses has been shown previously to give rise to an array of mRNAs via
differential splicing. In this study, the pattern of expression of these mRNAs during lytic infection was
examined, and two distinct temporal classes were defined. mRNAs of the early class were distinguished from
those of the late class by the presence, in the early class, of a sequence in the 3' half of the mRNA that was
removed as an intron in the late class. A single mRNA of the late class was found to show a strong dependence
on the presence of the 55-kDa protein from region Elb and the open reading frame 6 protein from region E4
for its normal cytoplasmic accumulation. One feature of this mRNA that distinguishes it from other E4 mRNAs
expressed at late times is the retention within it of an intron from the 5' half of E4; it may therefore be
recognized as incompletely spliced by the host cell and retained in the nucleus. It is proposed that the Elb
5S-kDa/E4 open reading frame 6 protein complex facilitates accumulation of this mRNA by overcoming this
retention mechanism.
The lytic infectious cycle of human adenovirus type 5
(AdS) is divided by convention into early and late phases,
separated by the initiation of viral DNA replication. The
products of genes expressed during the early phase of
intecuon are generally involved in the regulation of gene
expression and viral DNA replication, whereas the products
of genes expressed after DNA replication function in the
structure or assembly of the particle (reviewed in reference
14). However, expression of most of the viral genes is not
strictly con~ned to o~ly one phase of the infection: early
~enes are stili. transcribed ~ell into the late phase of infec-
tion, and restricted expression from the major late promoter
occurs at early times (reviewed in reference 9). Most AdS
primary transcripts are differentially spliced to allow expres-
sion of the virus's many open reading frames (ORFs) from a
limited number of promoters, and the pattern of differential
splicing observed changes during the course of infection.
This is exemplified ~y. expres~ion of the Ll segment of the
major late transcnption umt, during which only large
mRNAs are produced at early times, specifying the 52- and
SS-kDa proteins, and predominantly a distinct smaller spe-
cies at late times, specifying protein IlIa (I, 19).
The E4 region of AdS is located between 91.3 and 96.8
map units on the ~i~al ~e~~me and is t.ransc~ibed fr?m right
to left. E4 transcnptron initiates at a unique Site, begmning in
the early phase and continuing into the late phase of infec-
tion. RNA transcribed from the equivalent region of Ad2 is
subject to a complex pattern of differential splicing, produc-
ing a set of mRNAs that share a common poly(A) site (Fig.
1) (ID, 13, 32, 33). These f!1RNAs potentially encode at least
seven different polypeptides, products of ORF1, ORF2,
ORF3 ORF3/4, ORF4, ORF6, and ORF6/7, of which three,
ORF3: ORF6, and ORF6!7, have been identified duri~g the
course of infection of HeLa cells (5, 7, 29, 30). Studies of
appropriate mutants have implicated these proteins !n regu-
lating late protein synthesis, n.uclear an~ cytoplas':lllc accu-
mulation of late messages, viral protem synthesis at late
times, and the activation of the E2a promoter (3, 11, IS, 28,
• Corresponding author.
34). Recently, the ORF4 product has been shown to regulate
the phosphorylation of certain viral and cellular proteins
(24).
Previous studies of E4 mRNAs indicated some degree of
temporal regulation of the pattern of splicing (27, 32),
although individual mRNA species were not identified. To
characterize the pattern of expression of the known and
putative E4 products in more detail, a systematic study of
the levels of individual mRNAs during the infectious cycle
was undertaken, revealing distinct early and late classes of
E4 mRNA. Given the established role of the Elb 55-kDa and
E4 ORF6 proteins in regulating cytoplasmic levels of the
major late mRNAs (2, 26, 35), the effect on E4 mRNA levels
of deleting these functions was examined. Accumulation of
one E4 mRNA species was strongly dependent on both E1b
5S-kDa and E4 ORF6 protein functions. The structural
features and pattern of expression of this mRNA support the
idea that the presence of intact splice donor and/or acceptor
signals within an mRNA is a determinant of E1b dependence
for efficient mRNA efflux from the late adenovirus-infected
cell nucleus.
MATERIALS AND METHODS
The origins of AdS dl309, d1338, d1355, and d1367 and
methods for their growth in cell culture have been described
previously (5, 11, 26). Infections were at a multiplicity of 10
PFU per cell except as noted. Cytoplasmic and nuclear
fractions. of infected HeLa cells were prepared by Nonidet
P-40 lYSIS and subsequent low-speed centrifugation, and
total RNA was prepared from each fraction by phenol-
chloroform extraction in the presence of sodium dodecyl
sulfate a~d ~DT A, all as previously described (18).
QU?ntltatlve RNase protection assays were carried out as
described by Melton et al. (21), using unselected RNA and
an excess of [a-32P]UTP-labeled antisense probe RNA tran-
~cribed in vitro from cloned fragments of AdS genomic DNA
m pGEM vectors (Promega). The positions on the AdS
genome of the E4 probes generated for this study are shown
in Fig. 1. The E1a probe has been described previously (18)
and was the generous gift of J. Schaack. Protected fragments
3226
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FIG. 1. Constructs used. The right terminal portion of the Ad5 genome (bp 32500 to 35938) is s~own as a. line scale. Below the line is a
transcription map inferred from studies of the closely related virus, A~2. ~RNAs ~ to.Lwere described by VI~ta~en et al. .(33), and m~NAs
M and N are additional species described by Freyer et al. (10). Splice sites are indicated bel~w the transcrlp~lOn map ID the notation of
Virtanen et al. (33). The additional splice acceptor site inferred from the detection of mRNA M IS labeled A·: MInor .sP.lice~cceptor sites in
the 3' portion of E4 and the mRNAs deriving from their use (10, 32) are not.shown; the study reporte~ here did not distinguish these mRNA
species. The positions on the genome map of the cloned fragments from which RNA probes were derived are shown at the top (pIDl, -2, -3,
etc).
poly A A3
were separated on 5% polyacrylamide-7 M urea gels and
detected by exposure to preflashed Fuji RX film at -70°C.
Protected fragments were quantified by laser scanning den-
sitometry (Molecular Dynamics Corp.), using suitable film
exposures. To estimate relative levels of different RNA
species, these data were corrected to take account of the
number of uridine residues in the protected fragment, using
information from the Ad5 sequence (4, 6).
RESULTS
Temporal classes of E4 mRNA. The E4 region primary
transcript is spliced to produce at least 14 distinct mRNAs,
as indicated in Fig. 1 (10, 31, 32). To examine further the
temporal control of E4 RNA splicing, the cytoplasmic level
of each E4 mRNA was determined at various times after
infection with wild-type Ad5. Each RNA probe used gave
protected fragments of characteristic length, allowing iden-
tification and quantitation of individual mRNAs, or in some
cases of pairs of mRNAs predicted to encode the same
translation product. mRNA-probe RNA duplexes covering
the region around position 34350 consistently showed sensi-
tivity to RNase that resulted in 50 to 80% cleavage of the
probe. Fragment lengths were in each case consistent with
an mRNA-probe RNA discontinuity at this position, al-
though no splice donor or acceptor sequence was expected.
Inspection of the sequence revealed a stretch of 11 A
residues in the E4 mRNA. Stuttering of RNA polymerase on
this sequence, either in the cell or, in the antisense, during
probe synthesis in vitro, could explain this observation.
Results of representative assays are shown in Fig. 2. The
probe used to detect mRNA A did not distinguish mRNAs A
and B. However, other probes showed that mRNA B was
not present in these experiments. Similarly, the probe for
mRNA D did not distinguish mRNAs D and E. However,
from results with other probes detecting mRNAs G and H, I
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FIG. 2. Analysis of cytoplasmic levels of E4 mRNAs during
infection of HeLa cells by wild-type virus, d1309, by RNase protec-
tion assay. Total cytoplasmic RNA was isolated at the time p.i.
indicated above each lane. Ten micrograms of RNA was probed for
specific E4 mRNAs, indicated at the left. Fragments shown: DIE,
pID3 (345 nucleotides); C, pID2 (174 nucleotides); L, pID7 (178
nucleotides); A, pID1 (258 nucleotides).
and J, and E and H, it could be deduced that mRNA E was
significantly less abundant than mRNA D and was expressed
with different kinetics (see below). The major component of
the protection shown for probe D+E is therefore due to
mRNA D. A similar conclusion could be reached for levels
of mRNA G in relation to mRNA H (data not shown).
Two distinct classes of E4 mRNAs were identified by this
analysis. mRNAs belonging to the early class (mRNA D;
Fig',2) we:e first detected in cytoplasmic RNA 5 h postin-
fe~tlon (p.I.). Amo~nts of these mRNAs rose rapidly to 9 h
p.l. and then re~ame~ constant or declined slightly during
the late phase of infection, The small increase in the level of
~RNA_s D and. E tha.t was observed between 9 and 16 h p.i.
IS consistent with estimates of mRNA E synthesis from other
experiments. mRNA~ of the late class were only barely
detectable at 9 h p.i., and levels increased dramatically
thereafte:. mRNA A was observed in low amounts at 16 h
p.i., but ItS.lev,els did not peak until 20 h p.i. Other RNAs
with late .kmetlcs (mRNA L; Fig. 2) reached maximum or
near-mmumum levels at 16 h p.i. The temporal classification
of each E4 mRNA detected ISshown in Table 1
Relative abundance of E4 mRNAs Accurate det' . ti. • errruna Ion
of the relative amounts of the different mRNAs is compli-
cated by the need to assume that different probe RNA
h ific acti . s werelabeled to t e same speer c activity, This assumption is
reasonable only for probes prepared in parallel from the
TABLE 1. Classification of E4 mRNAs
Relative amt
Kinetic
classE4 RNA 20 h p.i.9 h p.i.
A ++
B
C + +
0 +++ +++
Ea ++
F
G ++ ++
Ha ++
I
J + +
K ++
L (+) ++++
M +
N
Late
Early
Early
Late
Early
Late
Early
Late
Late
Late
a Amounts shown are for mRNAs E and H collectively.
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same mixture of a-32P-labeled and unlabeled UTP. For such
pr?be sets, protected fragments were quantified, and length-
adjusted data were taken as a measure of relative mRNA
levels. A full data set was obtained by comparing the results
for groups of mRNAs having one or more members in
common. These estimates of relative E4 mRNA levels
which are in reasonable agreement with previous data fa;
Ad2 (32), are shown in Table 1. mRNAs E and H have not
been identified individually; however, neither is found in
significant amounts at 9 h p.i., and their collective abun-
dance is significantly less than that of mRNA D. mRNAs B,
F, J, and N were not detected in any experiment.
Late E4 mRNAs depend on DNA replication for accumula-
tio,n. Transcription of Ad5 late genes is severely restricted
pnor to the onset of viral DNA replication. To determine
whether expression of the late class of E4 mRNAs was
similarly dependent on viral DNA synthesis, their levels in
cells infected in the presence of the DNA synthesis inhibitor
hydroxyurea were assayed. As shown in Fig. 4, expression
of mRNA D (early class) in a wild-type infection was
unaffected by the inhibitor, whereas accumulation of the late
E4 mRNAs L and A was largely and completely prevented,
respectively. Thus, these late E4 mRNAs, like other viral
late mRNAs, depend on DNA replication for their expres-
sion.
Dependence of late E4 expression on Elb 55-kDa protein
function. Previous work has shown that cytoplasmic mRNA
accumulation for genes expressed from the Ad5 genome at
late times is dependent on a function provided by the Elb
55-kDa protein product (2, 18, 26, 34). The possible depen-
dence for proper accumulation of the late class of E4
mRNAs, as defined above, on this Elb function was there-
fore examined by using a mutant virus, dl338 (26), which is
unable to express the Elb 55-kDa protein.
E4 mRNAs present during a dl338 infection were quanti-
fied in a comparative analysis with wild-type virus (d/309).
Representative analyses are shown in Fig. 3. Results with
the control Ela probe confirmed that the multiplicities of
infection of the two viruses were similar. Because Ela
products are involved in the activation of the E4 promoter,
Ela mRNA appears in the cytoplasm before E4 mRNA. The
low levels of Ela mRNA detected at 5 h p.i. in this
experiment may explain why little or no E4 mRNA was
detected at this time point. Other experiments have shown
the presence of early E4 mRNAs at 5 h p.i.
As expected, the early class of E4 mRNA (mRNA 0; Fig.
3) accumulated in the cytoplasm of wild-type- and d1338-
infected cells with identical kinetics. More surprisingly,
most of the late class of E4 mRNAs showed only minimal
dependence on Elb 55-kDa protein function for normal
accumulation (mRNA L; Fig. 3). The one exception was
m~NA A, which had shown the latest kinetic profile in a
wtld-type infection. Accumulation of this mRNA was found
to be strongly dependent on Elb function with cytoplasmic
levels in dl338-infected cells only 5 to lO9'oof the wild-type
level at 20 to 24 h p.i.
E4 ORF6 is necessary for E4 mRNA A accumulation. Elb
55-kDa protein e:"ists as a molecular complex with the E4
~RF6 protem m infected cells (28), and in previous studies,
virus dl355 (lacking E~ ORF6) and dl367 (lacking E4 ORF6
and Elb 55-kDa protem) showed phenotypes very similar to
that of .Elb 55-kDa mutant dl338 in respect of late gene
expression (5, 11). To confirm that the effect of the Elb
mutation on levels of E4 mRNA A was due directly to
absence of the Elb m~NA transport regulatory function, the
levels of mRNA A 10 E4 ORF6 mutant infections were
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FIG. 3. (A) Analysis of cytoplasmic levels of E1a and E4
mRNAs during infection of HeLa cells by wild-type virus dl309 or
E1b 55-kDa mutant virus d1338, as indicated. The E1a fragment
shown is protected by the 3' common exon (404 nucleotides). Other
details are as for Fig. 2. (B) Quantification of data shown in panel A.
Results of laser scanning densitometry are shown in arbitrary units
plotted against time p.i. for dl309 (D) and dl338 (6). These data are
not corrected for protected fragment length and specific activity
differences; therefore, amounts are not comparable between panels.
O.D., optical density.
examined (Fig. 4). Levels of mRNA D (early class) were
unaffected at 9 h p.i. in these infections and only marginally
affected at 24 h p.i.; mRNA L showed a similar pattern at 24
h p.i. These marginal reductions at late times may be due to
the slight reduction in the rate of DNA replication previously
noted for these mutants (5, 11). In contrast, levels of mRNA
A were severely depressed in both E4 mutant infections, as
they were in dl338 infections.
E4 mRNA A dependence on Elb is at a postprocessing level.
Since all E4 mRNAs derive from the same primary tran-
script, the selective depression of mRNA A levels seen in
dl338 infection must be due to a posttranscriptional effect.
mRNA A results from non usage of the E4 5' splice donor site
01 (Fig. 1). To determine whether the absence of Elb
55-kOa protein resulted in increased usage of this site, the
relative abundance of RNA spliced and un spliced at this site
in nuclear RNA was assessed for cells infected with either
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FIG. 4. Analysis of cytoplasmic levels of E4 mRNAs in HeLa
cells infected by wild-type d1309, E4 ORF6 mutant d1355, or E1b
55-kDa/E4 ORF6 mutant dl367 at the times p.i. indicated, in either
the absence (- HU) or presence (+ HU) of hydroxyurea, added at 10
mM to the culture medium. Virus stocks were esC! gradient-purified
particle preparations and used at 500 particles per cell. Five micro-
grams of unselected RNA was probed for specific mRNAs indicated
at the left; other details are as for Fig. 2.
wild-type or dl338 virus. The results of this analysis are
shown in Fig. 5.
Levels of a control E4 RNA (mRNA L) in both nucleus
and cytoplasm were unaffected by the absence of Elb
55-kOa protein. Levels of mRNA A in the cytoplasm were,
as before, greatly reduced in the mutant infection. However,
no similar reduction in nuclear levels of mRNA A was seen.
This result shows that, as for other mRNAs which depend on
E1b 55-kOa protein function for accumulation, E4 mRNA A
requires this function for its efficient movement out of the
nucleus or for stabilization rather than to modulate its
splicing. No probe fragment protected by mRNAs spliced at
site 01 could be detected in either wild-type- or d1338-
infected cell nuclear RNA. Also, the cytoplasmic/nuclear
ratio for mRNA L was very much greater than that for
mRNA A. These findings suggest that, once spliced at the D1
site, E4 mRNA is rapidly exported to the cytoplasm. A
similar conclusion was reached previously regarding E2
mRNA expression (18).
DISCUSSION
The various AdS E4 mRNAs have been divided into two
temporal classes based on a detailed analysis of RNA levels
Cyt o Nuc
hrs p.i. 8 121622 8 121622
309
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309
FIG. 5. Analysis of cytoplasmic and nuclear levels of E4 mRNAs
during infection of HeLa cells by wild-type virus dl309 or E1b
55-kDa mutant virus d1338. Total cytoplasmic (Cyto) and total
nuclear (Nuc) RNAs were isolated at the times p.i. indicated, and
5-~g samples were analyzed. The virus used and E4 RNA detected
are indicated at the left. Other details are as for Fig. 2.
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over the time course of wild-type infection. mRNAs C, D, G,
and J form an early class, while mRNAs A, E, H, K, L, and
M form a late class, dependent on viral DNA replication for
expression. Previously described mRNAs B, F, I, and N
could not be detected. Within the late class, mRNA A is
unique, both in the late time p.i. at which its accumulation
peaks and in its dependence on E1b 55-kDa protein and E4
ORF6 functions for proper cytoplasmic accumulation.
When members of these E4 mRNA classes are compared
with one another, structural relationships can be identified.
Members of the early class all retain the sequences between
splice sites D3 and A3 in the 3' half of the E4 unit. This
donor-acceptor combination is utilized in mRNAs of the late
class to produce a family of shorter mRNAs. The usage of
these sites is therefore temporally regulated during the
course of Ad5 infection; recent studies of E4 expression in
abortively infected monkey cells suggested that the E2a
DNA-binding protein was important for this regulation (27).
As with other examples of regulated adenovirus splicing, in
expression of the E1a, E1b, and L1 genes (1, 8, 19, 22, 31),
processing in E4 moves toward more heavily spliced, shorter
mRNAs in the late phase of infection.
The undetected E4 mRNAs are also related, being formed
by the use of donor site D2a or D2b. The lack of usage of
these sites may be sequence related, as they are more
divergent from the consensus sequence (23) than are sites Dl
and D3, where splicing was observed. Given the detection of
mRNAs spliced at these sites by other workers, their ab-
sence in our experiments may indicate that usage of D2a or
D2b is regulated and apparent only under certain circum-
stances.
The observed temporal pattern of RNA expression from
the E4 region suggests that ORF2, ORF3, ORF4, and ORF6
products are synthesized initially during the early phase of
infection, while the products of ORFI and ORF6/7 are
synthesized later ..The early expression of ORF3 and ORF6
is in agreement wI.th the role of their products in facilitating
viral gene expression fr';lm the onset of the late phase (3, 11,
15, 28, ~4).. ORF4-medlated down-regulation of Ela phos-
phorylatI~n In.HeLa cells (24) was observed from early in
. the infectIOn, In agreement with our data. The delay in the
expression of ORF617 is surprising given its role in the
activation of the E2 early promoter (16,20,25). Formation of
an infection-specific, E4-dependent complex on an E2 pro-
moter fragment has been observed in extracts prepared from
HeLa cells from 6 hpj. (12). However, amounts of this
complex increased dramatically between 6 and 12 h p.i. in
these experiments. Given the differences in experimental
protocol used (multiplicity of infection and cell type), this
delayed-early increase in activity, now attributed to E4
ORF6J7 protein, is in reasonable agreement with our data on
expression of ORF6/7 mRNA. No function has yet been
assigned to the ORFl or ORF2 product in infections of HeLa
cells (11), although their conservation among human adeno-
viruses implies that they are important to the infectious
process in some circumstances. Recently, Javier et al. (17)
showed that the ORFl/2/3 segment of E4 from Ad9 was
essential for mammary tumor induction by this virus in rats.
Our data suggest that Ad5 ORFl functions late in infection,
while ORF2 is required earlier.
Among the E4 mRNAs detected in this study, mRNA A is
the only one to retain splice donor site Dl unused. Further-
more, this mRNA also retains a number of acceptor sites
(Ala to Ale) that are used, with Dl, to form other detectable
E4 mRNAs. Thus, mRNA A is an incompletely spliced
mRNA which contains a readily removable intron. Although
J. VIROL.
other E4 mRNAs are similarly incompletely spliced, through
retention of either the D2a/Ale, D2b/Ale or D3/A3 intron,
these mRNAs either are synthesized only in the early phase
of infection or else carry introns whose removal was not
detected in our experiments. In a previous study, strong
dependence on Elb function for accumulation of late viral
mRNA was shown to correlate with the presence in the
mRNA of unused splice acceptor sites (17a). It was argued
that this result was due to viral mRNAs, in the absence of
Elb 55-kDa protein, being held on the nuclear matrix by host
cell mechanisms whose function was to prevent the efflux of
immature RNA from the nucleus. The finding that the
partially spliced E4 mRNA A is, among the many E4
mRNAs detected, uniquely dependent on Elb 55-kDa pro-
tein function is further evidence that this function is neces-
sary for the efficient release from the nuclear matrix of
mRNAs that are otherwise partially retained. The implica-
tion that residual splicing sites in an mRNA are a cause of
Elb dependence for accumulation suggests that nuclear
proteins which recognize intron sequences in heterogeneous
nuclear RNA may be targets for the action of Elb 55-kDa
protein.
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